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Part 1 
Introduction 

Chapter 1 
Clinical aspects of ischemic heart disease 
1.1 Introduction 
Ischemia of the heat1 is characterized by a deprivation of oxygen combined with 
inadequate removal of metabolites. Myocardial ischemia may be due to an increased 
oxygen requirement, or to a decreased supply of oxygen to the myocardium. 
The myocardial consumption of oxygen is determined by myocardial wall tension, 
contractility, and heart rate. Processes in the myocardium, not directly related to contractile 
function, require only 20% of the total oxygen consumption, while the amount needed for 
electrical depolarization is only approximately 1% of total oxygen consumption I. '. The 
myocardial oxygen demand is increased by physical exercise or by mental stress. In 
healthy individuals, an increased oxygen demand is likely to be compensated via an 
increase of coronary blood flow 3. An increased oxygen demand may result in cardiac 
ischemia only in patients with existing coronary artery impairment 4. 
Myocardial oxygen supply is dependent mainly on coronaty blood supply. The 
coronary at1ery diameter declines passively when the lumen is narrowed by intimal 
hyperplasia or atherosclerosis, or by the formation of a secondaty thrombus in a 
susceptible coronary at1ery segment. In addition to that, the mechanisms regulating 
coronaty at1ery diameter may be altered in such a way that contraction of the coronaty 
artery smooth muscle contributes actively to the already present luminal naHowing. In a 
small group of patients, vasoconstriction may be solely responsible for myocardial 
ischemia. The coronary at1elY mechanisms underlying disturbed coronary m1elY flow 
regulation are outlined in chapter 2. 
For now it must be emphasized that the present chapter on clinical aspects of 
ischemic heart disease is bound to be incomplete when considering the voluminous 
detailed text books on this topic. However, this chapter should be read as a prologue, 
setting the stage for hypotheses and experimental investigations, which are only a modest 
reflection of clinical reality described here. 
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1.2 Categories of ischemic heart disease 
Ischemic heati disease is comprised of a spectrum of related syndromes, with related 
symptoms and pathological mechanisms. The spectlUm reaches from silent ischemia on 
one end to acute transmural infarction and sudden cardiac death on the other end. 
In stable angina pectoris the most imp0l1ant symptom is the typical anginal 
discomfOli in the chest, which usually begins gradually and reaches a maximal intensity 
over a period of minutes, before disappearing within 20 minutes after cessation of the 
precipitating activity, or within less than approx. 10 minutes, when nitrates are 
administered. The symptoms should be present over a longer period of time (>60 days), 
and remain constant. Anginal pain on the chest was described a long time ago: 
"... But there is a disorder of the breast marked with strong and peculiar symptoms, 
considerable for the kind of danger belonging to it, and not extremely rare, which deserves 
to be mentioned more at length, The seat of it, and the sense of strangling and anxiety with 
which it is attended, may make it not improperly be called angina pectoris ... " 
William Heberden, 1772 s 
Nowadays we would describe typical angina pectoris as a discomfOli in the chest or 
adjacent areas, caused by myocardial ischemia and associated with a disturbance of 
myocardial function, but without myocardial necrosis. Obviously, it is important to 
differentiate angina pectoris from other, non-ischemic, non-cardiogenic causes of chest 
pain. These include oesophageal reflux or spasm, acute pancreatitis, pulmonary 
hypertension, and many others. Although the ECG is not necessarily abnormal, 
abnormalities may include changes of the ST-segment, in particular during provocative 
exercise testing. Stable angina pectoris is induced by an increased oxygen demand, like 
in physical activity (as in provocative exercise testing), hunying, eating, emotions, but also 
in situations of excessive metabolic demand like in fever, thyrotoxicosis, severe anaemia, 
and hypoglycaemia. In stable angina an obstntction of the blood vessel results in a 
decreased but tixed coronary flow reserve. Characteristically, the patient can predict with 
some precision which level of activity will cause angina. This has also been called 'tixed 
threshold angina' 6. '. However, many patients have 'good days', when patients are able 
to perfonn substantial physical activity, or 'bad days', when even small physical activity 
can cause symptoms of myocardial ischemia. The latter form of angina has also been 
called 'variable threshold angina'. A number of patients suffer from episodes of 
myocardial ischemia, which are not always accompanied by the characteristic angina 
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pectoris. During this 'symptom-free' ischemia, changes of the BeG and a reduced 
myocardial perfusion may be observed '. This type of ischemia is denoted as silent 
ischemia. Silent ischemia may be present in patients who do not perform exercise intensely 
enough to provoke the symptomatic ischemia, in patients with diabetes mellitus, and in 
patients in which the pain threshhold is higher than in others 9. It may also occur in non-
symptomatic intervals in patients previously characterized as stable or unstable angina 
pectoris, or in patients with a previous myocardial infarction. 
Unstable angina pectoris is a clinical syndrome which requires particular interest 
because of its intense and frightening nature, and because of the fact that many patients 
with acute myocardial infarction repOlied symptoms resembling unstable angina, prior to 
infarction 10. The population of patients with unstable angina is characterized by one or 
more of the following signs: (i) crescendo angina, i.e. more severe, frequent, or prolonged 
aHacks, superimposed on an existing paHern of stable angina; (ii) angina at rest as well as 
in minimal exercise; (iii) angina of rccent onset « 60 days), brought on by minimal 
exercise. In general, responsiveness to nitrates is less than in stable angina. Changes of the 
ECG are often seen, but disappear with cessation of the pain. The specific enzymatic 
changes and persistent ECG alterations as in acute myocardial infarction should be absent. 
Many investigators also include a poor response to nitroglycerin or rest. The 
pathophysiology of unstable angina is more complex and dynamic than in stable angina. 
In unstable angina, progression of atherosclerotic lesions, (resulting in) altered vasomotor 
tone and endothelial damage, the l1Ipture of existing plaques and platelet aggregation and 
thrombosis, may all together, or separately, contribute to the disease ". Due to the obvious 
patient heterogeneity in nature and severity, and the important differences in already 
applied therapeutic measures, a classification has been developed to differentiate between 
subgroups ". 
In contrast to stable and unstable angina, myocardial infarction is characterized by 
ilTeversible myocardial damage or necrosis, followed by chronic functional changes and 
scalTing of the involved myocardium. Myocardial infarction' is caused by atheromatous 
nalTowing of the arterial lumen, often in combination with the l1Ipture of an existing 
atherosclerotic plaque, a superimposed occluding thrombus, and/or vasospasm 13. 14. Where 
the myocardium is damaged to a severe extent, the patient may develop cardiogenic shock, 
with a cyanotic appearance of cool, but clammy skin. Activation of vagal reflexes results 
in nausea and vomiting in a majority of patients (in pmiicular in inferior myocardial 
infarction), and feelings of weakness and dizziness are common. The chest pain is 
variable, but may be very severe, and lasts for more than 30 minutes to a number of 
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hours, and does not usually respond to nitrates (the latter two in contrast to stable and 
unstable angina pectoris). In 20-60% of non-fatal myocardial infarctions, the infarction 
remains unrecognized or is not perceived at all. These cases, which are recognized in 
routine EeG or post-mOltem investigations, are called silent myocardial infarction 15. 
Since the discovery of elevated levels of serum glutamic oxaloacetic transaminase 
(SGOT) in patients with myocardial infarction 16, the levels of SGOT and other cardiac 
enzymes in serum have become an imp0l1ant tool in the diagnosis of ilTeversible 
myocardial cell injmy. At present the most widely applied enzyme test is the detection of 
creatine kinase (CK), which exceeds the normal serum concentrations within 4-8 hours 
after onset of myocardial infarction and returns to normal within 3-4 days after the onset 
of chest pain. Three iso-forms of CK exist (MM, MB, and BB) of which CK-MB is the 
most specific for damage of cardiac myoc)1es 17.18. Other enzyme tests include lactate 
dehydrogenase (LOR). This enzyme consists in five isoenzyme forms, of which LORI is 
the most specific for the cardiac myocytes 19. Apatt from total LOR activity, the ratio of 
LORI/LOR, may also be measured, in which ratios of over 0.76 19 or 1.0 20 point at a 
previously experienced infarct. This enzyme exceeds normal levels by 24-48 hours, 
reaches a maximum in 3-6 days, and is back to normal levels in 8-14 days. Therefore, 
LOR isoenzyme analysis should be reserved for cases in which creatinine kinase levels 
have returned to normal levels (Le. after 3-4 days). Measurement of aspartate 
aminotransferase (AST: similar to the above mentioned SGOT test) is less specific and 
does not add to information obtained by measuring activity of CK-MB or LOR'I. 
Variant angina pectoris was described in 1959 by Myron Prinzmetal and co-
workers 22 as a distinct syndrome, characterized by angina pectoris at rest (therefore also: 
Prinzmetal's angina). Variant angina may lead to myocardial infarction, cardiac 
atTh)1hmias, and sudden death, but 5 year survival is relatively good (around 90%) 23. In 
contrast to (un)stable atlgina, variant angina is not provoked by exercise. Moreover, angina 
at rest in variant angina patients has usually not progressed from an earlier stage in which 
angina would be provoked by decreasing amounts of exercise, like in many patients with 
unstable angina. Ouring the attack, typical ST-segment alterations may OCCtll' in the ECG. 
Coronary arteries of patients with Prinzmetal's angina constrict with abnormal sensitivity 
to ergonovine infusion 24. Although the coronary angiogram of some patients reveals severe 
coronary obstmctions, these are not necessarily present. 
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1.3 Epidemiology 
Cardiovascular diseases are the most common cause of death in the western world. 
In the Netherlands in 1992, 40% of the total death count was due to cardiovascular 
disorders (see Ref. 25). 40% of the people dying of cardiovascular disease, died of 
ischemic heart disease, whereas 24% died of cerebrovascular accidents. Among those 
dying of ischemic heat1 disease, the major proportion of individuals suffered !i'om acute 
myocardial infarction (77%). Thus, acute myocardial infarction is the most common single 
cause of death in the Netherlands with a total number of 16.248 recorded fatalities in 
1992. 
Males are more at risk of dying of ischemic heart disease than females, and the risk 
increases with age. The risk for females of dying of acute myocardial infarction is similar 
to that of males who are ten years older. 
Since 1972, the age-related death rate due to ischemic hem1 disease has shown an 
impressive decrease of 43% and 44% for males and females, respectively (age-standardi-
zed for 1992, per 100.000). In contrast, the standardized hospital admission rate showed 
a constant increase since 1972. The combination of a decreased death rate and an increase 
in hospital admissions may point at improved survival rates or at an increase of the 
number of admissions for diagnostic or interventional purposes (De Nederlandse 
Hat1stichting, 1994 "). 
Public awareness of risk factors is considered a substantial contribution to the decline 
in death rate to ischemic hem1 disease. The three main risk factors in ischemic hem1 
disease are dyslipidaemia, smoking, and hypcliension. Risk factors often co~exist, and may 
act synergistic, for example in smoking-related hypertension. 
Dyslipidaemia is a complex of disorders, referring to abnormal metabolism of 
plasma lipids, which can be caused by genetic factors and by diet, or can be secondary to 
other diseases like diabetes. In pat1icular the ratio of low density lipoproteins (LDL) 
compared to high density lipoproteins (HDL), and also the selUm cholesterol concentra-
tions are now well established risk factors. It was shown, for instance, that 45% of the 
coronary artery disease differences between the male popUlations of different countries, 
could be accounted for by the variation in senlln cholesterol levels. Variability in HDL 
levels accounted for 32% of differences, whereas the ratio of total senlln cholesterol to 
HDL accounted for 55% of mortality differences ". Moreover, a number of studies 
reducing total selUm cholesterol by pharmacological or dietaty means have shown 
significant reductions in m0l1ality due to ischemic hemt disease compared to placebo 
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treatment 21. ". Such measures have also been shown to reduce development of 
atherosclerosis 29, and may even cause regression of existent atherosclerotic lesions 30, 31, 
Smoking of cigarettes is another major risk factor in ischemic healt disease. Several 
mechanisms of action have been proposed, for example a negative effect on HDLILDL 
ratio's 32, or increased platelet aggregation 33, FUlihermore, nicotine may stimulate the 
sympathetic nervous system, leading to the release of noradrenaline, which may result in 
increased coronary tone ". Cessation of smoking could reduce the risk of myocardial 
infarction within 2 years 35. 36, but others have shown that even men, who have given up 
smoking more than 20 years ago, have an increased risk of myocardial infarction ". 
Also hypeltension was shown to predispose for coronary atherosclerosis ". Although 
a beneficial effect of lowering blood pressure on the incidence of stroke was reported, the 
impact on ischemic hemt disease (if any) was much less pronounced 39. Other risk factors 
include lack of physical activity, a family history of ischemic hemt disease, diabetes 
mellitus, obesity, and perhaps mental stress or personality. 
1.4 The cunent therapeutic approach of ischemic heart disease 
The therapy of ischemic heart disease is primarily aimed at minimizing anginal pain 
and possible consequential damage of the myocardium. This can be achieved by increasing 
the supply of oxygen through augmentation of coronary flow, or by decreasing the demand 
of oxygen via suppression of myocardial contractility or hemt rate. Secondly, therapy is 
aimed at prevention of further myocardial ischemic events. In myocardial infarction, the 
therapeutic approach is also aimed at support and restoration of myocardial function when 
necessary. 
Like in other syndromes of ischemic hemt disease, the treatment of slable angina 
pecloris should first be aimed at the elimination of predisposing risk factors, such as 
hypeltension and smoking. The treatment of obesity is also impoltant in that an ideal body 
weight raises the threshhold of angina pectoris. A similar effect may be achieved by 
treating anaemia, fever, or pulmonary disease, which all have a detrimental effect on the 
oxygen supply/demand balance. Pharmacological treatment consists of nitrates, beta-
adrenoeeptor antagonists, and calcium channel blockade 40. Nitrates act by inducing 
vasodilatation in both venous and mterial blood vessels. Dilatation in venous blood vessels 
helps to reduce the preload, which relieves wall stress in the ventricles 41. In mteries, 
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vasodilatation alleviates ventricular afterload, and small changes in coronaty at1elY 
diameter contribute to a decreased coronaty artery flow resistance 42, Side effects include 
headache, flushing and hypotension, Antagonists at beta-adrenoceptors act by attenuating 
the positive inotropic and positive chrontropic responses to catecholamines on the 
myocardium (mediated primarily via betal receptors), Since sympathetic catecholaminergic 
stimulation takes place during activity and excitement, this class of dlUgs is particularly 
effective in increasing the threshhold of angina pectoris 43, Because stimulation of beta, 
receptors induces bronchodilatation, and because even so-called cardioselective (beta,) 
receptor blocking agents have only relative selectivity for beta, receptors, beta-
adrenoceptor antagonists should better not be prescribed to susceptible individuals, like 
asthma patients, Since beta, receptors may also mediate dilatation of peripheral blood 
vessels, intermittent claudication is considered a relative contraindication for treatment 
with beta receptor antagonists, Calcium antagonists act by decreasing the entry of calcium 
into smooth muscle cells and cardiomyocytes, thereby interfering with contraction, leading 
to vasodilatation and a negative inotropic response 44, Recent data suggest that calcium 
antagonists may also help to attenuate the development of new atheromatous lesions 45, ", 
Because the mode of action and the haemodynamic profile of nitrates, beta adrenoceptor 
antagonists, and calcium antagonists, is clearly different, several combination regiments 
have been suggested for patient subgroups of stable angina and have been established to 
be beneficial in large clinical trials, 
Non-pharmacological interventions include coronary m1ery bypass surgery, 
percutaneous transluminal coronaty angioplasty (PTCA) sometimes combined with intra-
arterial stent implantation, or laser angioplasty, or directional transluminal coronary 
atherectomy, 'Significant disability from moderate to severe angina pectoris, unresponsive 
to optimal medical care' remains a valid indication for the above mentioned interventional 
methods of treatment, although exact indications develop continuously as expel1ise 
increases 47, 48, Patients with depressed left ventricular function have better 10 year survival 
when treated with bypass surgery than after medical therapy, but medically-treated patients 
with mild stable angina and normal left ventricular function have a survival similar to 
patients assigned to surgery 49, Depressed left ventricular function below a critical level 
(ejection fraction <20%) is associated with increased operation m0l1ality ", Quality of life 
is increased in patients undergoing surgery during the first ten, years, but the difference 
disappears thereafter 51, The use of internal mammary artery bypass grafts in bypass 
surgery, has considerable advantages over the use of saphenous vein in 10 year survival", 
but occlusion of the graft is still a common problem of coronaty at1ery bypass surgery, 
The overall chance of occlusion at 10 years after surgery is 40-50% per distal anastomosis, 
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Occlusion may occur at an early stage (before hospital discharge, due to e.g. technical 
difficulties, like kinks) or over many years, due to neointimal formation and occlusion 
with an atherosclerotic plaque 53. Treatment with aspIrIn (with or without 
dipyridamole 54.55), and lowering of the LDL cholesterol / HDL cholesterol balance 56. JO, 
have been shown to be associated with prolonged patency of bypass grafts. 
The 'ideal lesion' for treatment with PTCA consists of a single, smooth, concentric 
lesion in an easily accessible proximal coronary artery segment 5-7. For patients with single-
vessel coronary aliery disease, PTCA offers earlier and more complete relief of angina 
than medical therapy 58. Coronary arteries with excessive tortuosity, or near complete 
obshuction are less suitable for PTCA ". The main and still unresolved problem is the 
frequent occurrence of chronic restenosis following PTCA. Between 20 and 30% of 
patients treated with PTCA, develop renarrowing of the dilated segment (restenosis), and 
subsequent recun-ent myocardial ischemia within 6 months after treatment. Platelet-derived 
vasocontrictors (e.g. 5-HT, thromboxane A,) and/or mitogens (e.g. platelet-derived growth 
factor or PDGF), released after platelet adherence to the luminal surface of the blood 
vessel aftel' dilatation, are believed to be involved in this process 60. Also other 
vasoconstrictors/mitogens, like angiotensin II, and endothelins have been implicated in the 
process of restenosis. However, medical treatment with aspirin 61, 5-HT receptor 
antagonists 62, thromboxane receptor antagonists 63, and angiotensin conve11ing enzyme 
inhibitors 64, have not been successful in the prevention of restenosis, despite promising 
previous results in animal studies 65. By contrast, the use of balloon expendable coronary 
stent implantation has recently been shown to reduce the rate of restenosis, when 
compared to balloon angioplasty 66, and treatment with antibody fragments aimed at 
platelet glycoprotein IIb/llla integrin (mediating the final common pathway leading to 
platelet aggregation), resulted in reduction of the need for subsequent coronary 
revascularization procedures in the first six months 67. 
Treatment of unstable angina pectoris is relatively similar to treatment of patients 
with stable angina, considering the use of nitrates, beta blocking dmgs, and calcium 
antagonists, and non-pharmacological interventions. However, in unstable angina the use 
of anticoagulants and antiplatelet dmgs is often recommended, which reflects the possible 
involvement of platelet activation and thrombus formation. Indeed, both aspirin and 
heparin, and their combination have been shown to improve clinical outcome of patients 
with unstable angina 68. ". Also PTCA and surgical coronary .. tery bypass grafts result in 
immediate abolition of ischemic episodes 10. ". The effectiveness of thrombolysis (vide 
infra) in unstable angina is still uncertain 72. 7J and may be detrimental 74. 
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The treatment of myocardial infarction is essentially different from the treatment of 
other ischemic heatt disorders, due to the acute and neal' complete occlusion of the artery, 
and due to the resulting itTeversible damage of the myocardium. After diagnosis and 
hospitalization, general measures of treatment include oxygen, bedrest, and analgesics. 
Inunediate measures should fiuthermore be aimed at the reperfi,sion of the ischemic 
myocardium ". This can be achieved by thrombolysis using streptokinase 01' recombinant 
tissue-type plasminogen activator ('i-PA), which are both ve,y eflective in the first hours 
after the infarction 76, 77. Aspirin, added to streptokinase, results in further improvement of 
vascular m0l1ality rate 78, Patients in which reperfusion cannot be achieved using 
thrombolysis, may benefit from rescue PTCA 79, and sometimes emergency bypass 
surge,y 80. Others even claim a small beneficial result of immediate PTCA compared to 
thrombolysis 81.82. Beta-adrenoceptor blockade early after infarction resulted in significant 
reduction of mortality ", but the use is contraindicated when common complications of 
myocardial infarction, like heart failure and heart block, are present. Intravenous 
administration of nitrates limits infarct size and the rate of complications, and improves 
post-infarction remodelling &4, Calcium antagonists, however, have not been shown to be 
effective in reducing mOltality and infarct size ". Relatively new therapeutical approaches, 
currently under investigation to achieve early reperfusion include additional thrombin 
inhibitors ". Other drugs used in acute myocardial infarction are aimed primarily at the 
prevention of arrhythmias, hypotension, heati-failure, and shock, and at a beneficial effect 
on postinfarction remodelling. These drugs are not within the scope of this thesis. 
In contrast to patients with myocardial infarction, patients with variant 01' 
Prinzllletal's angina respond extremely well to calcium antagonists but not to beta receptor 
antago-nists ". Nitrates are usually effective to abolish the attack ". PTCA is only rarely 
indicated in patients with Prinzmetal angina, when additional obstlUctive lesions are 
present 89, 
1.5 Myocardial ischemia induced by anti-migraine drugs 
Anti-migraine dmgs, like ergotamine and sumatriptan, may induce myocardial 
ischemia in some patients. Especially ergotamine, in use since many decades is renowned 
for its myocardial side effects. Therapeutic doses of ergotamine were shown to be 
associated with myocardial ischemia, myocardial infarction, cal'diac atTest, and sudden 
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death 90. The development of the novel anti-migraine dlUg sumatriptan was aimed at the 
development of a dlUg that would selectively stimulate the 5-HT, receptor in dilated 
extracerebral blood vessels. However, also this novel dlUg was found to lead to symptoms 
of angina in some patients 91. ". In exceptional cases, changes of the ECG have been 
recorded ". However, ECG abnormalities are usually absent in patients presenting with 
symptoms resembling angina, after taking anti-migraine dlUgS (W.H. Visser, personal 
communication). Patients suffering from cardiac side-effects do not necessarily belong to 
high risk categories for ischemic heart disease 91. Therefore, it has been speculated that 
some patients may be hyperresponsive to stimulation of their contractile coronary miery 
5-HT, receptors. The mechanisms involved in this putative hypel1'esponsiveness are 
ct1l1'ently under investigation. An altemative explanation for the chest-symptoms may be 
an effect on lungs 01' the oesophagns ". Although nitrates are effective in the treatment of 
anginal symptoms after anti-migraine dlUgS, symptoms usually disappear spontaneously. 
Lastly, it must be kept in mind that altemative anti-migraine dlUgs, like ergotamine and 
dihydroergotamine, m'e clearly more potent vasoconstrictors of the human isolated 
coronary miery 95. ", and therefore appeal' more likely to induce cardiac ischemia. 
1.6 Conclusions 
In summary, ischemic heati disease is a spectlUm of related disorders in which the 
oxygen supply does not meet the demand. This may result in stable, unstable 01' variant 
angina, 01' in myocardial infarction. All are usually due to both passive obstlUction by 
thrombus plugging 01' plaque formation, and also to active vasoconstriction caused by 
vasoconstrictor agonists. The contribution of active vasoconstrictor obstmction may vary 
from velY little in case of fixed obshuction in stable angina, upto almost hundred percent 
in case of variant angina pectoris. Treatment is aimed at reducing myocardial ischemia, 
and related anginal pain, and at early reperlhsion and prevention of haemodynamic 
complications in myocardial infarction. Large scale clinical trials are being undeliaken to 
establish the best choice of treatment for different groups of patients. 
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Chapter 2 
Physiology and pathophysiology of vasomotor tone 
2.1 Introduction 
The supply of oxygen to an organ is largely dependent on blood flow. Blood flow 
is determined by the pressure gradient and by resistance along the blood vessel. When 
blood flow in an aliery is considered as flow of fluid through a cylinder, resistance is 
determined by the length of the cylinder, by viscosity of the fluid, and most important-
ly, by diameter of the cylinder. Diameter of the blood vessel is dependent on its 
anatomical constitution (I.e. the natural diameter, and the presence or absence of 
luminal obstruction) and by vasomotor tone. This chapter describes mechanisms 
underlying vasomotor tone. Vasomotor tone is defined as the outcome of contractile 
and relaxant forces within the blood vessel wall. Although contraction and relaxation 
both result directly from processes in the vascular smooth muscle, it has now become 
evident that the endothelial lining is an important relaxant and contractile determinant 
of smooth muscle tone. Vasomotor tone is governed locally, via in situ release of 
contractile and relaxant mediators, and systelhically, via hormones released elsewhere. 
Disturbance of the equilibrium between relaxation and contraction is believed to be an 
important detenninant of ischemic disease. 
2.2 Smooth muscle physiology 
Structure of the cOII/l'ac/ile apparatus 
Interaction between the major contractile proteins actin and myosin generates 
vascular smooth muscle tone. Heads of the bundled myosin thick filaments bind to 
actin thin filaments in an, ATP driven, cyclic fashion, thereby generating tension as a 
result of conformational changes in the myosin head when bound to the actin filament. 
During this cycle, the angle of the myosin head is translocated from 90' to 45' with 
respect to the longitudinal axis of the actin-, and myosin-containing filaments I. '. The 
stmcture of the smooth muscle cell contl'actile apparatus is ordered in a less apparent 
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manner than the stlUcture of striated muscle, in which light microscopy may suffice to 
observe the organization of actin and myosin filaments. In smooth muscle, thin 
filaments containing actin and tropomyosin are attached to the cell membrane and to 
dense bodies which contain, among other proteins, a-actinin 3, Dense bodies may be 
compared to Z-Iines of striated muscle '. Additional three-dimensional networks, 
consisting of the proteins desmin and vimentin interconnect dense bodies, resulting in 
an extensive cellular skeleton '. 
Interaction of actin and myosill 
Vascular myosin consists of two heavy chain subunits (MW 204.000 Da and 
200.000 Da) and of two sets of light chain subunits: regulatory 20.000 Da (hence 
LC20) chains and alkali 17.000 Da (hence LCI7) chains. Myosin light-chain kinase 
(MLCK) phosphorylates the serine-19 of the LC20. MLCK itself is activated by Ca", 
and by the calcium binding protein calmodulin '. Phosphorylation of the LC20 initiates 
the cycle of actin-myosin cross-bridging, and thus initiates contraction. In pm1icular, 
the phosphorylation of the LC20 leads to activation of myosin Mg ATPase activity, 
which also requires the presence of actin (therefore also 'actin activated myosin Mg 
ATPase') '. The subsequent ATP hydrolysis provides the energy required for cycling of 
cross bridges. Cycling of cross bridges refers to the cycle of attachment of the actin 
binding domain of the globular head of myosin to the actin filament, the tilting of the 
myosin head, leading to translocation accompanied by the release of ADP and PI' the 
detachment of the actin chain, the re-tiiting, and the subsequent re-attachment further 
down the actin filament. The state of phosphorylation of the myosin light chain is 
reversed by dephosphorylation by protein phosphatase (MLCP, myosin light chain 
phosphatase) and by modulation of MLCK activity. Indeed, MLCK can be 
phosphorylated by several protein kinases, like cAMP- and cOMP-dependent protein 
kinase 8, and by protein kinase C 9 (for schematic representation, see Figure I). Other 
actin-binding proteins that modulate contractility have been identified more recently. 
First, it has been suggested that calponin modulates Ca'+ sensitivity of smooth muscle 
contraction I, 01' the effects of protein kinase C on smooth muscle contraction 10, 
Secondly, phosphorylated caldesmon has been suggested to slow actin-myosin 
crossbridge detachment II. I'. However, little is known in detail about the latter two 
presumed modulators of contraction. 
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Figure 1. Schematic representation of interaction of myosin and actin. +, positive 
effect/induction; ., negative effect/inhibition; MLCK, myosin light-chain kinase; LeI7, myosin 
light chain, 17.000 Da; Le20, myosin light chain, 20.000 Da; Mg-ATPase, myosin Mgl+ 
ATPase. 
Lalch slale 
In intact vascular smooth muscle, the extent of Le20 phosphorylation con'elates 
best with the velocity of muscle shOltening at zero-load, and is an estimate of the rate 
of actomyosin cross bridge cycling. Vascular smooth muscle contraction induced by 
electrical or pharmacological stimulation is characterized by rapid increases of Le20 
phosphOlylation and velocity of muscle shOltening, followed by a gradual return to 
near-basal levels of both shOltening velocity and Le20 phosphOlylation. Tension, 
however, increases more slowly, but is maintained while the Le20 phosphorylation 
level decreases 13, In this state of 'tension maintenance" cross bridges cycle at about 
one-qumter of the normal cycling rate, which allows the smooth muscle to maintain 
contraction at 101V energy cost. This state has been called 'latch state' by Hai and 
MlIll'hy I" who hypothesized that dephosphOlylation of the Le20, while in high 
affinity binding conformation, would alter the kinetics of crossbridge detachment, 
thereby prolonging actin-myosin binding, resulting in sustained tension. 
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diacylglycerol; IP 3, Inositol-l A,5-triphosphate. 
Excitation-conh'aclion coupling 
Cytoplasmic calcium is a primary determinant of tension generation. Calcium is 
present in the extracelluar compartment in millimolar concentrations, whereas the 
cytoplasmic resting concentration is around 100 nM. The pathways leading to a 
contractile response require only up to approximately 600·800 nM Ca'+ 15, for which 
the sarcoplasmic reticulum is an impOliant source. Several mechanisms affect the 
concentration of calcium in the cytoplasm (for schematic representation, see Figure 2). 
The cellular membrane is equipped with channels that, when activated, allow for a 
rapid influx of Ca'+ into the cell. These calcium channels may be opened by depolari· 
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zation of the membrane potential (voltage-dependent calcium channels, see Ref. 16). 
Membrane potential is determined by the concentration of the main anions and cations 
across the membrane. The concentration of ions is dependent on various ion transpor-
ting systems in the membrane, like Ca'+-dependent and A TP-sensitive potassium 
channels (K+Ca and K\TP) 17<19, Na+-K+ ATPase 20, and a Na+-Ca2+ exchanger. The latter 
utilizes the electrochemical Na + gradient across the cell membrane for concomitant 
cellular Ca'+ extmsion ". When the K+ channels are activated, and the K+ conductance 
increases, hypel]lolarization follows, leading to inactivation of voltage dependent Ca'+ 
channels and enhanced Ca'+ extmsion via the mentioned Na+-Ca'+ exchanger. Relax-
ation, or reduction of vasomotor tone follows. K+ c, channels may be activated by 
5'-GMP, the major metabolite of cGMP, which is formed after stimulation with e.g. 
nitrovasodilators and endothelium-derived relaxing factor (EDRF) ". K\TP channels 
can be activated by pharmacological agents like minoxidil and various neuropeptides, 
and can be inhibited by compounds like glibenclamide ". 
To remove Ca'+ from the cytoplasm, the cell utilizes outwardly directed 
ATP-dependent Ca'+ pumps 24 as well as the above mentioned Na+-Ca'+ exchanger ". It 
has been shown that these Ca'+ pumps are stimulated by compounds that increase 
cGMP like nitrovasodilators, in which the generation of phosphatidylinositol 
diphosphate appears to be involved as well ". 
The membrane of the sarcoplasmic reticulum contains Ca'+ channels which are 
activated by the second messenger inositol triphosphate and are therefore refen'ed to as 
second messenger operated calcium channels 6 (vide infra). In addition, the 
sarcoplasmic membrane contains a Ca'+ pump, which actively stores Ca'+ in the 
sarcoplasmic reticulum ". It has been suggested that the affinity of this sarcoplasmic 
reticulum Ca'+ pump is enhanced by agents that increase cGMP, whereas protein kinase 
C is believed to increase the maximal activity of the pump ". 
Signal transduction 
Binding of an agonist to its receptor induces a cascade of biochemical events, 
ultimately leading to relaxation or contraction. a- and 3-adrenergic, muscarinic, 5-HT-, 
angiotensin, arginine vasopressin, and endothelin receptors are all coupled to a specific 
intracellular second messenger system via guanine nucleotide (GTP, GOP) binding (G) 
proteins. These proteins consist of three subunits, a, 3, and y. Receptor activation can 
induce the replacement of GOP by GTP in the a subunit, thereby altering the confor-
mation of the protein and making the active site of the G-protein available for 
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activation or inhibition of enzymes or ion channels, Different G proteins exist in 
vascular smooth muscle. G, protein stimulates adenylyl cyclase, whereas G, protein 
inhibits adenylyl cyclase. Gp activates phospholipase-C, and G, proteins activate 
ion-channels (reviews, see Ref. 29 and 30). Receptors, mediating contraction after 
stimulation with 5-HT are, for instance, coupled to G,- (5-HT,) and Gp (5-HT,) 
proteins ". Endothelin receptors and vasopressin V I receptors are usually believed to be 
coupled to Gp proteins 32. ". 
Stimulation of phospholipase-C induces the conversion of the membrane constitu-
ent phosphatidyl-inositol 4,5-biphosphate (PIP,) to yield inositol triphosphate (IP,) and 
diacylglycerol (DAG) (see Ref. 34). IP, binds to receptors on the membrane of the 
sarcoplasmic reticulum, resulting in release of Ca" from the sarcoplasmic reticulum 
into the cytoplasm ". Diacylglycerol activates protein kinase C. Protein kinase C may 
be stimulated experimentally by phorbol esters ", which interact with the DAG binding 
site. Protein kinase C inhibits the activation of phospholipase C 36, and modulates the 
phosphorylation of various ion channels and -exchangers 37.". 
Adenylyl cyclase catalyses the formation of adenosine-3',5'-monophospate 
(cAMP) from adenosine triphosphate (ATP). cAMP may induce activation of K+ 
chrumels, resulting in hyperpolarization, decreased Ca2+ influx, and relaxation 16, 
Increased levels of cAMP also lead to enhanced Ca'+ cytoplasmic extl1lsion 40, which 
again results in relaxation. Finally, cAMP-induced activation of cAMP-dependent 
protein kinases leads to the phosphmylation of myosin light chain kinase (MLCK), 
thereby decreasing the Ca'+-sensitivity of the contractile apparatus, resulting in 
relaxation 41. Also the accumulation of cyclic guanosine monophosphate (cGMP) 
following stimulation of guanylate cyclase will result in relaxation via comparable 
mechanisms 42, 43, 
2.3 Physiology of the endothelium 
Endothelium-dependent relaxation 
In 1980 Robeli Furchgott and John Zawadzki 44 described that the response of 
rabbit isolated aorta is dependent on the presence of endothelium. Endothelium-intact 
aorta preparations relaxed after exposure to acetylcholine, whereas rings, in which the 
endothelium had been I1Ibbed, did not or even responded with contraction. It was 
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shown that the endothelium produced a very labile, relaxing substance, which was not 
a prostanoid. It was decided that the endothelial factor involved would be refelTed to as 
endothelium-derived relaxing factor (EDRF 45). Co-workers of Robel1 Furchgott 
decided that endothelium-derived relaxing 'factor' was to be preferred over 'substance' 
or 'material', basically because the abbreviation EDRF would contain its inventor's 
initials 46, 
Although several hypotheses had been proposed, the chemical identity of EDRF 
remained unknown. Even before the identification of the factor involved, it had been 
shown that EDRF would induce guanylate cyclase, thereby increasing levels of cOMP, 
ultimately resulting in vasodilatation 47. It was not until 1987 that EDRF was proposed 
to be similar to nitric oxide (NO) 48. ". Palmer and co-workers also showed that nitric 
oxide was synthesized from L-arginine, resulting in the production of nitric-oxide and 
citrulline so. False precursors of nitric oxide, like NG-monomethyl-L-arginine, inhibited 
the synthesis of nitric oxide 'I. 52. By use of these 'NO-synthase inhibitors' a basal 
dilatory nitric oxide tone could be shown 53. ", which contributed continuously to 
vasomotor tone. Moreover, it was shown that a large number of endogenous mediators, 
including those released by aggregating platelets ", could induce the endothelial 
production of EDRF 56.". Apart fi'om platelet-induced, EDRF-mediated relaxation of 
the vascular smooth muscle, nitric oxide also attenuated the aggregation and adhesion 
of platelets 58. so, thus offering two-way protection against platelet-induced 
vasoconstriction. 
Prostacyclin 
Also prostacyclin 60.61 is released by the vascular endothelium in response to a 
number of stimuli. Endothelial cells produce 10-20 times more prostacyclin than 
smooth muscle cells 62, but its production is not as confined to the endothelium, like in 
case of nitric oxide. Strictly speaking, prostacyclin is therefore not entirely an 
endothelium-derived relaxing factor. Prostacyclin is released by the endothelium in 
response to shear stress, hypoxia, and receptor-operated mechanisms. Receptor operated 
mechanisms include the release of prostacyclin in response to activation of receptors 
for acetylcholine, thrombin, and histamine (review, see Ref. 63). Prostacyclin may also 
be released under basal conditions and contributes to unstimulated va~omotor tone, and 
may induce relaxation via a cAMP-dependent mechanism 64 _ Prostacyclin may be 
released in response to platelet products like platelet-derived growth factor os, and 
inhibits both platelet adhesion and activation 61. Thus, prostacyclin is a physiologicai 
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antagonist of thromboxane A" both as an inhibitor of platelet aggregation and as a 
vasodilator. 
Endothelium-derived contracting factor 
Under celiain conditions the endothelium may release mediators that induce 01' 
augment contraction of the vascular smooth muscle. This suggestion was based on 
experiments in canine femoral alieries, in which removal of the endothelium reduced 
contractions evoked by potassium ". Several endothelium-derived mediators have been 
shown to modulate contractile responses of the underlying smooth muscle. 
First, it has been postulated that metabolites of arachidonic acid are involved in 
endothelium-dependent contractions. Indeed, arachidonic acid may induce contractions 
of canine veins, dependent on the presence of endothelium. These responses may be 
attenuated by inhibitors of cyclooxygenase 67. Secondly, it has been shown that anoxic 
conditions lead to augmented contractions to a number of stimuli. In a 'sandwich 
bioassay preparation' it was shown that the hypoxic endothelium dependent contractile 
factor may be delivered from an endothelium-intact donor-vessel to a coronal), artery 
strip without endothelium os. ". The exact nature of this hypoxic endothelium dependent 
contractile factor remains unknown. Thirdly, it has been shown that a 21 amino acid 
peptide is released upon endothelial stimulation using a variety of endogenous media-
tors, like thrombin, vasopressin, and angiotensin II 70. This peptide is endothelin (ET) 71, 
of which three endogenous isopeptides have been identified (ET-I, ET-2, and ET-3). 
Recent evidence suggests that endothelin plays a continuous role in the maintenance of 
blood pressure, not only as a tonic substance ", but possibly also as a dilator com-
pound 73. 
2.4 Synopsis: disturbed vasomotor tone 
The above has shown that vasodilatation and vasoconstriction both result from 
mechanisms within the vascular smooth muscle and the endothelium. These dilatory 
and contractile forces result in a balance, which, when disturbed, may be involved in 
various disease states. For instance, an increased endothelium-dependent dilatory 
response appears connected to endotoxin-induced septic shock ", whereas a dys-
functional endothelium may result in increased vasoconstrictor responses of the 
coronary arteries 75, 16, Moreover, diseased endothelium may result in increased aggre-
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gation of platelets at subendothelial collagen, and enhanced exposure of underlying 
smooth muscle to vasoconstrictor compounds. Thus, a disturbed balance may contribute 
to a variety of cardiovascular disorders, including cardiac ischemia. 
Alteration of the contraction-relaxation equilibriulII due to atherosclerosis 
It has now been established that atherosclerosis results in alteration of function of 
the endothelium. This endothelial disorder may be due to a reduction in the release of 
EDRF from endothelial cells. This was observed in functional studies measuring 
relaxation in human coronary mteries in vitro 77, and in vivo 78. In the human isolated 
coronary artery, both stimulated and basal release of nitric oxide were reduced 79. 
Shimokawa and co-workers 80 suggested that atherosclerosis-related impairment of 
endothelium-dependent relaxation is due to specific damage of a peltussis-toxin-
sensitive endothelial G, protein, connected to endothelial 5-HTI - and u,-receptors. In 
human coronary arteries, the small relaxant response to stimulation of endothelial 
muscarinic receptors was entirely abolished in atherosclerotic blood vessels, whereas 
the response to substance P, or calcium ionophore A23187, remained relatively 
intact ". This would suggest that atherosclerosis affects specific aspects of endothelium-
dependent relaxation. Lastly, evidence has been provided that EDRF impairs the release 
of the endothelium-derived contracting factor, endothelin 82. Hence, in atherosclerotic 
vessels with impaired EDRF release, the production of endothelin may well become 
enhanced. 
Whether formation of neointimal hyperplasia leads to an increased batTier of 
diffusion is yet unceltain. In the rabbit carotid artery, formation of intimal hyperplasia 
did not reduce endothelium-dependent relaxation ". Altematively, it has been hypothe-
sized that reduced smooth muscle sensitivity to EDRF, may be involved in the reduced 
responses to endothelium-dependent vasodilators. Vasodilatation by nitrovasodilators 
remained intact in perfused atherosclerotic rabbit carotid at1eries 84, and vasodilatation 
in atherosclerotic human isolated coronary arteries was decreased only in case of low 
concentrations of glyceryl trinitrate ". However, others have observed a clearly 
decreased sensitivity to the nitro vasodilators SIN-I and nitroglycerin, suggesting that 
the nitrovasodilator susceptibility of guanylate cyclase may be altered in athero-
sclerosis 85. 
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Figure 3. The balance between mediators of vasoralaxation and mediators of vasoconstriction. 
Mediators may be released by the endothelium or, for instance, by platelets which are 
activated upon exposure to subendothelial collagen. +, pro-aggregatory effect; -, anti-
aggregatory effect. 
There is still considerable debate whether alteration of responses is due solely to 
endothelial damage or whether hypercontractility of vascular smooth muscle could also 
contribute to the altered equilibrium. Fukai and colleagues 86 demonstrated that a 
segment of a porcine coronary atiery with denuded and regenerated endothelium 
exhibited both defective endothelium-dependent relaxation, and hypercontractility of 
vascular smooth muscle. However, they concluded that the main pOliion of the 
alteration of the response was due to enhanced smooth muscle reactivity. In another 
study, 5-HT and the thromboxane mimetic U466l9 produced a marked decrease in 
blood flow to the retina and choroid in atherosclerotic but not in normal monkeys 87. 
Although constrictor responses to serotonin are generally augmented following 
endothelial removal in healthy atieries 88, several studies have described that the 
constrictor response to U46619 is independent of the presence of endothelium ", 
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suggesting that smooth muscle hypercontractility played a role in the increased 
vasoconstrictor responses to U466l9 in atherosclerotic monkeys. Interestingly, smooth 
muscle hypercontractility, if existent, may not be an entirely non-specific phenomenon: 
Indeed, vasoconstrictor responses to angiotensin and (nor)adrenaline were not altered in 
atherosclerotic monkeys 90. Also atherosclerosis-related augmented contractile responses 
to ergonovine have been ascribed to smooth muscle hypersensitivity 91, and Chester and 
co-workers have described that the contractile response to the 5-HT1 receptor agonist 
sumatriptan is augmented in areas adjacent to the atherosclerotic lesion. The response 
to sumatriptan appeared independent of the presence of endothelium 92. 
Alteration of the cOl1h'action-relaxatioll equilibrium due to endothelial regeneration 
aj/er injwy 
After balloon catheter-induced injury of the endothelium, endothelial cells rapidly 
become involved in migration and replication 63, resulting in recovery of 
endothelium-dependent responses to e.g. bradykinin in denuded porcine coronary 
artery 93. However, the number of endothelial cells is increased foul' weeks after 
endothelial denudation, and the dilat01Y response to aggregating platelets is impaired ". 
Like in atherosclerotic blood vessels, the responses to 5-HT and the ex, receptor agonist 
UK 14304, are impaired, probably resulting from a defect in pertussis-toxin-sensitive 
G-proteins. Indeed, the response to e.g. calcium ionophore A23187 and, as mentioned, 
bradykinin retumed to similar levels as before endothelial denudation 80. In man, a 
more pronounced contractile response to 5-HT could be observed after coronaty 
angioplasty ". Recently, Shibano and Vanhoutte 96 have described that the decreased 
relaxation to 5-HT in coronaty at1eries previously denuded of the endothelium, was not 
observed in pigs treated with a 5-HT, receptor antagonist. The exact mechanism for 
this phenomenon remains unknown. Interestingly, Kalkman and co-workers have 
shown that the atherosclerosis related supersensitivity in rabbit a01ia is due to the 
unmasking of 5-HT, receptors ". 
Alteration of the contraction-relaxation equilibrium due to diet 
Despite an obvious correlation between hypercholesterolemia and atherosclerosis, 
there is evidence that diet itself may affect the contraction-relaxation equilibrium via 
other mechanisms. Specifically, it was shown that hypercholesterolemia may affect 
endothelium dependent relaxations, also in the absence of atherosclerosis 98,99, In 
particular oxidized low-density lipoproteins (ox-LDL) were shown to inhibit 
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endothelium-dependent relaxations, and may thus be involved in impaired relaxations 
in hypercholesterolemia 100. 101. Moreover, Boulanger and colleagues found that oxidized 
low-density lipoproteins induced the expression of preproendothelin mRNA 102. Lastly, 
Kaul and co-workers found that, compared to platelets obtained from normal indivi-
duals, vasodilator responses to platelets from hypercholesterolemic patients were 
profoundly impaired, and vasoconstrictor responses were enhanced IOJ. The latter 
phenomenon should be superimposed on an impaired dilatory endothelial function, 
possibly due to increased serum LDL levels and hypercholesterolemia. 
Alteration of the conh'action-relaxation equilibrium by physical stimuli 
A number of other factors may affect the contraction-relaxation equilibrium in the 
vascular smooth muscle wall. First, it has been shown that flow and shear stress can 
induce the release of EDRF, resulting in decreased resistance 10'. Flow-induced 
vasodilatation was decreased in atherosclerotic blood vessels 105. 106. Increased 
transmural pressure, however, results in the release of endothelium derived constricting 
factors (EDCF). Indeed the rapid increase of transmural pressure of an isolated canine 
carotid artery resulted in a contractile response. This pressure-induced increase of 
pressure is followed by a secondary increase of tension only in the presence of 
endothelium 107. The nature of the EDCF involved in pressure-induced vasoconstriction 
remains under debate 10.1, 
2.5 Objectives 
The objective of the studies described in this thesis was to investigate possible 
mechanisms involved in a disturbed equilibrium between relaxation and contraction in 
human isolated blood vessels. This was done in order to assist the development of 
novel drugs that may restore this balance, and also in order to understand and improve 
current drug treatment of ischemic heart disease. 
First, we set out to investigate the nature of the receptors involved in the contrac-
tile response to 5-hydroxyttyptamine (5-HT), using a series of selective 5-HT receptor 
agonists and antagoriists. We investigated 5-HT receptors involved in contractions of 
the human isolated saphenous vein (Chapter 4), and the human isolated coronary m1el)' 
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(Chapter 5). In both blood vessels we compared the fimctionally obtained affmity 
values of receptor agonists and antagonists to affinity values of these compounds for 
known 5-HT receptor subtypes, obtained in receptor binding assays. This was done to 
characterize the receptors mediating contraction as one or two of the known (Le. 
cloned) receptor subtypes. In the saphenous vein, we specifically investigated whether 
altered vascular architecture after being in use as a coronmy bypass graft for several 
years, would alter contractile responses to 5-HT receptor agonists. In the coronary 
miery, we specifically investigated whether the concentration of 5-HT which induces 
contraction, would affect the nature of the receptor subtype involved in the contractile 
response. The latter hypothesis and investigation could offer a possible explanation for 
the clinical ineffectiveness of the 5-HT, receptor antagonist ketanserin in disorders in 
which 5-HT-induced vasospasm is believed to playa role. 
In Chapter 6 we aimed at investigating the mediators involved in the contractile 
response of the human isolated coronaty artelY induced by activated platelets. This was 
done using receptor antagonist for thromboxane and 5-HT, both before and after the 
platelet-donors had taken low-dose aspirin, in order to understand and possibly improve 
this common form of treatment for patients with (un)stable angina and myocardial 
infarction. 
In Chapters 7 to 10, we set out to investigate endothelin receptors involved in 
contractile responses of the coronaty artelY and saphenous vein. First, we applied 
quantitative autoradiography to investigate the binding sites in human coronary atieries, 
using both [12SI]_ET_l and [125I]-sarafotoxin S6b as radioligands (Chapter 7). The 
involvement of functional correlates of the observed binding sites in contraction was 
subsequently investigated both in the human isolated saphenous vein (Chapter 8), and 
in the human isolated coronaty artery (Chapter 9). Because a number of observations 
had been made, that were difficult to interpret in terms of the thus far recognized 
receptors for endothelin, we inyestigated whether the type of preparation, or the 
removal of the endothelium, would affect our observations (Chapter 9). Lastly, we 
compared our results and those of other investigators to the existing endothelin receptor 
classification, in order to evaluate the possibility of additional endothelin receptor 
subtypes, and the general validity of the present classification (Chapter 10). 
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Throughout the study we attempted to relate contractile responses of various 
agonists, or platelets, to the functional capacity of the endothelium (measured as 
relaxation to substance P after precontraction with prostaglandin F,.), and to age of the 
coronary aI1ery donor. In Chapter 6, we histologically analyzed the vascular segments, 
used to obtain the control response to platelets, in order to relate this contractile 
response to microscopically observed signs of early atherosclerosis. 
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Chapter 3 
5-Hydroxytryptamine: 
An update on the receptor subtypes and their functional 
and therapeutical relevance in the cardiovascular system I 
3.1 The discovery and isolation of S-hydl'oxytryptamine (S-HT)' 
The vasoconstrictor propeliies of blood selUm had been known for over 75 years 
when serotonin was discovered, Ludwig and Schmidt repOlied as early as 1868 that 
perfusion with defibrinated blood increased vascular resistance in dog muscle', However, 
the underlying mechanism of vasoconstriction was disputed: some favoured involvement 
of adrenaline (epinephrine)', whereas others claimed that an unknown substance was 
released upon clotting of the blood', In 1911 and 1912, O'Connor showed that selUm 
constricted both the frog perfused vasculature and rabbit isolated intestines, whereas 
adrenaline caused constriction of the frog blood vessels, but dilatation of rabbit 
intestines 6, 7, This indicated that adrenaline was not the constricting factor in serum. The 
remaining confusion about the chemical propeliies of the compound was pOlirayed by 
Janeway and colleagues who summarized the available information in 1918 by saying that 
I!the substance is or is not dialysable, does or does not resist heat, if [a] protein, is or is 
not a globulin, [and] if a crystalloid, .. , is extracted by various solvents" '. Subsequently, 
Janeway and colleagues showed that the vasoconstrictor compound was localized in 
platelets and crystalloid in nature; the formation of the compound was dependent on the 
release from platelets, i11'espective of the formation of an actual clot. 
In the 19308, Erspamer and COM workers characterized a substance in rabbit stomach 
mucosa, which they called enteramine', They found this compound to be present 
particularly in enterochromaffin cells in the gastroinstestinal mucosa of many species. In 
an in vitro set-up, it stimulated intestinal strips and uterus, as well as molluscan heart. In 
1948, RappOli, Green and Page succeeded in isolating the vasoconstrictor compound in 
serum, and called it 'serotonin' 10, Soon after that, they concluded that the active structure 
I, For full drug names, see Ref. 30. 
2, Part of the cited papers were taken from Ref. J and Ref. 2. 
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was 5-hydroxytryptamine (5-HT), but they remained faithful to serotonin as a name 11. 
Around the same time, Erspamer and co-workers identified their enteramine as being 
similar to 5-HT or serotonin 12. The debate on whether the name 5-I-IT or serotonin should 
be used, has continued up to the present times. Bacq and colleagues (1951) stated that 
5-HT should be prefelTed since both enteramine and serotonin are incomplete indications 
of the locations where the substance can be found ". Despite this, the name serotonin has 
remained customary in the United States, where Page and RappOli had made their 
discoveries. Although perhaps somewhat inaccurate, the name serotonin was acknowledged 
to be more convenient and accessible when the 5-HT scientific community organized itself 
as the "Serotonin Club". 
3.2 The history of 5-HT receptor classification 
'M' and 'D j receptors 
Pharmacological investigations with respect to the functional receptors for 5-HT 
became possible after synthetic 5-HT had been made available 14. Gaddum and Picarelli 
observed that 5-HT-induced contractions of the guinea pig ileum could only patiially be 
blocked by morphine or dibenzyline (Le. phenoxybenzamine) I'. The combination of 
dibenzyline and morphine completely blocked the 5-HT-induced responses. In addition, 
they observed that 5-HT-induced responses in the morphine-pretreated intestine were 
completely blocked by LSD, 2-bromo-Iysergide or dihydroergotamine. However, 5-HT-
induced contraction of the dibenzyline-pretreated guinea-pig intestine was completely 
blocked by atropine and cocaine. Thus, Gaddum and Picarelli concluded that the effect of 
5-HT was likely to be mediated via two different receptor mechanisms. The first 5-HT 
receptor (M receptor, or morphine sensitive receptor) was located on the parasympathetic 
ganglion. Activation of this receptor 1V0uid lead to the release of acetylcholine, resulting 
in contraction. The second 5-HT receptor (D-rcceptor, or dibenzyline sensitive) lVas 
located on the smooth muscle. Activation of this receptor would result directly in 
contraction of smooth muscle cells 15, 
Towards the Bradley et al. classification 
Several observations were made that could not be classified as M- or D-receptol'-
mediated mechanisms. Mianserin, for instance, was a potent antagonist of S-HT-induced 
responses in vascular and non-vascular D-receptor preparations. However, miansel'in did 
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not attenuate the vasoconstrictor effect of 5-HT in the canine carotid vascular bed 16. The 
use of radioligands to label 5-HT receptors, resulted in rapid filliher advances towards a 
new receptor classification. Peroutka and Snyder observed distinct receptors in rat brain 
membranes, which had either high or low affinity for 5-HT. Only the 5-HT low-affinity 
site (5-HT,) had high affinity for spiperone, whereas both sites (5-HTI and 5-HT,) had 
high affinity for LSD. Affinities for 5-HT, sites correlated closely with previously 
obtained functional affinity parameters for 'D'-receptors. Data obtained with a steadily 
increasing amount of selective receptor agonists and antagonists resulted in the first 
consensus classification of 5-HT receptors by Bradley and colleagues in 1986 18 • 
Table 1. The Bradley et a!. criteria for the classification offullctional 5M HT receptors, as proposed 
in 1986 18• 
Proposed receptor Typical Response Selective Selective Binding 
nomenclature agonist antagonist site 
5-HTI-like Prejunctional inhibition of 5-CT Methiothepin 5-HT1 2 
neuronal transmitter release; Methysergide I 
smooth muscle relaxation, 
contraction of some smooth 
muscle preparations; tachy-
cardia ill the cat 
5-HT, gastrointestinal and vas- Ketanserin 5-HT, 
cular smooth muscle con- Cyproheptadine 
traction, platelet aggregation Methysergide 
neuronal depolarization 
5-HT, Depolarization of peri- 2-Methyl- MDL 72222 None 
pheral neurones 5-HT Tropisetron 
Cocaine 
I, Weak antagonist or partial agonist at some 5-HT1-like receptors; 2, Likely to be heterogeneolls 
in nature, 
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A novel subdivision was agreed upon, consisting of 5-HT,-like, 5-HT" and 5-HT, 
receptors (for criteria, see Table I). Radioligand binding resulted in a fmiher subdivision 
of 5-HT,-like receptors into 5-HT,A and 5-HT'B ", and later also 5-HT,c 20 and 5-HTID 
receptors ". An impOliant incentive for this development appeared to be the development 
of novel subtype selective compounds like the selective 5-HT'A receptor agonist, 
8-0H-DPAT ". 
A new ji'amewol'k resulting in a novel 5-HT receptor classification 
In 1985, it was repOlied that tachycardia in the pig after infusion of 5-HT was 
mediated via a receptor, which was not affected by antagonists for the a, B, H" H" 
5-HT,-like, 5-HT" or 5-HT, receptor. Thus, tachycardia in the pig appeared to mediated 
via a novel 5-HT receptor 23. 24. Dumuis and colleagues discovered a novel receptor in the 
mouse embryo colliculi neurones, positively coupled to adenylyl cyclase, which they 
tentatively called the 5-HT4 receptor". Subsequently, it was shown that the 5-I-IT-induced 
tachycardia in the pig 26 and positive inotropy in the human isolated atrium ", and the 
facilitation of peristalsis in the gastrointestinal tract of the guinea pig, were all mediated 
via the 5-HT4 receptor ". 
The early 1990's changed the emphasis from the fimcfiollol characterization of 
receptors to sfmc/urol characterization. The rapid development in molecular biology 
teclmiques resulted in the cloning of new genes encoding receptors of the 5-HT receptor 
family. On many occasions the function of a newly discovered receptor was unknown. 
This continuing advancement initiated the development of a new 5-HT receptor 
classification. In contrast to the early days when receptors could only be characterized 
from functional stimulation with almost non-selective agonists and antagonists, we were 
now often confronted with overwhelming information about the functional effects of many 
selective agonists and antagonists, the exact sequence of the gene encoding for the receptor 
protein, and about second messenger mechanisms. This large amount of information, taken 
together with the number of new receptors discovered, required rigorous classification 
criteria, which had previously been advocated 29 but were first adopted in the novel 
classification for 5-HT receptors. These tluee criteria are: i. operational «ant)agonist-
receptor interaction), ii. transductional (second messenger mechanisms), and iii. stmctural 
(gene and aminoacid sequence of the receptor peptide) (Table 2). Together, this body of 
information can provide a finger printing basis for the characterization of a certain 
receptor. To distinguish receptors that Illeet all criteria from those of which only a 
structure has been determined, lower case lettering is applied for the receptors that require 
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Table 2. Criteria for receptor characterization in general. Modified from Ref. 29~30. Definitive 
characterization of a receptor (resulting in upper case lettering) ideally requires clarification of all 
three criteria. 
Criterium 
1. Operational 
lao Selective agonists 
I b. Selective antagonists 
Definition of the criterium 
An agonist with i. high affinity and ii. selectivity relative to 
other receptors needs to be identified. 
An antagonist with i. high affinity and ii. selectivity relative 
to other receptors needs to be identified. 
I c. Ligand binding affinity Dissociation constants for a radioligalld should be identified, 
showing selective, high affinity binding to the receptor. 
2. Transductional Information should be obtained with respect to the 
3. Structural 
transductional mechanism, e.g. coupling to G-proteins or 
ligand-gated ion-channel: Families of receptors (Le. receptor-
types) are usually coupled to the same second messenger 
mechanism. 
Both the amino acid sequence and the nucleotide sequence 
encoding for the amino-acids should be identified. 
additional characterization. Upper case letters will be used when the missing characteri-
zation criteria will be fulfilled (for 5-HT receptor classification according to Hoyer and 
colleagues 30, see Table 3). 
When going over the general criteria for the classification of receptors (Table 2) and 
the 5-HT receptor classification (Ref. 30 and Table 3), a few points need special 
consideration. First, it can be seen that both 5-HT,-like receptors and 5-HT, receptors have 
been designated upper-case letters. One of the criteria (elucidation of the receptor 
structure) had however not been met at the time of publication, but the gene sequence and 
receptor structure of the 5-HT4 receptor have recently been disclosed 32. Moreover, there 
is some evidence to support the idea that 5-HT,-like receptors may be heterogeneous, or 
different in different blood vessels and species (see Table 4). 
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Table 3. The modem classification of 5-HT receptors: operational and transductional characteristics. Table adapted from Hoyer and colleagues 30. 
Data on the structure of the receptor subtypes were omitted. 
Receptor Subtype Location Response in Second Agonist Antagonist 
Type intact tissue/native cells Messenger 
5-HTj 5-HTjA Neuronal, CNS Neuronal hyperpola- Inhibition 8-0H-DPAT SDZ 216525 
zation, hypotension adenylyl cyclase buspiron WAY 100135 
5-CT methiothepin 
5-HTIB eNS and some peri- Inhibition of neuro- Inhibition CP 93.129 Cyanopindolol 
pheral nerves transmitter release adenylyl cyclase 5-CT SDZ 21009 
methiothepin 
5-HTIO Mainly CNS Inhibition of neuro- Inhibition Surnatriptan GR 127935 
transmitter release adenylyl cyclase L-694247, 5-CT metergoline 
methiothepin 
5-htjE CNS Not known Inhibition 5-HT None (methio-
adenylyl cyclase thepin weak) 
5-htlF CNS Not known Inhibition 5-HT None (methio-
adenylyl cyclase thepin weak) 
5-HTj-like Blood vessels Smooth muscle Inhibition Surnatriptan None (methio-
contraction adenylyl cyclase 5-CT thepin 
non-selective) 
5-HT, 5-HT2A 1 Vascular smooth Vasoconstriction, plate- Induction ino- a.-methyl-5-HT Ketanserin 
muscle, platelets, let aggregation, sitol phosphates DOl Ritanserin 
CNS, Ol-tract bronchoconsb1ction Pirenperone 
5-HT,. , Rat stomach fundus Stomach fundus Induction ino- ci-methyl-5-HT, SB 200646 
contraction sitol phosphates DOl 
5-HT2C 3 CNS Variety of effects Induction ino- a-methyl-5-HT Mesulergine 
in CNS (e.g. in sitol phosphates DOl Ritanserin 
choroid plexus) 
5-HT, Peripheral and Depolarization Cation channel 2-methyl-5-HT Ondansetron 
central neurones opening m-chloro- Tropisetron 
phenylbiguanide 
5-HT, GI-tract, CNS, Induction ACh4 release Induction Metoclopramide GR 113808 
heart, urinary in gut, tachycardia adenylyl cyclase renzapride SB 204070 
bladder (partial agonist) Tropisetron 
5-ht,A and 5-ht,. CNS Not known Not known 5-HT Methiothepin 
5-ht,; CNS Not known Induction 5-HT Methiothepin 
adenylyl cyclase 
in HEK293 cells 
5-ht, CNS Not known Induction 5-HT Methiothepin 
adenylyl cyclase 
in HeLa/COS cells 
1, previous name: 5-HT2;-2, previous name: 5-HT2B; 3, previous name: 5-HT16 4, ACh, Acetylcholine. 
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3.3 The effects of the endogenous ligand 5-HT on the cardiovascular system 
5-HT can be found in the central nervous system, where it acts as a neurotransmitter, 
and in several peripheral tissues, such as the gut and platelets in the blood. Most of the 
5-HT present in man is synthesized in the enterochromaffin cells in the gastrointestinal 
tract. Part of this is released into the portal circulation where a substantial fraction of that 
amount will be stored into platelets. Due to the effective clearance of 5-HT from the 
plasma by platelets, but pat1icularly by the liver and lungs, the plasma level of 5-HT in 
the systemic circulation remains extremely low (in nanomolar range) and it is not likely 
that such concentrations will affect the cardiovascular system (review. see Ref. 33). 
Or, as Erspamer put it in 1954 ": 
... We must not forget that to have an insignificant short-lived effect on arterial 
pressure in human beings at least 60 to 120 fIg of 5-HT injected intravenously are 
required, that is to sayan amount of substance equivalent to that contained in 1200 
to 2400 ml blood; that the sudden, massive release into the plasma of the entire 
platelet 5-HT of a dog (7.3 /lglkg) would cause nothing but an insignificant and brief 
pressure change; and that the subcutaneous injection, in both the dog and the rat, of 
quantities of 5-HT equivalent to the total content of the substance in the organism 
has no effect whatever on the blood pressure .... 
Thus, for 5-HT to playa role in the cardiovascular system, it should either act locally 
at sites where platelets aggregate and release 5-HT in sufficiently high concentrations, or 
it could playa role via its actions in the central nervous system. Although a tonic presence 
of 5-HT may play an insignificant role in pathology, this does not nIle out the potentially 
effective access of 5-HT receptors for pharmacological intervention with agonists. Indeed, 
intravenous administration of exogenous 5-HT induced a transient bradycardia and 
hypotension (Von Bezold-Jarisch reflex), followed by a pressor response, succeeded by 
a late, but lasting depressor response ". 
Cardiovascular efficts of 5-HT mediated via the central nervous system or peripheral 
neurons 
Pat1 of the above mentioned effects after Lv. administration of 5-HT resulted from 
activation of 5-HT receptors in the central nervous system and peripheral neurons. In 
palticular, the initial bradycardia resulted from stimulation of 5-HT, receptors on afferent 
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cardiac vagal nerve endings. Also the late depressor response may be mediated via an 
effect on neuronal 5R HT receptors. This response was insensitive to selective 5-HTz, or 
5-HT, receptor antagonists, but it was antagonized by the non-selective 5-HT,-receptor 
antagonists methysergide and methiothepin 35.36. Indeed the i.v. or i.c.v. infusion of 
agonists for the 5-HT'A receptor resulted in lowering of blood pressure via inhibition of 
sympatic tone 37, However, the nature and magnitUde of the response after intracerebral 
administration of the non-selective ligand 5-HT, depended largely on the exact site of 
application. Different 5-HT receptors in different sites of the brain can mediate either 
pressor 01' depressor responses (review, see Ref. 38). 5-HT may also have an effect on 
postganglionic sympatic neurones, where it may either inhibit the release of noradrenaline 
via a 5-HTID-like receptor (in the human saphenous vcin: Ref. 39), or induce a tyramine-
like effect leading to the release of noradrenaline 40. 
5-HT receptors alld myocardial cOlltractility 
After the discovery that 5-HT4 receptors mediated a positive chronotropic response 
in the anaesthetized pig 26, 42 as well as a positive inotropic response in the human isolated 
atrium 27, it was postulated that 5-HT, receptors may p1'Ovide a possible target for the 
treatment of heart failure 44. However, because a positive inotropic response was absent 
in both human and porcine isolated ventricular trabeculae, the possibility for such 
treatment wasviItually ruled out 45. 46. Recently, it was suggested that 5-HT4 receptors may 
playa 1'Ole in the precipitation of cardiac an'ythmia, and that antagonists at this receptor 
could serve as anti-anhythmic drug-treatment 47.48. "'. However, it should be noted that 
the ill vitro experiments, leading to this p1'Oposition, involved isolated atrial trabeculae 
paced at less than 1 Hz. The observed itl'egular contractile responses, although described 
as extrasystoles and ectopic tachycardia, may also be regarded as abnormal contractions 
with low contractile force related to a low stimulation frequency. The putative all'hythmias 
were p1'Ovoked by 5-HT and attenuated by 5-HT, receptor antagonists. Certainly, this 
interesting phenomenon appears mediated via 5-HT4 receptors. However, it is quite likely 
that the observations are not analogous to cardiac alThythmia, which involves a complex 
of spontaneous rhythmical discharge and conduction in the sino-atrial node and Purkinje 
fibres. All of these are virtually absent in stimulated isolated trabeculae. Therefore, there 
is yet little evidence that the 5-HT4 receptor is involved in arrhythmia. In particular, ill 
vivo animal studies or human clinical trials are necessmy to provide furdler clues about 
the use of 5-HT, receptor antagonists as a novel approach in anti-arrhythmic treatment. 
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5-HT receptors in blood vessels 
5-HT induced endothelium-dependent relaxation in porcine 49 and canine 50 coronary 
al1eries, In porcine coronary arteries, relaxation was shown to be mediated via 5-HT10-like 
receptors". Alteration of vascular architecture due to experimentally-induced 
atherosclerosis, or endothelial denudation after balloon angioplasty, were shown to result 
in altered responses to 5-HT, both in vivo and in vill'o. In vivo, endothelial denudation or 
diet-induced atherosclerosis resulted in increased vasocons.triction after infusion of 
5-HT 52. 53. In Vill'o, the 5-HT-induced relaxant response was attenuated after balloon 
denudation of the porcine coronary miefY 49, 54, 
5-HT, infused in the coronary at1ery of healthy humans, induced vasodilatation, 
which was potentiated by pretreatment with ketanserin, a 5-HT, receptor antagonist. In 
patients with Prinzmetal's angina pectoris or atherosclerotic coronaty at1ery disease, 
intracoronaty infusion of 5-HT induced constriction 55. so. This response lVas completely 
attenuated by ketanserin in proximal coronaty arteries, and pm1ially attenuated in distal 
coronary at1eries 51, Moreover, the constrictor response induced by 5-HT was more 
pronounced in coronary at1eries after a single percutaneous transluminal angioplasty 
(PTCA) 58. In human coronary at1eries ill vill'o, the contractile response mediated via 
5-HT,-like receptors was relatively more pronounced in the segment distal to an occluded 
coronary a11el), segment 59, Thus, also in man, the response to 5-HT may be altered in 
diseased blood vessels. It may be concluded that 5-HT induces vasodilatation of human 
corona,y arteries ill vivo via a ketanserin-insensitive (presumably 5-HT,) receptor. 
Moreover, 5-HT induces vasoconstriction via ketanserin-sensitive (5-HT,) receptors, as 
well as via a ketanserin-insensitive, sumatriptan sensitive (5-HT,) receptor. 
In addition to alteration of the response of the blood vessels to 5-HT, an increased 
5-HT plasma concentration was observed in patients with angina and complex coronal), 
artety lesions 60. Moreover, the coronary sinus plasma of patients with coronary at1ety 
stenosis, induced vasoconstriction of canine coronary artery rings, correlating with the 
extent and severity of coronary artery nan·owing. The coronary sinus plasma obtained from 
patients with normal coronaty arteries did not elicit a contractile response ". In another 
study, vasoconstriction developed after undergoing angioplasty, correlating significantly 
with the concentration of 5-HT measured in the coronary sinus plasma ". 
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Table 4. Examples of operational discrepancies ofa selection of vascular 5~HTID-like receptors. 
The differences may reflect different 5-HT1(Oflike receptors. Values between brackets refer to 
pA2/pKO values. Antagonists are tested against receptor agonists at 5-HTt -like receptors. 
Species Localization 
Dog Saphenous vein 64 
Rabbit Saphenolls vein 65,66 
Renal m1ery 67 
Guinea-pig Iliac artery 68 
Human Basilar at1ery 69 
Pial m1eriole 10 
Saphenous vein 71 
Agonist I Antagonist actions 
Methiothepin relatively potent (8.3-8.6) 
Metergoline relatively weak (6.4) 
Rauwolscine inactive (1 ~M) 
Ketanserin inactive (I JtM) 
Methiothepin relatively potent (9.5 65; 8.3 66) 
Cyanopindolol inactive (I ~M) 66 
Ketanserin active (7.5 66; ±6.7 65) 
Ketanserin active (6.6) 
Methiothepin relatively potent (8.6) 
Metergoline inactive (O.! ~M) 
Cyanopindolol and metergoline 
low affinity agonists: pD2 6.0 and 5.8, resp. 
As antagonist: l11etergoline relatively weak (7.0) 
Ketanserin active (6.2) 
Methiothepin relatively potent (8.4) 
Methiothepin potent (8.8) 
Ketanserin and cyanopindolol inactive (0.1 ~M) 
Methiothepin relatively potent (8.6*) 
Metel'goline relatively weak (6.9*) 
Ketanserin inactive (l J..lM) 
Ketanserin inactive (I ~M) 
Metel'goline relatively potent (6.9-7.3) 
Cyanopindolol (6.5) & ranwolscine (6.7) active 
Methiothepin relatively weak (7.1-7.9) 
>1<, Slope of the regression line in the SchildMplot differed significantly from unity. 
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Contl'action of vascular smooth muscle is often mediated by 5-RT, receptors, except 
in the cranial vasculature, where 5-RT,-like receptors are involved ". Rowever, this 
concept of peripheral 5-RT, receptor-mediated vasoconstriction vs. cranial 5-RT,-like 
receptor-mediated vasoconstriction did not entirely apply to the human vasculature. Only 
the human femoral vein 74 contracted solely via 5-HT, receptors. 5-RT,-like receptors 
played an additional role in the 5-RT-induced contractile response of other investigated 
human blood vessels. 
The nature of the 5-HT,-like receptor is still under considerable debate. Recent 
evidence suggests that 5-RTlDu 75 or 5-RT1D3 16. 17 receptors may be present in the coronary 
artelY of dogs and man, respectively. Also in pial arterioles it was suggested that the 
receptor mediating contraction is similar to the 5-RTlD3 receptor 72. However, it should be 
emphasized that no selective ligands with high affinity are available. Both in the canine 
coronmy 8lielY and in the pial alieriole the receptor was shown via PCR, which supported 
the presence of mRNA for the respective receptors but provided no evidence on their 
involvement in the contractile responses to 5-RT. In addition, there is evidence to suppOli 
heterogeneity of 5-RT, receptors that mediate the contractile response to 5-RT. For 
instance, the potency of methiothepin as compm'ed to metergoline as antagonists against 
5-HT, receptor agonism, as well as the potency of ketanserin and cyanopindolol may vmy 
considerably. Discrepancies exist both between the vascular beds within species, as well 
as between species (Table 4). 
3.4 Therapeutic applications for 5-RT receptor ligands in the cardiovascular system 
Hyper/ens/oil 
Inhibition of peripheral 5-RT receptors has been suggested as a mode of treatment 
of hypeliension, and ketanserin is marketed as an antihypertensive dmg with 5-RT, 
receptor antagonistic effects. Several lines of evidence dispute this mechanism of action 
of ketanserin. First, it should be remembered that endogenous 5-RT exists in the plasma 
at clearly lower concentrations than needed to evoke generalized pressor responses ". High 
levels may be reached locally, following platelet aggregation, but this remains insufficient 
to evoke systemic responses, albeit that local vasospasm may occur. Secondly, it was 
shown that ritanserin -also a 5-HT, receptor antagonist, but devoid of the a-adl'enoceptor 
antagonist effect of ketanserin- did not decrease blood pressure 78, 79. Thus, it was 
concluded that mainly the a-adrenergic receptor antagonism was responsible for the 
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antihypertensive effect. In addition, it was suggested that central 5-HT, receptors may play 
a role in the anti-hypel1ensive effects of ketanserin 80. 81, but the significance of this 
phenomenon in hypel1ensive individuals remains unclear. 
Urapidil is marketed as antihypel1ensive drug with u 1 receptor antagonist effects ". 
However, urapidil also displayed antihypel1ensive activity when administered centrally. It 
was established in animal experiments that this was mediated via central 5-HT1A receptors 
for which urapidil has substantial affinity. The precise relevance of the 5-HTIA receptor 
agonism in the hypotensive effect in man is yet unclear, but treatment with urapidil was 
devoid of reflex tachycardia, which may be due to urapidil's effect on central 5-HT1A 
receptors, resulting in sympathoinhibition ". 
Flesinoxan is a 5-HT1A receptor agonist without u-adrenoceptor antagonist activity. 
Based on subchronical studies in spontaneously hypel1ensive rats, 5-HT1A receptor-
mediated sympathoinhibition in the central nervous system was believed to be an 
interesting alternative approach in the treatment of hypertension 31. ". However, despite 
promising results with single doses of flesinoxan in patients with mild hype,1ension ", 
patients developed tolerance to the antihypel1ensive effect of flesinoxan during a double 
blind placebo-controlled clinical trial 37. Flesinoxan is presently under investigation for the 
treatment of anxiety, depression, or obsessive compulsive disorders. 
Migraine 
Considerable debate stin exists on the pathophysiological mechanism of migraine, and 
on the mode of action of anti-migraine drugs. Some researchers advocate the assumption 
that migrainous pain is induced by pUlsations in dilated cranial blood vessels, caused by 
yet unknown migraine triggers. This theOlY proposes that anti-migraine drugs like 
sumatriptan constrict the cranial blood vessels to normal diameter and pulsation, thereby 
alleviating pain 86-". Others support the notion that yet unknown triggers of migraine 
induce neurogenic-inflammation. These triggers result in the release of a number of 
mediators (presumably vasoactive neuropeptides like CORP and perhaps substance P), 
which increase vascular permeability, leading to vasodilatation and stimulation of sensOlY 
nerve fibers. Anti-migraine drugs, like sumatriptan, suppress the migraine attack by 
activating presynaptic 5-HT,-like receptors, resulting in a decreased release of the 
inflammatory peptides, a reduced vascular permeability and vascular diameter, which 
would lead to cessation of pain ". It is not unlikely that both theories may ultimately prove 
to be correct. However, from a drug developer's point of view, it is extremely important 
to establish the precise nature of mechanisms and receptor subtypes involved in both 
theories. It may become possible to develop compounds selective for presynaptic 5-HT,-
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like receptors that do not induce constriction of blood vessels. Although it is not certain 
that such 'anti-neurogenic-intlammation drugs' would be sufficiently effective in the 
treatment of migraine, they may prove to be devoid of the vasoconstrictor side effects of 
the current generation of anti-migraine drugs. Indeed, sumatriptan as well as ergotamine 
and dihydroergotamine (DHE) cause coronary vasocollstriction and cm'diac ischemia in 
some patients 90.92. 
Restenosis following percutaneous trans/umina/ angiop/asty (PTCA) 
Although PTCA is a relatively safe and effective treatment for luminal occlusion of 
the coronary mieries, recurrence of stenosis (restenosis) occurs in 20-40% of patients 93. 
Restenosis following PTCA should be divided into acute restenosis (Le. within 24 hours 
after the procedure) and chronic restenosis (Le. peak at 6-8 weeks, up to 6 months) ". ". 
Acute restenosis occun'ed in 2-11 % of patients undergoing PTCA and was the main cause 
of in-hospital morbidity and mOltality ". Balloon angioplasty may lead to impaired 
endothelium- dependent relaxation in response to administration of S-HT in the porcine 
isolated coronary miery 49, whereas in man the contractile response to exogenously 
administered S-HT was increased ". It was also shown that endogenous S-HT was released 
into the coronalY circulation during angioplasty, which may contribute to the 
vasoconstriction in segments distal to the site of dilatation, observed immediately after 
angioplasty. FUlthermore, it was shown that this post-angioplasty vasoconstriction could 
be attenuated by ketanserin 6'. Indeed, ketanserin reduced the fi'equency of early 
restenosis ". S-HT was also shown to induce the mitogenesis of vasculm' smooth muscle 
cells in vitro ", which could be attenuated by ketanserin, indicating involvement of S-HT, 
receptors ". However, ketanserin was ineffective in the prevention of clu'onic 
restenosis 96. ", and it may therefore be speculated that in vivo the S-I-IT, receptor 
contributes only little to the complex process ofneointima formation. Interestingly, 10 flM 
ketanserin did not completely block S-I-IT-induced vascular smooth muscle proliferation 
in vitro ", and S-I-ITID-like receptors have been suggested to be involved in the mitogenic 
effects of S-HT as well 100. Recently, S-I-ITID receptors were shown to be involved in cell 
proliferation in human small cell lung carcinoma 101. FUl1her studies are required to 
establish the potential for a mixed S-I-ITID-like / S-I-IT, receptor antagonist against early 
and late restenosis after PTCA. 
68 
Chapter 3 
Vasospasm 
Clinical trials have been conducted to investigate the efficacy of 5-HT receptor 
antagonists in diseases involving peripheral vasospasm. Atherosclerosis 10' and endothelial 
damage ", as well as potentiation by alternative vasoconstrictor compounds 103, and 
enhanced activation of platelets 104 may all result in abnormal vasoconstriction induced by 
5-HT released from aggregating platelets. In addition, coronary artery disease is known 
to be associated with increased levels of serum 5-HT 60. ". Therefore, it was rather 
disappointing that no beneficial results of treatment with ketanserin were observed in five 
patients with Prinzmetal's angina lOS. 
5-HT has also been implicated in the pathophysiology of Raynaud's phenomenon, 
which is a syndrome of cold- or stress-induced vasospasm in digits, resulting in local 
hypoxia and paleness 106. 5-HT induced potent vasoconstriction of digital vasculature 107. lOS, 
and platelet aggregation may be accelerated in patients with Raynaud's phenomenon 109. 
Indeed, ketanserin has sometimes been shown to be effective in treating Raynaud's 
phenomenon 110, III, but like in hypertension, its mechanism of action via S-HT2 receptors 
was questioned II'. A recent study observed no alterations in plasma levels of 5-HT, even 
during vasospastic attacks Ill, and it is quite likely that the beneficial effects ofketanserin 
in Raynaud's phenomenon can be attributed to the a-antagonist activity of the com-
pound ". 
3.5 Conclusions 
The field of 5-HT receptors, and the role in cardiovascular and non-cardiovascular 
diseases has seen tremendous developments over recent years. In particular the area of 
5-HT receptor classification has developed itself as an example for the classification of 
receptors of other endogenous mediators. Also the progress in the understanding and 
treatment of migraine (selective 5-HTID-like receptoragonists), chemostatic-induced nausea 
(5-HT, receptor antagonists), and a variety of psychiatric disorders (depression, anxiety, 
obsessive compulsive disorder: 5-HT
'A receptor agonists; 5-HTuptake inhibitors), has been 
impressive, and is still in full swing. 
In cardiovascular disorders, in which a pathophysiological tone of 5-HT was believed 
to play a role (like hypertension, restenosis and vasospastic angina), 5-HT receptor 
antagonists have thus far not been proven very effective. This could be due to 
overestimation of the relative involvement of 5-HT in the disease.' Indeed, the renin-
angiotensin system and cathecholamines appeal' to playa more significant role, as can be 
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judged from the clinical efficacy of inhibitors of these endogenous compounds. Also in 
the chronic development of restenosis, growth factors like platelet-derived growth factor 
and endothelins could playa more significant role than 5-HT. However, it must be kept 
in mind that the 5-HT receptor antagonist used in clinical trials, was an antagonist 
selective for 5-HT, receptors. Thus, the effect at other 5-HT receptors was preserved, and 
this may be of significance when considering additional involvement of a 5-HT,-like 
receptor in vascular constriction, and perhaps also in vascular smooth muscle mitogenesis. 
3.6 References 
I. Page, I.H. (1954) Serotonin (5-Hydroxytryptamine). Physiol. Rev. 34,563-588. 
2. Saxena, P.R. (1992) Historical aspects of 5-hydroxytryptamine: discovery and receptor 
classification, In: Saxena, P.R. and Olesen, J., eds.} 5-Hydroxybypfamine mechanisms in primary 
headaches. Raven Press, New York, pp 3-18. 
3. Ludwig, C. and Schmidt, A. (1868) Das verhalten def Gase welche mit dem Blut durch den 
reizbaren Saugethiermuskel str(jmen. Arb. a.d. physiol. Ans/alt. z. Leipzig 3, I. 
4. Broking, E. and Trendelenberg, P. (1911) Adrenalinnachioes und Adrenalingehalt des 
menschlichen Blutes. DIsch. Arch. KIi11. Mecl 103, 168~ 187. 
5. Brodie, T.O. (1903) The perfusion of surviving organs. J. Physiol. (Londoll) 29, 266-275. 
6. O'Connor, J.M. (l912) Adrenalingehait des Blutes. Arch ! expel'. Palh II. Pharmakol. 67, 195. 
7. O'Connor, J.M. (1911) Adrenalin bestimnHlIlg in Blut. Miinchell med. WcJmschr. 58, 1439. 
8. Janeway T.C., Richardson H.B. and Park, E.A. (1918) Experiments on the vasoconstrictor action 
of blood semm. Arch 1111. Med. 21,265-603. 
9. Vialli, M. and Erspamer. V. (1933) Cellule Enterochromaffin e cellule basigranulose acidofile 
nei vertebrati. Zlschr. Zellforsch 1I. mikr. Anal. 19,743. 
10. Rapport, M.M., Green, A.A. and Page, I.H. (1948) Crystalline serotonin. Science 108, 329. 
It. Rapport, M.M. (1949) Serum vasoconstrictor (serotonin) V. The presence of creatinine in the 
complex. A proposed structure of the vasoconstrictor principle. J. BioI. Chem. 180, 961-969 
12. Erspamer, V. and Asero, B. (1952) Identification of enteramille, the specific hormone of the 
enterochromaffin cell system, as 5-hydroxytryptamine. Nalure 169, 800-801. 
13. Bacq. Z.M., Fischer, P. and Ghiretti, Fr. (1951) Action de la 5-hydl'oxytryptamine chez les 
cephalopodes. Arch 1111. Physiol. 59, 165-171. 
14. Hamlin, KE. and Fisher, F.E. (1951) Synthesis of 5-hydroxytryptamine. J. Am. Chem. Soc. 73, 
5007. 
15. Gaddulll, J.H. and Picarelli, Z.P. (1957) Two kinds of tryptamine receptor. Er. J. Pharmacal. 
12, 323-328. 
70 
Chapter 3 
16. Saxena, P.R., Van Houwelingen, P. and Bonta I.L. (1971) The effects of mianserin 
hydrochloride on the vascular responses avoked by 5-hydroxytryptamine and related vasoactive 
substances. EliI'. J. Pharmacal. 13,295-305. 
17. Peroutka, SJ. and Snyder, S.H. (1979) Multiple serotonin receptors: differential binding of eH5-
Hydroxytryptamine, {3H]Lysergic acid diethylamide and eHJspipero1. Mol. Pharmacal. 16,687-
699. 
18. Bradley, P.B., Engel, G., FClliuk, W., Fozard, J.R., Humphrey, P,P.A., Middlemiss, D.N., 
Mylecharane, EJ., Richardson, B.P. and Saxena, P.R. (1986) Proposals for the classification and 
nomenclature offunctional receptors for 5-hydroxytryptamine. Nelffopharmacology25, 563-576. 
19. Pedigo, B.W., Yamamura, HI and Nelson, DL (1981) Discrimination of multiple serotonin 
binding sites by the neuroleptic spiperone in rat brain, J. Nellf'Ochem, 36, 220-226, 
20. Pazos, A, Hoyer, D. and Palacios, J.M. (1984) The binding of serotonergic ligands to the 
porcine choroid plexus: characterization of a new type of serotonin recognition site. Ew'. J. 
Pharmacal. 106,539-547. 
21. Heuring, R.E. and Peroutka, SJ. (1987) Characterization of a novel 3H-5-hydroxytryptamine 
binding site subtype in in bovine brain membranes. J. Nellrosci. 7, 894-903. 
22. Middlemiss. D.N. and Fozard. l.R. (1983) 8-Hydroxy-2-(di-n-propyl-amino)-tetralin 
discriminates between subtypes of the 5-HTJ recogntion site. Ellr. J. Pharmacol. 90, 151-153. 
23. Duncker, DJ., Saxena, P.R. and Verdouw, P.D. (1985) 5-Hydroxytlyptamine causes tachycardia 
in pigs by acting 011 receptors unrelated to 5-HTJ• 5-HT2 or M type. Br. J. Pharmacol. 86, 596P 
(abstract). 
24. Bom, AH., Duncker, DJ., Saxena, P.R. and Verdouw, P.O. (1988) 5-HT-indllced tachycardia 
in the pig: possible involvement ofa new type of 5-HT receptor. Br. J. Pharmacol. 93, 663-671. 
25. DUlllUis, A., Bouhelal, R, Sebben, M, and Bockaert, J. (1988) A 5-HT receptor in the central 
nervolls system, positively coupled with adenyl cyclase, is antagonized by ICS 205-930. EliI'. 
J. Pharmacal. 146, 187-188. 
26. Villal6n, C.M" Den Boer, M.O., Heiligers, J.P.C. and Saxena, P.R. (1990) Mediation of 
5-hydroxytryptamille-indllced tachycardia in the pig by the putative 5-HT4 receptor. EI'. J. 
Pharmacal. 100,665-668. 
27. Kaumann, AJ., Sanders, L., Brown, AM., Murray, KJ. and Brown, M,J. (1990) A 
5-hydroxytryptamine receptor in human atrium. BI'. J. Pharmacal. 100, 879-885. 
28. Clarke, D,E. and Bockaert, J. (1993) 5-HT4 receptor: current status. In: Vanhoutte, P,M., Saxena, 
P.R., Paoletti, R" Bnll1ello, N, and Jackson, AS" eds. Serolonin, from cell biology 10 
pharmacology and therapeutics. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 
107-117. 
29. Kenakil1, T,P., Bond, R.A and Bonner, T.I. (1992) Definition of phannacological receptors. 
Pharmacal. Rev. 44,351-362. 
71 
5-Hydroxyllypfamine 
30. Hoyer, D" Clarke, D.E., FOZ<1rd, J,R., Hartig, P.R .• Martin, a.R., Mylecharane, EJ., Saxena, 
P.R, and Humphrey, P,P,A. (1994) International Union of Pharmacology Classification of 
receptors for 5-Hydroxytlyptamillc (Serotonin), Pharmacal. Rev. 46, 157-203. 
31. Humphrey, P,P,A., Hartig, P. and Hoyer, D. (1993) A proposed new nomenclature for 5-HT 
receptors. Tr. Pharmacal. Sci. 14,233-236. 
32, Adham, N., Gerald, C., Vayssc, P,l-J., Weinshank, RL. and Branchek, T.A. (1995) 
Characterization of the fUllctional responses mediated by two splice variants of the cloned rat 
5-HT4 receptor in heterologous expression systems. Er. 1. Pharacol. (in press, abstract). 
33. Van Zwietcn, P.A., Blauw, OJ. and Van Bnnllmclen, P. (1990) Pathophysiological and 
phannacotherapeutic aspects of serotonin and serotonergic drugs. Clin. Physiol. Biochem. 
8(Suppl. 3), 1-18. 
34. Erspamer, V. (1954) Pharmacology of indolealkylamines. Pharmacol. Rev. 6,425 M 487. 
35. Kalkman, RD., Engel, G. and Hoyer, D. (1984) Three distinct types of serotonergic receptors 
mediate the triphasic blood pressure response to serotonin in rats. J. H)pertensiol1 6(SUPI)I. 2), 
S421-5428. 
36. Dalton, D.W., Feniuk, W. and Humphrey, P.P.A. (1986) An investigation into the mechanisms 
of the cardiovascular effects of 5~hydroxyhyptamine in concious nonllotensive and DOCA-salt 
hypertensive rats. J. AU/Ollom. Pharmacol. 6,219-228. 
37. Dreteler, G.H. (1991) The role of the 5-HT1A receptor in central cardiovascular regulation. Ph.D. 
Thesis, Erasmus University Rotterdam, The Netherlands. 
38. Mir, A.K. and Fouud, lR. (1990) 5-Hydroxytryptamine in central cardiovascular regulation. In: 
Saxena, P.R., Wallis, D.I., Wouters, W. and Bevan, P., eds. Cardiovascular Pharmacology of 
5M HydrO,\yflyptamil1e: Prospective Therapeutic Applications. Dordrecht Kluwer Academic 
Puplishers, pp 247-258. 
39. Molderings, G.J., Werner, K, Likungu, J. and Gothert, M. (1990) Inhibition of noradrenaline 
release from the sympathetic nerves of the human saphenous vein via presynaptic 5-HT receptors 
similar to the 5-HTm subtype. Naunyn-Schmiedeberg's Arch. Phamracol. 342,371-377. 
40. McGrath, M.A. (1977) 5M Hydroxytryptamille and neurotransmitter release in canine blood 
vessels, inhibition by low and augmentation by high concentrations. Circ. Res. 41, 428 M 435. 
42. Villal6n, C.M., Den Boer, M.O., Heiligers, lP.C. and Saxena, P.R. (1991) Further characterizM 
atioll, using tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating 
tachycardia in the pig. Br. J. Pharmacal. 102, lO7-112. 
44. Saxena, P.R. and Villal6n, C.M. (1991) 5-Hydroxytryptamine, a chameleon in the heart. Trends 
Pharmacol. Sci. 12,223-227. 
45. Schoemaker, R.G., Du, x.y., Bax, W.A., Bos, E. and Saxena, P.R. (1992) 5~l-Iydroxytryptamine 
stimulates human isolated atrium but not ventricle. EliI'. J. Pharmacol. 230, 103-lO5. 
46. Schoemaker. R.O .• Du. X.Y .• Bax. W.A. aud Saxeua. P.R. (1992) 5-Hydroxytryptamiue 
increases contractile force in porcine right atrium but not in left ventricle. Naun)'n 
Schmiedeberg's Arch. Pharmacol. 346, 486~489. 
72 
Chapter 3 
47. Kaumauu, A.J. and Sanders, L. (1993) 5~Hydroxytryptamil1e causes arrhythmias in isolated 
human atrium. Dr. 1. Pharmacol, 108, 24SP (abstract), 
48. Kaumallll, A,J. and Sanders, L. (1994) 5-Hydroxytryptamine causes rate-dependent arrhythmias 
through 5-HT4 receptors in human atrium: facilitation by chronic fi-adrenoceptor blockade. 
Nat/llyn Schmiedeberg's Arch. Pharmacol, 349,331-337. 
48a. Kaumann, AJ. (1994) Do human atrial 5-HT4 receptors mediate arrhytmias? Trends Pharmacal. 
Sci. 15,451-455. 
49. Shimokawa, H., Aarhus, L.L. and Vanhoutte, P.M. (1987) Porcine coronary arteries with 
regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating 
platelets and serotonin. eire. Res. 61,256-270. 
50. Cohen, R.A, Shepherd, J.T. and Vanhoutte, P,M. (1983) 5-Hydroxytryptamine can mediate 
endothelium-dependent relaxation of coronary arteries. Am. J. Physio/, 245, HI077-HI080. 
51. Schoeffler, P. and Hoyer, D. (1990) 5-Hydroxytryptamine (5-HT)-illduced elldothelium-
dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 
5-HTID receptor subtype. J. Pharmacal. E.,p. Ther. 25,387-395. 
52. Fukai, T., Egashira, K., Hata, H., Numaguchi, K., Ohara, Y., Takahashi, T" Tomoike, H. and 
Takeshita, A (1993) Serotonin-induced coronary spasm in a swine model; A minor role of 
defective endothelium-derived relaxing factor. Circulation 88, 1922-1930. 
53. Lopez, J.A.G" Armstrong, M.L., Piegors, OJ. and Heistad, D.D. (1989) Effect of early and 
advanced atherosclerosis on vascular responses to serotonin, thromboxane A2, and ADP. 
Circlilation79, 116-124. 
54. Shibano, T. and Vanhoutte, P,M. (1994) Involvement of 5-HT2 receptors in chronic endothelial 
dysfunction after balloon injury of porcine coronary 311eries. Circulation 89, 1776-1785. 
55. Golino, P., Piscione, F., Willerson, 1T., Capelli-Bigazzi, M., Focaccio, A, Villari, B., IndoIfi, 
G., Russolillo, E., Condorelli, M. and Chiariello, M. (1991) Divergent effects of serotonin on 
coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control 
patients. New Engl. J. Med. 324, 641-645. 
56. McFadden, E.P., Clarke, J.O., Davies, OJ., Kaski, J.C., Haider A.W., and Maseri, A. (1991) 
Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients 
with variant angina. New Engl. J. Med. 324, 648-654. 
57. McFadden, E.P., Bauters, C., Lablanche, 1M., Leroy, F., Clarke, J.G., Henry, M., Schandrin, 
C., Davies, GJ., Maseri, A. and Bertrand, M.E. (1992) Effect of ketanserin on proximal and 
distal coronary constrictor responses to intracorollaJ), infusion of serotonin in patients with stable 
angina, patients with variant angina, and control patients. Circulation 86, 187-195. 
58. McFadden, E.P., Bauters, C" Lablanche, J.-M" Quandalle, P., Leroy, F. and Bertrand, M,E. 
(1993) Response of human coronary arteries to serotonin after injury by coronary angioplasty. 
Circulation 88, 2076-2085. 
73 
5-Hydroxylryplamine 
59. Chester, A.I-I., Martin, O.R., Bodelssoll, M., Ameklo-Nobin, B., Tadjkarimi, S" Tornebrandt, 
K. and Yacoub, M.H. (1990) S·Hydroxytryptamil1c receptor profile in healthy and diseased 
human epicardial coronary arteries. Cardiovasc. Res. 24,932·937. 
60. Van den Berg, EX., Schmitz, lM., Benedict, C.R., Malloy, C.R., Willerson, J,T. and Dehmer, 
OJ. (1989) Transcardiac serotonin concentration is increasing in selected patients with limiting 
angina and complex coronary morphology. CirclIlatio1l79, 116-124. 
61. Rubanyi, G,M., Frye, R,L., Holmes, n.R. and Vanhoutte, P.M. (1987) Vasoconstrictor activity 
of coronary sinus plasma from patients with coronary artery disease. J. Am. Coil. Cardial. 9, 
1243-1249. 
62. Oolino, P., Piscione, F" Benedict, C,R" Anderson, H,V., Cappelli-Bigazzi, M" Indolfi, C., 
Condorelli, M., Chiariello, M., and Willerson, J.T. (1994) Local effect of serotonin released 
duriug corouary angioplasty. N Engl. J. Med 330, 523-528. 
63, Connor, H.E., Humphrey, P.P.A. and Feniuk, W. (1991) Serotonin receptors, therapeutic 
prospects in cardiovascular disease. Trends Cardiovasc. Med. 1,205-210. 
64. Perren, MJ., Felliuk, W. and HlIlllpphrey, P.P.A (1989) Vascular 5-HT,-like receptors that 
mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in 
anaethetized dogs are not of the 5-HT'A or 5-HTID subtype. BI'. J. Pharmacol. 102, 191-197. 
65. Martin, G.R. and MacLennan, SJ. (1990) Analysis of the 5-HT receptor in rabbit saphenous 
vein exemplifies the problem of using exclusion criteria for receptor classification. NaunYll 
Schmiedeberg's Arch. Pharmacal. 342, 111-119. 
66. Van Heuven-Nolseu, D., Thijsse Klasen, T.H.M., Luo, Q. and Saxena, P.R. (1990) 5-HT,-like 
receptors mediate contractions of the rabbit saphenous vein. Eul'. J. Phannacol 191, 375-382. 
67, Tadipatri, S., Van Heuven-Nolsen, D., Feniuk, W. and Saxena, P.R. (1991) Analysis of the 5-HT 
receptors mediating contractions in the rabbit isolated renal artery. BI'. J. Pharmacol. 104,887-
894. 
68. Schoeffier P. and Sahin-Erdemli, I. (1992) Further characterization ofyhe 5-hydroxytryptamine 
5-HT\-like receptor mediating contraction of guinea-pig iliac artery. Eur. J. Pharmacol. 219, 
295-301. 
69. Parsolls, AA, Whalley, E.T., Feniuk, \V., Connor, H.E. and Humphrey, P.P.A. (1989) 
5-HT,-like receptors mediate 5-hydroxyt\yptamine-induced contraction of human isolated basilar 
artery. Br. J. Pharmacol. 96, 434-440. 
70. Hamel, E. and Bouchard, D. (1991) Contractile 5-HT,-like receptors in human isolated pial 
arterioles: correlation with 5-HTID binding sites. Br. J. Pharmacol. 102,227-233. 
71. Bax, \V.A., Van Heuven~Nolsen, D., Bos, E., Simoons, M.L. and Saxena, P.R. (1992) 
5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement 
of 5-HTz and 5-HTID-like receptors, and a comparison with grafted veins. Natmyn-
Schmiedeberg's Arch. Pharmacol. 345, 500~508. 
74 
Chapter 3 
72, Hamel, E., Fan, E., Linville, D., Ting, V., Villemure, J.-O. and Chia, L.-S. (1993) Expression 
of mRNA for serotonin S-hydroxytryptamil1c
'
Dll receptor subtype in human and bovine cerebral 
arteries. Mol. Pharmacol. 44, 242-246. 
74. Glusa, E. and Milller-Schweinitzer, E. (1993) Heterogeneity of S-HT receptor subtypes in 
isolated human femoral and saphenous veins. Naullyn-Schmiedeberg's Arch. Pharmacal. 347, 
133-136. 
75. Cushing, DJ., Baez, M., KUfsar, D., Schenck, K. and Cohen, M.L. (1994) Serotonin-induced 
contraction in canine coronary artery and saphenous vein: role of a 5-HTm-like receptor. Life 
Sci. 54, 1671-1680. 
76. Kaumann, AJ., Parsons, A.A. and Brown, A.M. (1993) Human arterial constrictor serotonin 
receptors. Cardiovasc. Res. 27,2094-2103. 
77. Kaumann, A.1., Frenken, M., Posival, H. and Brown. A.M. (1994) Variable participation of 5-
HT)-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated 
coronary arteries. Circulation 90, 1141-1153. 
78. Hosie, 1., Stott, OJ., Robertson. 1.I.S., and Ball, 8.G. (1987) Does acute serotonergic type-2 
antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and 
ketanserin in essential hypertension. J. Cardiovasc. Pharmacol. 10[Supp1.3), S86-S88. 
79. Blauw, G.J., Van Bnlmmelen, P., Chang, P.C., Vemleij, P., Van Zwieten, P.A. (1988) Regional 
vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension 11, 256-
263. 
80. McCall, R.B. and Schuette, M.R. (1984) Evidence for an alpha-l receptor-mediated central 
sympathoinhibitory action of ketanserin. J. Pharmacol. Exp. Ther. 228, 704-710. 
81. McCall, R.B. and Clement, M,E. (1994) Role of serotollin lA and serotonin2 receptors in the 
central regulation of the cardiovascular system. Pharmacol. Rev. 46, 231-243. 
82. Van Zwieten, P.A., de Jonge, A., Wilffert, B., Timmennans, P.B.M.W.M., Beckeringh, J.1. and 
Thoolen, M.1.M.C. (1985) Cardiovascular effects and interaction with adrenoceptors of urapidil. 
Arch. lilt. Pharmacodyn. 276, 180-20 I. 
83. Van Zwieten, P.A., Blauw, G.1., and Van Bmmmelen, P. (1992) Serotonergic receptors and 
drugs in hypertension. Pharmacology & Toxicology 70(Suppl.II), S 17-S22. 
84. Wouters, W., Hartog, 1. and Bevan, P. (1988) Flesinoxan. Cardiovasc. Drug Rev. 6,71-83. 
85. De Voogd, 1.M. and Prager, G. (1990) Early clinical experience with flesinoxan, a new selective 
5-HT1A receptor agonist. In: Saxena, P.R., Wallis, 0.1., Wouters, W. and Bevan, P., eds. 
Cardiovascularpharmacology of 5-hydro.\Ytryplamine. Kluwer Academic Publishers, Oordrecht, 
The Netherlands, pp 355-359. 
86. Saxena, P.R. and Ferrari, M.D. (1989) 5-HT1-like receptor agonists and the pathophysiology of 
migraine. Trends Pharmacol. Sci. 10, 200-204. 
87. Humphrey, P.P.A., Apperley, E., Feniuk, W. and Perren, M. (1991) A rational approach to 
identifying a fundamentally new dnlg for the treatment of migraine. In: Saxena, P.R., Wallis, 
75 
5-Hydlmytryplamine 
D.L, Wouters, W. and Bevan, p" eds. Cardiovascular pharmacology of 5-hydroxyhyptamine. 
Kluwer Academic Publishers, Dordrecht, The Netherlands, pp 417-431. 
88. Saxena P.R., Bax, \V.A. and Ferrari, M.D. (1993) 5-HydroxytIyptarnine receptor subtypes and 
8ntimigraine action. Indiml J. Pharmacal, 25, 60·67. 
89. Moskowitz, M.A. (1992) Neurogenic versus vascular mechanisms of sumatriptall and ergot 
alkaloids in migraine. 1'1'. Pharmacal. Sci, 13, 307-311. 
90. Galer, B.S., Lipton, RB., Solomon, S., Newman, L.e. and Spierings, E.L.H. (1991) Myocardial 
ischemia related to ergot alkaloids: a case report and literature review. Headache 31,446-451. 
91. Stricker, B.H.C. and Ottervanger, J.P. (1992) Pijn op de borst door slIl1latriptan (Chest pain due 
to sumatriptan. Ned. Tijdschl'. Geneeskul1de 136, 1774~ 1776. 
92. Bax, W.A., Renzenbrink, GJ., Van HeuvenwNolsen, D., Thijssens HJ.M., Bas, E. and Saxena, 
P.R. (1993) 5~HT receptors mediating contractions of the isolated human coronary artery. Ellr. 
J. Pharmacol, 239, 203-210, 
93. Se1l11Ys, P.W., Luijten, H.E., BeaU, KJ., Geuskens, R., De Feyter, PJ., Van den Brand, M., 
Reiber, J.H.C., Ten Katen, HJ., Van Es, G.A and Hugenholtz, P.G. (1988) Incidence of 
restenosis after successful coronary angioplasty: A time related phenomenon: A quantitative 
angiographic study in 342 consecutive patients at I, 2, 3, and 4 months. Circulation 77, 361-371. 
94. Cox, J.L. and Gotlieb, AI. (1986) Restellosisfollowing percutaneous translumil1al angioplasty: 
Clinical, physiological and pathological featmes. Can. Med Assoc. J. 134, 1129wl132. 
95. De Feyter, PJ" Van den Brand, M" Jaarman, G.-J., Van Domburg, R., Serruys, P.W. and 
Suryapranata, H. (1991) Acute coronary artery occlusion during and after percutaneous 
trails luminal coronary angioplasty. Circulation 83, 927-936. 
96. Klein, W., Eber, B" Dusieag, J., Rotman, B., Koitringer, P., Luha, O. and Vanhoutte, P.M. 
(1990) Ketanserin prevents early restenosis following percutaneous transluminal coronary 
angioplasty, Clill, Physiol, Biochem, 8ISuppl,31, 101-107, 
97. Nemecek, G.M., Coughlin, S.R., Handley, D.A and Moskowitz~ M,A. (1986) Stimulation of 
aortic smooth muscle cell mitogenesis by serotonin. Proc. Nat!. Acad Sci. USA 83, 674w678. 
98. Uehara, Y., Nagata, T., Matsuoka, H, Numabe, A, Hirawa, N., Takada, S., Ishimitsu, T., Vagi, 
S, and Sugimoto, T. (1991) Antiproliferative effects of the serotonin type 2 receptor antagonist, 
ketanserin, on smooth muscle cell growth in rats. J. Cardiovasc. Pharmacol. 17ISuppl.21, S 154-
8156, 
99. Serruys P,W" Klein, W., Tijssen, J.P,G" Rutsch, W., Heyndrickx, G.R., Emanuelsson, H., Ball, 
S.O., Decoster, 0., Schroeder, E., Libel111an, H., Eichhorn, E., Willerson, J.T., Anderson, H.V., 
Khaja, F., Alexander, R.W., Baim, D" Melkert, R, Van Dene, J.C. and Van Gool, R. (1993) 
Evaluation of ketanserin in the prevetion of restenosis after percutaneolls translulllinal coronary 
angioplastyj A multicentre randomized double-blind placebo-controlled trial. Circulation 88, 
1588-160 I. 
100. Seuwen, K. and Pouyssegur, J, (1990) Serotonin as a growth factor. Biochem. Pharmacol, 39, 
985-990, 
76 
Chapter 3 
101. Cattaneo, M.G., Palazzi, E., Bondiolotti, G, and Vicentini, L.M. (1994) 5-HTlD receptor type 
is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. 
Eur. J. Pharmacal. 268, 425-430. 
102. Kalil, S., Padge«, R.C., Waack, RI., Brooks, R.M. and Heistad, D.O. (1992) Effect of 
atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. Arterioscler. 
Thromb. 12, 1206-1213 
103. Chester, A,H., Allen, S.P., Tadjkarimi, S. and Yacoub, M.H. (1993) Interaction between 
thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries, 
Circulation 87, 874-880. 
104. Kaul, S" 'Vaaek, RJ" Padgett, R,C" Brooks, R.M. and Heistad, D.D. (1993) Altered vascular 
responses to platelets from hypercholesterolemic humans. eire. Res. 72,737-743. 
105. De Caterina, R, Carpeggiani, C. and UAbbate, A. (1984) A double~blind, placebo-controlled 
study of ketanseriu in patients with Prinzmetal's angina: evidence against a role for serotonin 
in the genesis of coronary vasospasm. Circulation 69, 889·894. 
106. Halpern, A., Kuhn, P.H, Shaftel, HE., Samuels, S.S., Shaftel, N., Selman, D. and Birch, HG. 
(1960) RaYllaud's disease, Raynaud's phenomenon, and serotonin. AI/giology, 11, 151·167. 
107. Roddie, I.C., Shephert, J.T. and Whelan, R.F. (1955) The action of 5-hydroxytryptamine on the 
blood vessels of the human hand and forearm. Br. J. Pharmacol. 10,445·450. 
108. Scherbel, AL. and Harrison, lW. (1959) Response to serotonin and its antagonists in patients 
with rheumatoid arthritis and related diseases. Angiology 10, 29-38. 
109. Hutton, R.A, Mikhailidis, D.P., Bernstein, R.M., Jeremy, J.Y., Hughes, G.R.V. and Dandona, 
P. (1984) Assessment of platelet function in patients with Raynaud's syndrome. J. Clin. Palhol. 
37, 182-187. 
110. Arosio, E., Montesi, G., Zannolli, M., Paluani, F. and Lechi, A. (1989) Comparative efficacy 
of ketanserill and pentoxiphylline in treatment of Raynaud's phenomenon. Angiology 40, 633-
638. 
Ill. Tooke, J.E., Williams, S.A, Rawlinson, D.W. and Black, C. (1990) Ketanserin and capillary 
flow in Raynaud's phenomenon. Inl. J. Microcirc. Clill. Exp. 9, 249~255. 
112. Marasini, Band Bassani, C. (1990) Digital blood flow and 5~hydroxytryptamine receptor 
blockade after kelanserin in patients with Rayl1aud's phenomenon. Br. J. Clill. Pharmacal. 30, 
847-851. 
113. Coffulan, J.D. and Cohen, R.A (1994) Plasma levels of 5"hydroxytryptamine during sympathetic 
stimulation and in Raynalld's phenomenon. Clill. Sci. Colclt. 86,269"273. 
77 

Chapter 4 
5-Hydroxytryptamine-induced contractions of 
the human isolated saphenous vein: 
Involvement of 5-HT2 and 5-HTm-like receptors, 
and a comparison with grafted veins *,1 
Summary - The receptors mediating the contractile effect of 5-hydroxytryptamine 
(5-RT) in the human isolated saphenous vein, obtained from 42 patients undergoing 
coronary bypass surgery, have been fi,rther characterized using a number of 
5-RT-related dl1lgs. The rank order of agonist potency was 5-CT ., 5-RT > 
methysergide ., sumatriptan ., a-methyl-5-I-IT ., RU 24969., DOl > 2-methyl-5-RT 
> S-OR-DPAT. Flesinoxan was inactive as an agonist. Ketanserin (I funoVI) hardly 
affected sumatriptan-induced contractions but it caused a rightward shift of the upper 
part of the concentration-response curve of 5-RT and 5-CT. The same concentration 
of ketanserin caused a paraHel rightward shift of the concentration-response curves 
of a-methyl-5-I-IT and DOl with pKB values of 7.1 and 7.1, respectively. The 
responses to sumatriptan were antagonized by methiothepin (0.1 J.lmol/l), metergoline 
(0.1 and I J.lmoVI), rauwolscine (I J.lmoVI) and cyanopilldolol (I J.lmoVI); the 
calculated pKB values were 7.3, 6.9, 7.3, 6.7 and 6.5, respectively. Contractions to 
5-I-IT were antagonized by methysergide (I IlmoVl), methiothepill (0.1 J.lmoVI; 
"', Based on: 8ax, W.A., Van Heuven~Nolsen, D" Bos, E" Simoons, M.L. and Saxena, P.R. 
(1992) 5-Hydroxytryptamine-induced contractions of the human isolated saphenous vein: 
Involvement of 5-HT2 and S-HTJD-Iike receptors, and a comparison with grafted veins. Naunyn 
Schmiedeberg's Arch. Pharmacal. 345, 500-508. 
I J Novel information on 5-HT receptors has become available since the experiments in the present 
chapter were performed and analyzed. The 5-HT1C receptor was redefined as 5-HT2C receptor. 
Recently identified 5-HT receptor subtypes with a 5-HTJV-like receptor profile appear either 
positively coupled to adenylyl cyclase (5-HT" 5-HT,), or do not match the presently obtained 
profile for 5-HT, receptor agonists, or antagonists against sllmatriptan. The phannacological 
distinction between the 5-HTIDIl and 5-HTID13 receptor subtypes can not be made in functional 
studies at present, due to lack of selective receptor agonists and antagonists (See Ref. 47). 
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pKB=7.1), ICS 205-930 (I J.1molll; pKB=5.9) and flesinoxan (30 J.1molll; pKB=5.3). 
Remarkably, the contractions elicited by 2-methyl-5-HT were not attenuated by 
ICS 205-930, but were antagonized by methiothepin (0.1 J.1mol/l) and, more 
markedly, by ketanserin (I J.1molll). 
There was a high conelation between the functional pD, values of 5-HT,-like 
receptor agonists (5-CT, 5-HT, methysergide, sumatriptan, RU 24969 and 
8-0H-DPAT) and their reported binding affinities for the 5-HTID receptor in human 
or calf brain membranes. Such a correlation for the antagonism of sumatrip-
tan-induced responses was less marked than for the agonists, but of the 5-HT,-like 
receptor subtypes it was the highest for the 5-HTID receptor identified in human or 
calf brain membranes. 
In 3 patients, undergoing heal1 transplantation, saphenous vein which had previ-
ously functioned as a graft for 6-11 years, was dissected out from the heart. Though 
the contractions to potassium were significantly smaller in the grafted veins, the pD, 
and EMAX values (calculated as percentage of potassium-induced contractions) for 
5-HT and sumatriptan were similar to those found in the veins obtained directly from 
the lower leg. 
It is concluded that contractions in the human isolated saphenous vein induced by 
5-HT are mediated by 5-HT, receptors as well as by a 5-HT,-like receptor 
resembling the 5-HT,o subtype found in brain membranes. It is also to be noted that 
2-methyl-5-HT, considered selective for the 5-HT, receptor, contracts the saphenous 
vein mainly via 5-HT, receptors. 
4.1 Introduction 
Saphenous vein and internal mammary m1ery are frequently used as a graft in 
coronary bypass surgery. Several differences between these two vessels have been found 
that could possibly account for the superior patency of mammary at1ery grafts I. '. 
Recently, Yang and co-workers' reported that, when precontracted with noradrenaline, the 
human isolated saphenous vein contracts, but the humat} isolated internal manunary artery 
relaxes to platelets. Platelet-derived ADP caused the manunary at1ery to relax while 
contractions in the saphenous vein were shown to be mediated by thromboxane A, and 
5-HT. The 5-HT-induced saphenous vein contractions are sensitive to ketanserin and 
spiperone, both 5-HT, receptor antagonists. This ketanserin-sensitive receptor is activated 
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mainly at high concentrations of 5-HT, while lower concentrations seem to activate a 
yohimbine- and methiothepin-sensitive 5-HT receptor 4.'. The present study was unde11aken 
to fu11her characterize the 5-HT receptors mediating contractions in the human saphenous 
vein. In addition, we also had the opportunity to compare the responses mediated by 5-HT 
receptors in the vessels which had functioned as coronary bypass grafts for a number of 
years. A pati of the results of this investigation was presented to the British Phar-
macological Society'. 
4.2 Materials and methods 
Tissue preparation 
Leftover human saphenous vein was obtained intra-operatively during bypass surgery 
from 42 patients (29 males and 13 females; age: 44 to 77 years). The tissue was 
immediately placed in a cold, oxygenated Krebs bicarbonate solution of the following 
composition (mmolll): sodium chloride, 118; potassium chloride, 4.7; calcium chloride, 
2.5; magnesium sulphate, 1.2; potassium dihydrogen phosphate, 1.2; sodium bicarbonate, 
25; and glucose, 8.3; pH 7.4. The vein was brought to the laboratory within 30 min of 
removal and cleaned of adhesive fat and connective tissue. In addition, saphenous vein 
could also be obtained from three male patients (aged 46, 48 and 61 years) with 
progressive ischemic heart disease, undergoing cardiac transplantation. These patients had 
previously undergone coronary bypass surgery where saphenous vein had been used as a 
graft for a period of 6, 7 and II years, respectively, prior to transplantation. The vein was 
collected /l'om these hearts within 45 minutes of cardiectomy. The vessels were cut into 
rings of approximately 4-5 mm of length and suspended on stainless steel hooks in 8 ml 
organ baths containing the Krebs' bicarbonate solution, aerated with 95% 0, and 5% CO, 
and maintained at 37° C. The tissues were allowed to equilibrate for at least 30 min and 
washed every 10 min. Changes in isometric tension were recorded with a Harvard 
isometric transducer. Preparations were then stretched to the optimum point of the 
length-tension relation, as determined by tension developed to 30 nuno!/! K+. The rings 
were then left to equilibrate for another 30 min after which the actual experiment began. 
Endothelia! integrity was not assessed in these experiments, since the presence of 
endothelium does not influence 5-HT-induced contractions in this vessel'. 
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Determination of agonist potellcy 
A cumulative concentration-response curve to S-RT was obtained on each preparation 
until a maximum response (EMAX) was obtained. After frequent washing the tissue was left 
to equilibrate for at least 30 min. When the baseline tone was reached, the tissue was 
exposed to either S-RT again or to another test agonist. In each vessel segment, the second 
S-RT concentration-response curve or the ollly concentration-response curve to the other 
agonists was expressed as percentage of the EMAX of the first S-RT curve. 
To determine agonist potency in saphenous vein grafts that had been in sitn for some 
years, a single concentration effect curve was obtained with either S-RT or sumatriptan. 
These responses were expressed as a percentage of potassium (30 mmol/I)-induced 
contractions in the grafted veins. The response to potassium (30 mmol/I), and the EMAX and 
pD, values (see below) ofS-RT and sumatriptan were compared to the respective response 
in the ungrafted saphenous veins. 
Determinatioll of antagonist potency 
A concentration-response curve to S-RT was made and the preparation was washed 
as described above. About 30 min later, a second cumulative concentration-response curve 
was obtained with either S-RT or another agonist, without or after incubation (30 min) 
with a ce'iain concentration of an antagonist. The second curve without antagonist, mostly 
obtained in parallel, served as a control for the curve in the presence of the antagonist. 
Analysis of data 
All curves were analyzed by means of a computerized curve fitting teclUlique 10 to 
obtain EMAX (maximal response) and pD, (-Log of the molar concentration of an agonist 
eliciting half maximal effect) values, which were averaged for the respective agonists. For 
antagonists approximate pKB values were calculated, assuming the nature of antagonism 
to be competitive, by the equation described by Furchgott in 1972 ": 
pKB = -Log[B] + Log{([A,]/[A,])-I), 
where [B] is the antagonist concentration and [A,l and [A,l are, respectively, the 
equi-effective molar concentrations of the agonist needed to elicit half maximal effect in 
the absence and presence of [Bl. For calculation of pKB values, only paired experiments 
were taken into account, unless mentioned otherwise. All data are presented as mean ± 
SEM. A conelation coefficient Was calculated according to Pearson. To test the hypothesis 
of a straight line underlying the points in Figure 6, lack of fit statistics 12 was performed 
using u=O.OS as a critical value. Student's t-test for unpaired data was used for 
82 
Chapter 4 
comparison of mean values. A p-value of ';0.05 was assumed to denote a sIgnificant 
difference. 
Compounds 
The following dmgs were used in this study: S-carboxamidotryptamine maleate 
(S-CT; gift: Glaxo, Ware, UK), (±)cyanopindolol (gift: Sandoz AG, Basel, Switzerland), 
1-(2,S-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOl; Research 
Biochemicals Inc., Natie, Ma., USA), flesinoxan hydrochloride (gift: Duphar B.V., Weesp, 
The Netherlands), 8-hydroxy-2(di-n-propylamino)tetralin (8-0R-DPAT; gift: Mend Dow 
Research Institute, Strassbourg, France), S-hydl'Oxytryptamine creatinine sulphate (S-RT; 
Sigma Chemical Co., St. Louis, Mo., USA), 3a-tropanyl-lH-indole-3-carboxylate (ICS 
205-930; gift: Sandoz AG, Basel, Switzerland), ketanserin tartrate (gift: Janssen 
Pharmaceutica, Beerse, Belgium), metergoline (gift: Farmitalia, Milan, Italy), methiothepin 
maleate (gift: Roffman La Roche B.V., Mijdrecht, The Netherlands), S-methoxy-
3-(I,2,3,6-tetrahydropyridin-4-yl)-IH-indole succinate (RU 24969; gift: Roussel Labora-
tories, Roevelaken, The Netherlands), 2-methyl-S-hydroxytryptamine maleate (2-methyl-
-S-RT; gift: Glaxo, Ware, UK), a-methyl-S-hydroxytryptamine maleate (a-methyl-S-RT; 
gift: Glaxo, Ware, UK), rauwolscine hydl'Ochloride (Fluka AG, Buchs, Switzerland) and 
sumatriptan (gift: Glaxo, Ware, UK). We appreciate the generosity of the companies in 
providing the compounds. 
4.3 Results 
Effiet of agonists 
The concentration-response curves obtained on the human isolated saphenous vein 
with the different agonists and the derived values of pD, and EMAX are shown in Figure I 
and Table I, respectively. It is to be noted that contractions in the second S-RT con-
centration-response curve were only slightly less than in the first S-RT curve. All other 
agonists, except flesinoxan, were found to contract the saphenous vein in a concentration-
dependent manner. The rank order of potency was: S-CT '" S-HT > methysergide '" 
sumatriptan '" a-methyl-S-RT '" RU 24969 '" DOl > 2-methyl-S-RT > 8-0R-DPAT. 
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Table 1. Agonist potency and maximal effect in the human isolated saphenous vein. pD2 is 
expressed as -log(ECso) and E~fAX is expressed as a percentage of the maximal 5-HT contraction 
in the first concentration-response curve 
Agonist n pD, (± S.E.M.) E.IAX (± S.E.M.) 
5-CT 5 7.1 (0.2) 89 (4) 
5-HT, first 18 7.0 (0.1) 100 (0) 
5-HT, second 18 6.8 (0.1) 93 (3) 
Methysergide 4 6.3 (0.4) 16 (3) 
Sumatriptan IS 6.1 (0.1) 37 (4) 
a-Methyl-5-HT 3 6.0 (0.1) 94 (3) 
RU 24969 5 5.S (0.2) 62 (6) 
DOl S 5.7 (0.3) 57 (7) 
2-Methyl-5-HT 7 4.S (0.2) 49 (5) 
S-OH-DPAT' 8 < 4.6 (0.2) > 52 (10) 
Flesinoxan 3 inactive inactive 
a, The concentration-response curve did not achieve a plateau even at the 
highest concentrations studied (10-4 molll); n, Number of observations. 
Table 2. Comparison of the effect (developed tension in g) of potassium (30 mmoVI), and the pD, 
(expressed as -Log[EC,,]) and E.IAX (expressed as a percentage of the potassium-induced 
contraction) values of 5-HT and sumatriptan in ungrafted saphenous veins, obtained directly fl"Om 
the lower leg (n= IS), and in those which had been used as a coronary bypass graft (n=3) 
Effect 30 mmol/l potassium 
pD,5-HT 
EMAX 5-HT 
pD2 sumatriptan 
E~tAX sumatriptan 
Ungrafted vein (± S.E.M.) 
5.5 (0.8) 
7.0 (0.1) 
lSI (13) 
6.1 (0.1) 
59 (8) 
*, p<O.05, when compared to data in ungrafted vein. 
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Bypass graft (± S.E.M.) 
0.5 (0.9) • 
6.7 (0.5) 
242 (23) 
5.8 (0.4) 
70 (15) 
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Figure 1. Contractions of the human isolated saphenous vein to 5-HT receptor agonists. Graph A: 
0, 5-HT (2nd curve); ., 5-CT; v, RU 24969; A, sum.triptan; 0, 8-0H-DPAT and l1li, flesino-
xan. Graph B: 1II,5-HT (lsI curve); 0,5-HT (2nd curve); " a-melhy(-5-HT; 6, DOl; 
0, 2-methyl-5-HT and +, methysergide. Agonist concentration refers to molli. 
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Figure 2. Contractions to 5-HT (A) and sumatriptan (B) in previously grafted saphenous veins 
(n=3) against a shaded area of the 95% confidence interval of data obtained in saphenous veins 
obtained directly fi'om the lower leg (11= 18). Agonist concentration refers to mol/I. Contractions 
expressed as a percentage of potassium (30 mmoVI)-induced contractions. 
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Figure 3. Hematoxylin~eosin stained segments of ungrafted (upper picture) and grafted saphenous 
vein segments. In the media of the ungrafted vein, a regular organization of circular (A) and 
longitudinal (B) smooth muscle cells can be observed. Intimal hyperplasia is virtually absent. In 
the grafted vein, pronounced luminal stenosis was observed due to intimal hyperplasia (C), 
consisting of myofibroblasts in extracellular matrix. The longitudinal and circular smooth muscle 
layers are partially reduced, and may be absent in some areas (D). 
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Figure 4. Contractions of the human isolated saphenous vein to several 5-HT receptor agollists 
in the absence (control, 0) or presence ofketanserin (I ~mol/l, .), ICS 20S-930 (I ~moUI, +; 
hidden behind methiothepin curve), methiothepin (0.1 Mmol/l, III), methysergide (I ~mol/l, 0) 
and/or flesinoxan (30 ~tmoUl, v). Agonist concentration refers to moUI. pKB values are mentioned 
in Table 3. Number of segments tested: 5-HT (control, 18; ICS 205-930, 5; flesinoxan,4; 
ketanserin, 5; methiothepin, 5 and methysergide, 3), 5-CT (control, 5; ketanserin, 5 and 
methiothepin, 6), RU 24969 (control, Sand methiothepin, S), a·methyl·S·HT (control, 3 and 
ketanserin, 3), DOl (control, 7 and ketanserin, 5)and 2-methyl-5-HT (control, 7; ICS 205-930, 5; 
ketanserin, 5 and methiothepin, 5), In cases where the number of experiments mentioned here does 
not correspond to the number mentioned in Table 3, unpaired experiments are displayed also 
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Figure 5. Contractions of the human isolated saphenous vein to sumatriptan in the absence 
(control, 0) or presence of antagonists (0.1 ~tmoI/J, A. and 1 I-tmolll, e). Agonist concentration 
refers to mol/I. Number of segments tested: control, 18; methiothepin, 8; ketanserin, 8; 
metergoline (l ~tmol/l), 7; metergoline (0.1 ~unoUI), 6; cyanopindolol, 6 and rauwolscine, 8. pKB 
values, calculated from paired experiments only, can be found in Table 3. In cases where the 
number of experiments mentioned here does not correspond to the number mentioned in Table 
3, unpaired experiments are displayed also. 
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As shown in Table 2, the exposure to potassium (30 mmolll) caused contractions of 
the saphenous veins that had been used as a graft, but the tension generated in these 
vessels was only about 10% ofthat observed in the ungrafted veins. Though the responses 
to both 5-HT and sumatriptan in the grafted vessels were also diminished, the respective 
EMAX values, when expressed as a percentage of potassium (30 mmolll)-induced 
contraction, as well as the pD, values were similar to those in the non-grafted veins 
(Table 2; Figure 2). 
Effect of antagonists 
The effects of ketanserin (I ~1I1101/1), methiothepin (0.1 Ilmol/l), methysergide (I 
limo III), flesinoxan (30 flmolll) and rcs 205-930 (I limo III) were studied against the 
responses to at least one of the following agonists: 5-HT, 5-CT, RU 24969, a-methyl-
5-HT, DOl and 2-methyl-5-HT (Figure 4). The calculated pKn values are shown in 
Table 3. The responses to 5-HT were antagonized by methysergide, ketanserin and 
methiothepin (pK"~7.1±0.4), but also to some extent by rcs 205-930 (PKn~5.9±0.1) and 
flesinoxan (PKB~5.3±0.2). The pKB values for methysergide (concentration-response 
curve did not reach plateau) and ketanserin (biphasic concentration-response curve) 
were not calculated (see Table 3). The antagonism by ketanserin was more marked against 
contractions due to higher concentrations of 5-HT. The effects of low concentrations of 
5-CT were little affected by ketanserin (I Ilmol/l) or methiothepin (0.1 J.lmolll), but those 
of high concentrations (;'0.1 ~lmolll) were attenuated by both methiothepin and ketanserin. 
The contractile effects of RU 24969 were antagonized by methiothepin (0.1 flmolll). 
Contractions to a-methyl-5-HT and DOl were attenuated by ketanserin (I J.lmolll), while 
those to 2-methyl-5-HT, being unaffected by rcs 205-930, were antagonized by 
methiothepin (0.1 Ilmolll) and, even more potently, by ketanserin (I Ilmolll) (Figure 4). 
Figure 5 shows the effects of methiothepin (0.1 ~lmolll), metergoline (0.1 and I limo III), 
ketanserin (I Ilmolll), cyanopindolol (I ~lmolll) and rauwolscine (I Ilmol/l) on the 
responses to sumatriptan. The sumatriptan-induced contractions remained unaffected by 
ketanserin, but methiothepin, metergoline, cyanopindolol and rauwolscine behaved as 
antagonists (Figure 5; Table 3). 
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Table 3, Approximate pKo values of various antagonists against the agonists indicated. 
Antagonist Concentration n Agonist pKB (±SEM), 
Ketanserin I ,"mol/l 5 5-HT Not calculated b 
I ,"mol/l 5 5-CT Not calculated b 
I ,"molll 3 a-Methyl-5-HT 7.1 (0.1) 
I ,"molll 5 001 7.1 (0.3) 
I ,"mol/l 5 2-Methyl-5-HT Not calculated \l 
I ~Imol/l 8 Sumatriptan No antagonism 
Methiothepin 0.1 ~Imolll 5' 5-HT 7.1 (0.4) 
0.1 ~Imolll 6 5-CT Not calculated b 
0.1 ,"1110111 3 RU 24969 7.9 (0.8) 
0.1 ,"11101/1 5 2-Methyl-5-HT 7.3 (0.1) 
0.1 ~unolll 4 Sllmatriptan 7.3 (0.1) 
Methysergide I ,"molll 3 5-HT Not calculated C 
Rauwolscine I ,"1110111 6 Sllmatriptan 6.7 (0.2) 
Metergoline 0.1 ,"1110111 4 Sllmatriptan 6.9 (0.3) 
I ,"11101/1 4 Sumatriptan 7.3 (0.3) 
Cyanopindolol I ~111101l1 4 Sllmatriptan 6.5 (0.3) 
Flesinoxan 30 ,"mol/l 3 5-HT 5.3 (0.2) 
ICS 205-930 I ,"molll 3 5-HT 5.9(0.1) 
I ,"mol/l 5 2-Methyl-5-HT No antagonism 
a, For calculation of pKo only paired experiments were taken into account unless marked 
by *; b, Not calculated due to biphasic nature of antagonism; c, Not calculated because 
concentration-response curve did not reach a plateau; tI, Number of observations. 
4.4 Discussion 
Previous studies 4-1. \3 in the human isolated saphenous vein have revealed that 
5-HT-induced contractions were: (i) pat1ially antagonized by spipemne and ketanserin, 
both of which preferentially affected the contractions following high concentrations of 
5-HT; and (ii) mimicked by 5-CT, sumatriptan, RU 24969, a-methyl-5-HT, 5-methoxy-
tryptamine and 8-0H-DPA T. Since contractions to a-methyl-5-HT and high concentrations 
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of 5-HT were antagonized by ketanserin and since the effect of sumatriptan was 
antagonized by methiothepin but not markedly by ketanserin, both 5-HT,-like and 5-HT, 
receptors seem to be present in the human saphenous vein 6,13, 
The frame-work of 5-HT receptor classification, originally proposed by Bradley and 
colleagues 14, has now been expanded 15 and at least four types of 5-HT receptors 
(5-HTI-like, 5-HT" 5-HT, and 5-HT4) are recognized (see Ref. 16). It is well established 
that the 5-HT,-like receptor category is heterogeneous in nature (5-HTIA> 5-HTIB' 5-HT1C 
and 5-HTiD) and even this subdivision seemingly does not completely correspond to the 
functional responses observed \6.". It is with this background that we have attempted to 
further characterize the human saphenous vein 5-HT receptors by using a large number 
of 5-HT receptor agonists and antagonists. 
Identification of the 5-HT receptors 
The presence of a contractile 5-HT,-like receptor in the human saphenous vein is 
revealed by the fact that: (i) 5-CT, sumatriptan, RU 24969 and 8-0H-DPAT, all of which 
have more or less selective agonist action at 5-HT,-like receptors, elicited saphenous vein 
contractions; (ii) the contractions elicited by sumatriptan were resistant to blockade by 
ketanserin, but were antagonized by methiothepin and other compounds with affmilies for 
5-HT1 binding sites (metergoline, cyanopindolo1 and rauwolscine); and (iii) methiothepin 
clearly antagonized the responses to RU 24969. It should, however, be noted that the 
putative 5-HTIA receptor agonist f1esinoxan 19. '0 did not behave as an agonist, but rather 
as a weak antagonist of the responses to 5-HT; such an antagonist effect offlesinoxan has 
been described at the 5-HT,-like receptor in the rabbit saphenous vein ". Lastly, despite 
the above evidence for the presence of 5-HTI-like receptors in the saphenous vein, we 
have no adequate explanation why methiothepin, in contrast to its interaction with 
sumatriptan and RU 24969, did not cause a parallel shift of the lower part of the 
concentration-response curve of 5-CT. Possibly 5-CT acts as an agonist on other receptors 
than the 5-HTI-like receptor present in this vessel; the antagonism by ketanserin of the 
upper part of the 5-CT-curve indicates that 5-CT activates 5-HT, receptors, especially at 
high concentrations. This phenomenon has been observed before in the human coronary 
artery 22 and the rabbit aOlia ". 
Our experiments also provide evidence in favour of 5-HT, receptor-mediated 
contractions of the human saphenous vein. Thus, the contractile effects of 5-HT were 
antagonized by ketanserin in a clearly biphasic manner, mainly affecting the higher 
concentrations of 5-HT. Moreover, the relatively selective 5-HT, receptor agonist DOl, as 
well as ct-methyl-5-HT, caused concentration-dependent saphenous vein contractions that 
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were also antagonized by ketanserin (Figure 4). The calculated pKn values (7.1 against 
both 5-HT, receptor agonists) are admittedly somewhat low compared to those in other 
tissues 24.". It is, however, possible that the blocking activity of ketanserin is being 
underestimated because a-methyl-5-HT has appreciable binding as well as functional 
affinity for 5-HT, receptor subtypes "'''. The presence of both 5-HT,-like and 5-HT, 
receptors in the saphenous vein is fUliher strengthened by the nature of the effects of 
methiothepin and methysergide; these mixed 5-HT,-like and 5-HT, receptor antagonists 
shifted the concentration-response curve of 5-HT in a near parallel manner. 
We would like to draw attention to three other findings in our present investigation. 
Firstly, as found earlier, paliicularly at 5-HT,-like receptors '6.29, methysergide had a 
p3liial agonist action weakly contracting the saphenous vein. Secondly, 2-methyl-5-HT 
contracted the human saphenous vein (Figure 4). Since this compound is generally 
considered selective for the 5-HT, receptor 14. ", it may be argued that 5-HT, receptors also 
mediate contraction in this tissue. However, as also recently found in the rabbit isolated 
renal aliel'Y 30, the contractions elicited by 2-methyl-5-HT were not attenuated (perhaps 
somewhat potentiated) by ICS 205-930. The low pD, value of 2-methyl-5-HT (4.8±0.2) 
and the antagonism of its effects by methiothepin and, p3liicularly, ketanserin strongly 
suggests that 2-methyl-5-HT contracted the human saphenous vein via 5-HT, receptors. 
However, in view of the tenfold higher affinity of2-methyl-5-HT for the 5-HT, receptor 
subtypes than for the 5-HT, receptor 26. ", an additional involvement of 5-HT,-like 
receptors can not be excluded. Thirdly, in the absence of 5-HT, receptors, the ability of 
ICS 205-930 (\ ",mol/l) to weakly attenuate 5-HT-induced contractions may point to the 
existence of 5-HT, receptors in the human saphenous vein. On the other hand, though 
present in the brain ", heart 3]·33 and gastro-intestinal system ", the 5-HT, receptor has not 
yet been located in blood vessels. 
Is the 5-HTr like receptor related to 5-HT/ binding site subtypes? 
Since receptor binding experiments clearly distinguish at least foUl' 5-HT, binding site 
subtypes (5-HT'A> 5-HT'B' 5-HT,c and 5-HT ID) (see Ref. 26, 35, and 36), we compared 
agonist pD, and antagonist pKB values obtained in the present experiments with the 
binding affinities at the above 5-HT, binding subtypes (Figure 6). Admittedly, such a 
comparison is slightly hampered by the fact that we deal with two different receptor 
populations (5-HT,-like and 5-HT,) in the saphenous vein. In order to counter this 
potential disadvantage, we chose agonists (including 5-HT) with a relatively high aftinity 
for 5-HT,-like receptors and the pKB values of antagonists against the selective 5-HT,-like 
receptor agonist sumatriptan. The above comparison yielded the following con'elation 
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coefficients (1'): 0.12,0.74,0040,0.97 and 0.98 for the agonists; and 0.65, 0045, 0.21, 0.77 
and 0.89 for the antagonists at, respectively, 5·HT IA, 5·HTm, 5-HT,c, 5-HTJD (calf 
caudate) and 5-HTJD (human caudate) receptors. The cOlTelation at the 5-HT'A> 5-HT'B and 
5-HT,c was not only lower than that at the 5-HTJD receptors (both in the human and calf 
caudate membranes), but also a theoretical straight line connecting the correlation points 
(see Figure 6) for these three 5-HT, binding subtypes (but not 5-HTJD) could be rejected 
(a~0.05). Therefore, the 5-HT,-like receptor mediating contraction of the human isolated 
saphenous vein resembles the 5-HTJD receptor subtype, a conclusion that is also supported 
by data reported earlier 7. 37. However, this receptor may not be entirely identical to the 
5-HTJD receptor identified in the calf or human caudate membranes, since the order of 
binding affinity at the 5-HT'D receptor site of methiothepin and metergoline is contradic-
tory to the potency order of functional antagonism against sumatriptan. An analogue 
observation was made by Hamel and Bouchard J8 for the 5-HTJD receptor contracting the 
human isolated pial arteries. Indeed, SUlnner and Humphrey 39 have already proposed a 
subdivision for 5-HTJD receptors, and the primary stmcture and function of the cloned 
5-HTJD receptor 40 shows several marked discrepancies with the published 5-HTJD receptor 
affinities )s. 
Comparison between IIl1grajled alld graj/ed saphenous veins 
Apali from a recent repoti on a 12-year old saphenous vein graft 41, we are not aware 
of any other pharmacologic investigations in such vessels. As also observed by us in the 
microscopic sections (Figure 3), Steen and colleagues found a marked proliferation of 
intimal and smooth muscle layers 41. Their pharmacological findings indicated that 
a-adrenoceptors mediating contraction of this grafted venous segment were 'atypical' in 
nature. However, with regard to 5-HT receptors, we observed no obvious change in the 
three grafted vessel segments studied by us; the pO, values as well as the maximal effects 
of 5-HT and sumatriptan, expressed as a percentage of potassium-induced contractions, 
were not different from those in the ungrafted saphenous veins. But, it appears that the 
general ability to contract, as indicated by the contractions to potassium (Table 2), was 
substantially less in the grafted vessels. Possibly, the mechanical inhibition by newly 
fanned intimal myofibroblasts, and altered organization of areas of the medial smooth 
muscle layers, lead to an overall less effective contractile response. By contrast, in venous 
grafts in animals, others have reported hyper-reactivity to 5-HT, which correlated with 
intimal thickening 4'. 43. However, we only had the opportunity to study grafted saphenous 
veins from three patients undergoing heart transplantation who are likely to have more 
extensive pathological lesions than those individuals undergoing coronary bypass surgery. 
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Figure 6, Correlation between agonist pD2 or antagonist pKn (against sumatriptan) values obtained 
in our functional tesls (Table I and 3) and pKD (expressed as .Log mol/l) values for 5·HT, 
binding site subtypes. All binding data are from Ref. 26, except those for sUlmitriptan 36 and for 
5-HTID binding in the human caudate membrane 35. Receptor binding was studied by the quoted 
authors in the following tissues: 5-HT1Al pig frontal cortex; 5-HTIBJ rat frontal cortex; 5-HT10 pig 
choroid plexus; and 5·HTID, calf (filled symbols) or human (open symbols) caudale membranes. 
For ketanserin a pKn value of 5.0 was calculated from four paired experiments. For metergoline 
a pA2 of 7.0 was calculated using multiple regression analysis. Symbols for agonists: v J 5-HT; 
., 5·CT; +, melhysergide; 10, sum.lriplan; ., RU 24969 and l1li, 8·0H·DPAT. Symbols for 
antagonists: 11, metergoline; A, methiothepin; v, rauwolscine; • J cyanopindolol; 0, ketanserin. 
For correlation coefficients, see text. 
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Comparison with 5-HT receptors ill olher human vessels 
Extensive studies characterizing 5-HT receptors in the human basilar 44 and pial 38 
arteries have been performed. Some imp0l1ant differences between the results obtained 
here and those rep0l1ed earlier may be pointed out. Firstly, in the basilar and pial arteries 
5-I-IT-induced contractions were unaffected by ketanserin, indicating the absence of 5-HT, 
receptors. Secondly, unlike our experiments, 2-methyl-5-HT lVas ineffective in the basilar 
at1ery; however, despite the fact that contractile 5-HT, and 5-HT, receptors are absent, pial 
at1eries did contract to 2-methyl-5-HT, presumably via a 5-I-IT,-like mechanism. Thirdly, 
(±)cyanopindolol did not affect sumatriptan-induced contractions in the basilar artelY, but 
the concentrations used were ten times lower (0.1 f,mol/l) than in our experiments. Lastly, 
the affinity for methiothepin lVas higher in the basilar (pKB: 8.8) or pial (pA,: 8.55) 
arteries than in our experiments (pKB: approximately 7.1). It is possible that the 5-HT,-like 
receptor subtype present in the saphenous vein may not be identical with that present in 
the basilar at1eries. However, as in the present experiments, a high con'elation was found 
between the functional pD, values in the pial arteries and the pKD values for the 5-HTLD 
binding sites in the human caudate membranes 3&, 
Like in the saphenous vein, both 5-HT,-like and 5-HT, receptors have been rep0l1ed 
in the human coronaty at1e,y and similar pD, values for sumatriptan, 5-HT and 5-CT have 
been found 22. 44. 4S. However, at this time not enough experimental data in human isolated 
coronary atiery is available to make a valid comparison between the 5-HT,-like receptor 
subtype contracting coronary mie,y and saphenous vein. 
In conclusion, a mixed population of5-HT,-like and 5-I-IT, receptors is present in the 
human isolated saphenous vein. Low concentrations of 5-HT contract the vessel mainly 
via the 5-I-IT,-like receptor, but at higher concentrations 5-HT, receptors are recruited as 
well. This 5-HT,-like receptor in the saphenous vein closely resembles the 5-HTLD binding 
site. These results imply that, should 5-I-IT be involved in the pathophysiology, 5-HT, 
receptor antagonists, such as ketanserin, would not be entirely effective in preventing peri-
or postoperative spasm of the saphenous vein graft. Since the human coronmy vessels also 
contain 5-HT,-like and 5-HT, receptors, the use of a mixed 5-HT,-like I 5-I-IT, receptor 
antagonist may well be more efficacious in ameliorating coronary artery or saphenous vein 
graft spasm. 
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Chapter 5 
5-Hydroxytryptamine receptors mediating contractions 
of the human isolated coronary artery* 
Summary" We investigated contractile responses of the human isolated coronary 
aliery to 5-HT, human washed platelets, sumatriptan and ergotamine. 5-HT (pD,: 
6.8 ± 0.1, EMAX: 47.7 ± 6.8 mN) and platelets (effect 14.4 ± 2.8 mN with 3.10 10 
platelets/l) caused contractile responses which were attenuated by ketanserin (111M). 
In the presence of ketanserin (111M), both rauwolscine (I alld 10 11M) and 
cyanopindolol (1 and 10 flM) caused concentration-dependent additional antagonism 
against leftover contractions induced by low (:': 111M) concentrations of 5-HT. 
Sumatriptan-induced contractions (pD,: 6.2 ± 0.1; EMAX : 10.7 ± 2.4 mN) were 
antagonized to a similar extent by both rauwolscine (1 11M) and cyanopindolol 
(111M) (PKB: 6.5 ± 0.1 and 6.4 ± 0.1, respectively) and also by metergoline 
(0.1 11M; pKB:7.2 ± 0.1). The order of potency of antagonists against sumatriptan 
resembles the order repOlied for the human saphenous vein 5-HTID-like receptor. 
Against platelet-induced contractile responses we observed no significant additional 
antagonism by cyanopindolol (1 flM) 01' rauwolscine (111M). Ergotamine caused 
potent contractile responses (pD,: 8.4 ± 0.3, EMAX: 19.4 ± 2.4 mN). It is concluded 
that, although 5-HT, receptors predominantly mediate 5-HT-induced contractions, the 
5-HT,-like receptor seems to playa role in coronary vasospasm caused by low 
concentrations of 5-HT. 
*, Based on: Bax, W.A" Renzenbrink, GJ., Van Heuven-Noisen, D., Thijssen, H.J.M .• Bos, E. 
and Saxena, P.R. (1993) 5-HT receptors mediating contractions of the isolated human coronary 
artery. Eul'. J. Phal'macal. 239, 203-210. 
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5.1 Introduction 
5-Hydroxytryptamine (5-HT) released from aggregating platelets is thought to play 
a role in the cascade of events that leads to an acute ischemic state of the heart such as 
in unstable angina or Prinzmeta!'s angina pectoris '-3. Indeed, 5-HT is well known to 
contract the human coronary artery both in vitro 4-7 and in vivo; the latter only in case of 
high concentrations of 5-HT', or in case of a diseased coronary artery '.10. The healthy 
coronary artery was found to dilate after infusion of low concentrations of 5-HT in vivo, 
and this dilatation was potentiated by ketanserin, a 5-HT, receptor antagonist '. The human 
isolated coronary at1ery contracts to 5-HT via both 5-HT,-like and 5-HT, receptors. 
Predominant mediation by the 5-HT, receptor 4.' but also by a 5-HT,-like receptor 6 has 
been suggested. Despite involvement of 5-HT, receptors, ketanserin has been shown to be 
clinically ineffective against vasospastic atlgilla " or ergometrine-induced coronary at1ery 
constriction ". This has tempted investigators to speculate on the potential beneficial 
effects of a mixed 5-HT,-like / 5-HT, receptor antagonist over a selective 5-HT, receptor 
antagonist '. \3.". Interestingly, the receptor binding affinity of 5-HT for the 5-HT,-like 
receptor subtypes is more than 100-fold higher than that for the 5-HT, receptor '6. Indeed, 
in the human saphenous vein, which also contracts to 5-HT via a mixed 5-HT,-like / 
5-HT, receptor population, low concentrations of5-HT were found to mediate contractions 
mainly via a 5-HT,-like receptor ". '7. In the human coronary artery, this may be of 
pa,1iculat· interest since studies of this vessel have revealed a ketanserin-resistant 6.' or 
5-HT,-like contractile receptor 7, possibly related to the presence of atherosclerotic plaques. 
In the present study we have therefore investigated the effect of two 5-HT,-like 
receptor antagonists (cyanopindolol and rauwolscine) in the presence of the 5-HT, receptor 
blockade by ketanserin on contractions induced by 5-HT and human activated platelets. 
Rauwolscine and cyanopindolol have high affinity for a., atld II adrenoceptors respectively, 
but they also have affinity for 5-HTID and 5-HT'A receptor subtypes, especially in 
comparison to 5-HT, receptors ". Using these two antagonists and also metergoline, we 
further investigated the nature of the 5-HT,-like receptor involved. 
Also the recent development of a novel anti-migraine d111g, sumatriptan, a selective 
5-HT,-like receptor agonist IS, has raised interest in the relevance of contractile 5-HT,-like 
receptors and possible coronary side-effects 19.20. We therefore compared the contractile 
effect of sumatriptan to that of ergotamine, an anti-migraine dlug with well documented 
coronary side-effects (see Ref. 21) and in clinical use since many decades. 
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5.2 Materials and methods 
Tissue preparation 
The right epicardial coronaty atiery was obtained from 21 heart beating organ donors 
who died of non-cat'diac disorders less than 24 h before the tissue was taken to the 
laboratOlY (8 cerebrovascular accident, 8 polytrauma, 4 cerebral hypoxia, I pulmonaty 
embolus; 14 male, 7 female; age 1-49 years). The hearts were provided by the Rotterdam 
Heart Valve Bank (Bio Implant Services Foundation / Eurotransplant Foundation) after 
removal of the aOliic and pulmona,y valves for homograft valve transplantation. The study 
was approved by the Ethical COIrullittee of the University Hospital Rotterdam 'Dijkzigt'. 
The hearts were stored at 0-4 °C in a sterile organ protecting solution (UW, EuroCollins, 
or HTK-Brettschneider; see Ref. 22) innllediately following circulatOlY arrest. After an'ival 
in the laboratOly, the right coronaty artery was removed and placed in a cold, oxygenated 
Krebs bicarbonate solution of the following composition: 118 mM sodium chloride, 4.7 
mM potassium chloride, 2.5 mM calcium chloride, 1.2 mM magnesium sulphate, 1.2 mM 
potassium dihydrogenphosphate, 25 mM sodium bicarbonate and 8.3 mM glucose; pH 7.4. 
The vessel was cut into rings of approximately 4 mOl of length and suspended on stainless 
steel hooks in 8 ml organ baths containing the Krebs bicarbonate solution, aerated with 
95% 0, and 5% CO, and maintained at 37° C. Vessel segments containing macroscopi-
cally visible atherosclerotic lesions, were not used in the present study. The segments were 
allowed to equilibrate for at least 30 min and washed eve,y 15 min. Changes in tension 
were recorded using a Harvard isometric transducer. Preparations were stretched to a 
pretension of 20 mN. The tissue was exposed to K+ (30 mM) twice. Subsequently, the 
functional integrity of the endothelium was verified by observing relaxation to substance 
P (I nM) after precontraction with prostaglandin F,. (pGF,o' I flM). Five segments from 
two hearts did not relax to substance P, and were discarded from the experiments. After 
washout, the tissue was exposed to 100 mM K+ to determine the maximal contractile 
response to K+. The tissue was then allowed to equilibrate in the Krebs solution for a 
period of 30 min. 
Determination of agonist alld alltagonist potency 
After this period of equilibration, some segments remained untreated (controls), 
whereas others were incubated with a receptor antagonist for thirty minutes. After that, a 
cumulative concentration response curve was obtained on every segment until the 
maximum response (EMAX) was reached. Responses were expressed as increase of tension 
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(mN). Curves obtained in the presence of a receptor antagonist were compared to the 
control cUl've. All curves were obtained in a paired, parallel experimental set-up. 
Isolation of platelets and platelet experiments 
Approximately 23 ml of blood was obtained from each of 6 healthy male donors, age 
26-52 years, who had not taken anti-platelet dlUgs for at least 14 days prior to the 
experiment. Platelets were isolated essentially according to Ref. 23. In brief, the blood was 
centrifuged for 40 min at 55 g and 20°C, after which the platelet rich plasma was pipetted 
off and an equal volume of citrate anticoagulant solution (5 mM potassium chloride, 105 
mM glucose, 93 mM sodium citrate, 7 mM citric acid; pi-i 6.5) was added. Centrifugation 
for 20 min at 570 g (20°C) produced a platelet pellet which was resuspended in 2.5 ml 
of the citrate solution. The platelet concentration in the obtained suspension was 
determined using a Platelet Analyzer, Hematology Series 810 (Baker instJuments, 
Allentown PA, USA). The platelets were added in a cumulative manner to the organ baths 
in volumes to result in concentrations of 10' - 3.10 10 platelets pel' litre. Responses were 
expressed as increase of tension (mN). Care was taken to minimize the amount of time 
during which the platelets had to be kept before adding (less than 35 min at room 
temperature). A sample (500 Jll), taken thit1y min after the last platelet concentration had 
been added, was centrifuged for 20 min at 570 g in the presence of 30 JlM indomethacin, 
pipetted off and frozen at -70°C until 5-HT was detennined using high performance 
liquid chromatography (HPLC) with electrochemical detection. 
Analysis of Data 
Curves that covered the fhll sigmoidal range were analyzed by means of a 
computerized cUl've fitting technique 24 to obtain EMAJ( (maximal response) and pD, (-Log 
of the molar concentration of an agonist needed to reach half of its maximal effect, i.e. 
-LogECso) values, which were averaged for the respective agonists. For antagonists against 
sumatriptan, approximate pK[) values were calculated, assuming the nahlre of antagonism 
to be competitive, by the equation described by Furchgott ": 
pKD = -Log[Bl + Log{([A,l/[Ad)-I}, 
where [Bl is the antagonist concentration and [All and [A,l are, respectively, the EC" 
values of the agonist in the absence and presence of [Bl. For calculation of approximate 
pKD values only paired experiments were taken into account. 
All data are presented as mean ± S.E.M .. Multiple analysis of variance (MANDV A) 
followed by Student's t-test for paired data was used for comparison of mean contractile 
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responses. pD2 and E",fAX of sumatriptan-induced contractions without or in the presence 
of an antagonist were compared using a paired Student's t-test. A correlation coefficient 
was calculated according to Pearson. A P value less than 0.05 was assumed to denote a 
significant difference. 
Compol/nds 
The following dlUgs were used in this study: cyanopindolol (gift: Sandoz AG, Basel, 
Switzerland), ergotamine tartrate (Pharmacy A.Z.R.-Dijkzigt, Rotterdam, the Netherlands), 
5-hydroxyttyptamine creatinine sulphate (5-HT; Sigma Chemical Co., st. Louis, USA), 
ketanserin tartrate (gift: Janssen Phannaceutica, Beerse, Belgium), meter go line (gift: 
Farmitalia, Milan, Italy), prostaglandin F," (tris salt), substance P acetate (both: Sigma 
Chemical Co., st. Louis, USA), rauwolscine hydrochloride (Fluka AG, Buchs, Switzer-
land) and sumatriptan (gift: Glaxo, Ware, U.K.). 
5.3 Results 
The effict of substance P and potassium 
Vessel segments relaxed to substance P (I nM) after precontract ion with 
prostaglandin F," (l J.lM) with 75.9 ± 6.1% (range 15-108%) of the contractile response 
to prostaglandin F2(I' which is in accordance with previous studies on substance P in the 
human isolated coronary mtery obtained from patients undergoing cardiac transplanta-
tion 26-28. K+ (100 mM) caused a mean contractile response of 47.3 ± 3.5 mN. No 
difference in the mean contractile response to K+ (100 mM) was observed in any of the 
compared groups. 
Analysis of the responses to 5-HT, sUlllatriptan and human washed platelets 
5-HT caused concentration dependent contractions of the vessel segments (pD,: 
6.8 ± 0.1, E'lAx: 47.7 ± 6.8 mN, n~II). Ketanserin (l J.lM) biphasically antagonized 
5-HT-induced contractions (n~II). The 5-HT,-like receptor antagonists cyanopindolol and 
rauwolscine (both: I J.lM, n~ II and 10 J.lM, n~6) significantly attenuated the leftover first 
phase in the presence of ketanserin (Le. 5-HT concentration'; I J.lM) in a concentration-
dependent manner (Figure I). 
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Figure ], Contractions of the human isolated coronary m1ery to 5-HT. Control concentration 
response curves (n=ll, 0) or curves made in the presence of ketanserin (l ~M, n=ll, e), 
ketanserin (I ~M) combined with rauwolscine (I ~M, n=ll, .; to pM, n=6, D) or ketanserin 
(I I'M) combined with cyanopindolol (I liM. n~ll •• ; 10 I,M. n~ll. v). Contractions are 
expressed in mN increase of tension, *, Left panel: statistically different (P<O,05) from the control 
response; *, Middle and right panel: both I ~lM and to ~M of rauwolscine and cyanopindolol 
cause significant (p<O.05) attenuation compared to contraction in the presence of ketanserin 
(I I,M) alone; #: Only 10 liM cyanopindolol causes significant (P<O.05) additional antagonism. 
when compared to curve in the presence of ketansel'in (l ~M) alone, 
Sumatriptan generated concentration·dependent coronary m1ery contractions (n~8; 
pO,: 6.2±0.1; EMAx:10.7 ± 2.4 mN 01' 22% of the maximal response to 5-HT). A 
significant rightward shift of the sumatriptan-induced concentration response curve was 
caused by rauwolscine (I (.1M) or cyanopindolol (I liM) and also metergoline (0.1 liM) 
(Figure 2). A pK. value of6.5 ± 0.1, 6.4 ± 0.1 and 7.2 ± 0.1 respectively, was calculated 
for these antagonists. 
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Figure 2. Contractions of the human isolated coronary artery to slimatriptan (n=5) without 
(0, conlrol) or in the presence of melergoline (0.1 I'M, +), rauwolscine (I I'M, III) or 
cyanopindolol (l I-lM, ... ). The concentration of sumatriptan refers to moUI. Contractions are 
expressed in mN increase of tension. 
15 T 8 8 
Z 
E-
" 
10 
0 
'u 4 4 
~ 6 E 
0 () 
0 
* 
0 o 
3 10 30 3 10 30 3 10 30 
.10' platelets!1 .10' platelets!1 .10' platelets!1 
Figure 3, Contractions of the human isolated coronary artery to human platelets (n=6). Control 
concentration response curves (0) or curves made in the presence of ketanserin (l JlM, fit), 
ketanserin combined with rauwolscine (both 111M. II) or ketanserin combined with cyanopindolol 
(both 1 J.l.M, v). Contractions are expressed in mN increase of tension. *, statistically different 
(p<0.05) from control response. 
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Human washed platelet-induced contractions reached 14.4 ± 2.8 mN. At the highest 
platelet concentration tested, the concentration response curve had not reached the 
maximum response (Figure 3). Since one is restricted with the amount of blood that can 
be drawn from the platelet donor, higher platelet concentrations were not used. Ketanserin 
(I J.lM) antagonized contractions induced by platelets to reach 6.5 ± 1.8 mN. Against 
leftover platelet-induced contractions in the presence of ketanserin (I J.lM), rauwolseine 
(1 !IM) or cyanopindolol (I !IM) did not cause significant additional antagonism of the 
contractile response (Figure 3). The concentration of 5-HT, measured in the organ bath 
30 min after adding the highest platelet concentration, was 65 ± 10 nM. 
The pD, and EMAX values for sumatriptan and 5-HT, or the maximal effect of 
platelets, did not correlate with the functional endothelial integrity, as determined by 
relaxation to substance P (0.03 ,; r ,; 0.64; P <: 0.12). 
The e.!foct of ergotamine 
Ergotamine caused a concentration dependent contractile response of the vessel 
segment, reaching 19.4 ± 2.4 mN or 40.7% of 5-HT-induced contractions (n~6). The pD, 
of ergotamine was 8.4 ± 0.3 (Figure 4). A full concentration response curve to ergotamine 
took 54 ± 14 min, whereas a full concentration response curve to sumatriptan took 17 ± 1 
min (data from six paired experiments). 
5.4 Discussion 
In the present study, we compared the effect of selective 5-HT, receptor antagonism 
to the effect of mixed 5-HT,t5-HT,-like receptor antagonism on contractions evoked both 
by 5-HT and activated human washed platelets. Moreover, we attempted to funher 
characterize the 5-HT,-like receptor subtype, using the selective 5-HT,-like receptor 
agonist sumatriptan as a tool. We showed that ketanserin significantly attenuated 5-HT-
andlor platelet-induced contractions. For 5-HT, this inhibition was biphasic. In the 
presence of ketanserin, rauwolseine and cyanopindolol caused a significant, concentration 
dependent ft1l1her attenuation of contractions induced by low (,; 1 J.lM) concentrations of 
5-HT. Sumatriptan-induced contractions were competitively antagonized to a similar extent 
by both rauwolseine (I !IM) and cyanopindolol (I !IM) and also by metergoline (0.1 !IM). 
In platelet experiments, cyanopindolol and rauwolscine did not contribute significantly to 
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Figure 4. Contractions of the human isolated coronary artery to the anti-migraine drugs 
ergotamine (A) and slimatriptan (D)j and 5-HT (0); n=6-11. Agonist concentration refers to moili. 
Contractions are expressed in mN increase of tension. 
antagonism produced by a combination of 5-HT,-like and 5-HT, receptor antagonists 
(Figure 3), There may, however, be a trend similar to data obtained with 5-HT (Figure I), 
The present results are to a certain extent in keeping with those of other investigators 4, " 
who concluded that, in terms of efficacy, human coronary artery contractions to 5-HT are 
mediated predominantly via 5-HT, receptors, These authors drew their conclusions from 
the fact that ketanserin was a potent antagonist of 5-HT-induced contractions and that 
contractions to sumatriptan of the human coronary artery amounted only up to 21 % of the 
maximal response to 5-HT 4, Later, Chester and colleagues 7 showed that methiothepin 
antagonized sumatriptan-induced contractions, whereas ketanserin and MDL 72222 (a 
5-HT, receptor antagonist) did not have such an effect, indicating that sumatriptan 
contracts the human coronary at1ery via a population of contractile 5-HT,-like receptors, 
The significance of contracli/e 5-HT,-like receplors as compared 10 5-HT, receptors 
From a theoretical point of view one would expect that, given the presence of a 
mixed receptor population mediating contraction, low concentrations of 5-HT activate 
primarily the 5-HT,-like receptor since 5-HT has approximately 100-fold higher affinity 
for 5-HT,-receptor subtypes than for 5-HT, receptor subtypes in the brain 16, On the other 
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hand, in view of functional pD, values in S-RT,-like and S-RT,-receptor assays (e.g. dog 
saphenous vein and rabbit aorta "), one could argue that the difference in affinity for 
vascular receptors may be less, or that this difference is blunted by second messenger 
mechanisms. When considering the potential advantages of a mixed S-RT, / S-RT,-like 
receptor antagonist, a possible difference in receptor affinity suggests that, at low 
concentrations of S-RT, the relative contribution of the S-RT,-like receptor antagonism 
would be increased when compared to the contribution of S-RT, receptor antagonism. In 
our experiments, ketanserin (1 J.lM) reduced the small contractile response elicited by 
0.01 J.lM S-RT from 1.2 ± OJ mN to 0.6 ± 0.1 mN. Both cyanopindolol and rauwolscine 
(10 J.lM) completely and significantly abolished the small leftover contractile response. 
Although indeed the contractions caused by this concentration of S-RT are small, these 
data indicate that, at this concentration of S-RT, approximately 50% of the contractile 
response was mediated by S-RT,-like receptors. At S-RT concentrations of 0.1 !lM and 
1 J.lM the relative contribution of the S-RT,-like receptor antagonism to total antagonism 
(i.e. by the combinations of ketanserin and rauwolscine or cyanopindolol) decreased to 
approximately 16% and 9%, respectively. 
At present, to our knowledge, one can only speculate on the actual concentration of 
S-RT ill vivo, when platelets aggregate close to the vascular smooth muscle cell. The 
concentration of S-RT, measured in the organ bath after addition of 3.1010 platelets per 
litre, was 65 ± 10 nM. The concentration of S-RT, as measured by Van den Berg and 
co-workers' in the aOlia in vivo was approximately 85 nM, which may relate to S-RT 
concentrations near the smooth muscle cell, but which could also be much lower. In this 
respect, it is important to keep in mind that the platelet-release of S-RT is accompanied 
by several other contractile (thromboxane A" TxA" and prostaglandin E" POE,) but also 
relaxant (adenosine diphosphate, ADP) agents I. The endothelium-dependent relaxant effect 
by the latter, however, appears to be of less significance in atherosclerotic patients. In 
cooperation with the cyclooxygenase-derived contractile agonists, a low concentration of 
S-RT may cause severe vasoconstriction. Therefore, it is of particular interest that several 
authors have suggested synergistic interaction between S-RT- and thromboxane 
A,-receptor-mediated responses 30.". Interestingly, in the rabbit femoral artery, which also 
contains contractile S-HT,-like and S-HT, receptors, the presence of the stable 
thromboxane A,-mimetic U46619 altered the efficiency of S-HT,-like- but not S-HT, 
receptor occupancy-effect coupling, thereby increasing the maximal effect to sumatriptan 
but not to a-methyl-S-HT 34. 
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Does the contractile 5-HTr like receptor resemble any of the known receptor subtypes? 
We concentrated on the contractile response elicited by the selective 5-HTI-like 
receptor agonist sllmatriptan, as was also done previously in the human saphenous vein I'. 
Metergoline (0.1 J.IM), rauwolscine (1 J.IM) and cyanopindolol (1 J.IM) all caused a small 
but significant rightward shift of the sumatriptan-induced concentration response curve. 
The order of potency of these antagonists (metergoline > rauwolscine '" cyanopindolol) 
was similm' to the order found for antagonism against sumatriptan in the human saphenous 
vein, in which the receptor was characterized as being 5-HTID-like (human isolated 
saphenous vein: pK.: 6.9 ± 0.3, 6.7 ± 0.2 and 6.5 ± 0.3, respectively; pD, sumatriptan: 
6.1 ± 0.1, see Ref. 15). In this aspect, a shift of 1.05 log units, as found for methiothepin 
(0.1 flM) against sumatriptan-induced contractions of the human coronary artery', appears 
to be in line with the present results and the human saphenous vein 5-HTID-like receptor. 
An almost equal potency of rauwolscine and cyanopindolol, and the fact that ketanserin 
was inactive as an antagonist against sumatriptan ' virtually lUles out involvement of a 
contractile 5-HTINIB 01' a 5-HTlc (now: 5-HT,c) receptor, respectively. Further charac-
terization of the contractile coronary m1ery 5-HTI -like receptor as one of the recently 
cloned 5-HTlDa 01' 5-HTlDp receptors" may benefit from mRNA identifying techniques 
more than from functional tests such as the organ bath. A remarkably enduring lack of 
sufficiently selective agonists and antagonists and a steadily increasing amount of closely 
related newly cloned receptor subtypes severely impairs detailed functional receptor 
analysis. 
Contractile 5-HTr like receptors and atherosclerotic changes of the vascular wall 
Contractile 5-HTI-like receptors in the human coronary m1ery have been emphasized 
before 6, especially with respect to an increase in 5-HTI-like receptor mediated responses 
in 01' near atherosclerotic areas of the vessel'. We have found no cOlTelation between pD, 
and EMAX of sumatriptan, 5-HT 01' platelets mId the relaxation to substance P after 
precontraction with prostaglandin F'a' Substance P relaxes the vessel via an endo-
thelium-dependent (nitric oxide-mediated) mechanism, the effect of which is decreased in 
case of atherosclerosis 27.". In contrast to Chester and colleagues " who compared 
atherosclerotic segments to non-atherosclerotic segments within one patient, we have only 
studied macroscopically non-atherosclerotic tissue in which relaxation to substance P 
varied from 15 to 108% of precontraction. The latter variation may be a reflection of 
generalized intimal hyperplasia and early atherosclerosis (which were observed using light 
microscopy), whereas the differences found by Chester and co-workers' reflect localized 
atherosclerotic plaque formation. This discrepancy may be an explanation for the 
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divergence, Our data suggest, however, that there may not be an unequivocal link between 
atherosclerotic changes and the response to 5-RT related ligands, Similar conclusions were 
reached for the potency of 5-RT by Kaumann and Brown 6, 
Comparisoll ojthe cOlltractile effoct ojswllah'iptan alld ergotamine, 
The potential coronary side-effects of the new anti-migraine dl1lg sumatriptan have 
gained widespread attention 19,20,37, First, it must be admitted that the concentration 
response curves of sumatriptan and ergotamine are not easily compared due to the 
extremely slow nature of the contractile response caused by ergotamine 38. For this reason 
we have not fU1iher analyzed the receptor that mediates the contractile response to 
ergotamine. The slow response to ergotamine may have resulted in a somewhat 
underestimation of the ergotamine-induced contractile responses. Yet, ergotamine was 
functionally approximately 100-fold more potent than sumatriptan, Since the affinity of 
ergotamine and sumatriptan for the 5-I-ITID receptor is approximately similar 16, the major 
difference in functionally determined pD, values may well be due to the high affinity of 
ergotamine for the 5-RT,receptor (100 times that of 5-RT) 16,39, Sumatriptan, on the other 
hand, is selective for the 5-RTI-like receptor 18, Also the higher efficacy of ergotamine 
may indicate that other receptors than the 5-HTI-like receptor are involved 40, Indeed, it 
is not unlikely that a-adrenoceptors, dopamine- and other Cas yet unknown) receptors are 
involved in the contractile response to ergotamine, Ergotamine has substantial affinity for 
e,g, a-adrenergic and dopamine receptors 41, Our results suggest that the cardiac liability 
of ergotamine is higher than that of sumatriptan, Still, extreme care has to be taken when 
prescribing sumatriptan to possibly coronary miery compromised patients, 
We conclude that the 5-HTI -like receptor plays a role in coronary miery contractions 
induced by low concentrations of 5-RT C'; I flM), although 5-RT, receptors predominantly 
mediate 5-RT-induced contractions 4,', The contractile 5-RT I-like receptor resembles the 
human saphenous vein 5-RTID-like receptor, FU1ihermore, ergotamine is 100-fold more 
potent than sumatriptan as a constrictor of the human isolated coronary m1ery, 
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Low dose aspirin inhibits platelet-induced contraction 
of the human isolated coronary artery; 
A role for additional 5-HT receptor antagonism 
against coronary vasospasm?* 
Summary - Background. The beneficial effect of low dose aspirin in the prevention 
of coronary vasospasm is well documented. In this study we investigated the 
contractile effect of human washed platelets on the human isolated coronary mtery. 
We concentrated on the effect of low dose aspirin (40 mg per day), taken by the 
platelet-donor and on the efficacy of thromboxane A, (TxA,)- and 5-hydroxy-
tryptamine (5-HT) receptor mltagonists. 
Methods and Results. Human coronary altery segments were suspended in an organ 
bath set-up for isometric tension measurement. Platelets (10'-3.1010/1) elicited 
concentration dependent contractile responses of the coronary artery segments 
reaching 28.4 ± 7.1% of contractions induced by 100 mM K+. The contractile 
response tended to be decreased in vessel segments with histological signs of early 
atherosclerosis. Contraction was significantly attenuated after pretreatment of the 
vessel segments with ketanserin (5-HT, receptor antagonist, 111M) or SQ30741 
(TxA, receptor antagonist, 0.01 11M), reaching 8.8 ± 2.3% and 3.2 ± 2.2% of 
contraction to 100 mM K+, respectively. Platelets obtained fi'om the same platelet-
donors after taking aspirin (40 mg/day for 7-13 days) caused significantly lower 
contractile responses (7.6 ± 2.7% of 100 mM K+) associated with an almost selective 
inhibition of the synthesis of thromboxane measured in the organ bath solution 
(untreated platelets: 2.19 ± 0.43 nM; aspirin-treated platelets: 0.66 ± 0.05 nM). The 
amount of 5-HT secreted in the organ bath remained unaltered (65.17 ± 9.94 11M and 
64.03 ± 8.98 nM, respectively). This explains why ketanserin significantly attenuated 
*. Based on: Bax, W.A., Renzenbrink, OJ., Zijistra, FJ., Fekkes, D., Van Heuven-Nolsen, D., 
Van del' Linden, E.A., Bos, E. and Saxena, P.R. (1994) Low dose aspirin inhibits platelet-induced 
contraction of the human isolated coronary artery; a role for additional 5-HT receptor antagonism 
against coronary vasospasm? Circulation 89, 623-629. 
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the residual contractile responses caused by platelets obtained from aspirin-treated 
subjects, whereas SQ30741 caused minor, non-significant additional attenuation, 
Conclusion. The results of the present study theretore suggest that additional 
antagonism of the contractile 5-HT receptors in the coronary mtery may increase the 
efficacy of low dose aspirin in vivo, 
6,1 Introduction 
Aspirin has been shown extensively to be effective in the prevention of a number of 
cardiovascular diseases, A daily dose of 325 mg reduced the risk of myocardial infm'ction 
by 44% ',A much lower dose of20 to 40 mg already caused complete inhibition of the 
synthesis ofthromboxane A, (TxA,) " which, together with 5-hydroxytryptamine (5-HT, 
serotonin), are the major vasoconstrictor products involved in platelet-induced vaso-
contraction 3,', This same dose of aspirin (20-40 mg daily) hardly affected the endothelial 
production ofprostacyclin (PGI,), which has anti-aggregatory and vasorelaxant effects 5,6, 
Guided by the latter observations, clinical investigators have focused their attention on low 
doses of aspirin, Thus, 75 mg aspirin daily resulted in a significant (60%) reduction of the 
risk of myocardial infarction and subsequent death 7 in silent as well as in symptomatic 
ischemia " An even lower dose of aspirin -30 mg- was found to be equally effective in 
the prevention of vascular events and had fewer adverse effects than a 283 mg dose in 
patients with a transient ischemic attack or minor stroke " 
Damage of the endothelial lining of the vascular wall is thought to incite platelet 
adhesion to the exposed subendothelial collagen with the subsequent release of platelet 
products 10, ", Experimentally induced atherosclerosis in monkeys was found to alter the 
response to important platelet products like 5-HT, ADP and TxA, in a direction that would 
favour vasoconstriction when these products are released from aggregating platelets ", 
Indeed, elevated levels of both 5-HT 13 and thromboxane B, (TxB,), the stable metabolite 
of TxA, 14, IS, have been observed in patients with coronary artery lesions and angina, 
In the present experiments we investigated the effect of low dose aspirin, taken by 
the platelet-donors, on platelet-induced contractions of the human isolated coronary m1ery, 
We concentrated on the relative importance of cyclooxygenase products and 5-HT, before 
and after aspirin treatment. We attempted to relate the contractile responses to the organ 
bath concentration of various vasoactive compounds which are believed to be involved in 
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the generation and prevention of coronary vasospasm. Lastly, we microscopically 
examined sections of the vessel segments and tried to correlate early signs of 
atherosclerosis to ftmctional responses. 
6.2 Methods 
Preparation of the tisslle 
Right epicardial coronary arteries were obtained from 10 heart beating organ-donors 
who had died of non-cardiac disorders less than 24 h before the tissue was taken to the 
laboratory (3 cerebrovascular accident, 3 polytrauma, 4 cerebral hypoxia; 8 male, 2 
female; age 7-48 years). The hearts were provided by the Rotterdam Hemi Valve Bank 
(Bio Implant Services / Eurotransplant Foundation) after removal of the aOliic and 
pulmonm')' valves for valve transplantation. The slndy was approved by the Ethical 
Committee of the University Hospital Rotterdam 'Dijkzigt'. The.hemis were stored at 
0-4 °C in a sterile organ protecting solution immediately following circulatory an·est. After 
an'ival in the laboratOl')', the right coronal')' miel,), was removed and placed in a cold, 
oxygenated Krebs bicarbonate solution of the following composition: 118 mM NaCI, 4.7 
mM KCI, 2.5 mM CaCI" 1.2 mM MgS04, 1.2 mM KHP04, 25 mM NaHC03 and 8.3 mM 
glucose; pH 7.4. Vessels were cut into rings of approximately 4 mm of length and 
suspended on stainless steel hooks in 8 ml organ baths containing the Krebs bicarbonate 
solution, aerated with 95% 0, and 5% CO, and maintained at 37° C. Vessel segments 
containing distinct, macroscopically visible atherosclerotic lesions, were not used. 
Experimental protocol 
The segments were allowed to equilibrate for at least 30 min and washed every 15 
min. Changes in tension were recorded using a Harvard isometric transducer. Preparations 
were stretched to a pretension of 2 g. The tissue was exposed to potassium (30 mM) twice. 
Subsequently, the functional integrity of the endothelium was verified as relaxation to 
substance P (I nM) after precontraction to prostaglandin F,o (pGF,u' I ~IM). One segment 
did not relax to substance P and was discarded fi'om the experiments. After washout, the 
tissue was exposed to 100 mM potassium to determine the maximal contractile response. 
The tissue was then allowed to equilibrate for 30 min. A cumulative concentration 
response curve (CRe) was obtained after another 30 min period. During this period, some 
segments remained untreated (controls), whereas others were incubated in parallel with a 
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receptor antagonist. In some cases control curves were obtained in duplicate or triplicate, 
which were averaged and regarded as one curve in futiher analysis. The contractile 
response was expressed as a percentage of contraction induced by 100 mM potassium. 
Isolalioll of plalelets 
Approximately 23 ml of blood was obtained fi'Om each of 6 healthy male donors 
(age: 26-52 yrs) who had not taken anti-platelet dlUgs for at least 14 days prior to the 
experiment. Platelets were isolated essentially according to Yang et ai. (1991) 4. In brief, 
blood was centrifuged for 40 min at 55 g and 20°C, after which the platelet rich plasma 
was pipetted off and an equal volume of citrate anticoagulant solution (5 mM potassium 
chloride, 105 mM glucose, 93 mM sodium citrate, 7 mM citric acid; pH 6.5) was added. 
Centrifugation for 20 min at 570 g (20°C) resulted in a platelet pellet which was 
resuspended in 2.5 ml of the citrate solution. The platelet concentration in the obtained 
suspension was determined using a Platelet Analyzer (Hematology Series SIO, Baker 
InstlUments, Allentown PA, USA). The suspension was added in a cumulative manner to 
the organ baths in appropriate volumes to result in bath concentrations of ]0' - 3.1010 
piatelets/i. Since the platelets were readily activated after adding to the organ bath, 
resulting in platelet product release and consequential functional responses, we did not 
ftuiher regulate or induce the state of platelet activation. Care was taken to minimize the 
time during which the platelets had to be kept before adding (less than 35 min). After the 
first experiment the platelet-donors were treated with aspirin (acetyl salicylic acid, 
Pharmachemie b.v., Haarlem, The Netherlands); 40 mglday, once daily at regular 
intervals) for a period until again human coronary tissue was available for experimenta-
tion. This period varied between 7 and 13 days. Then, another 23 ml of blood was drawn 
from the platelet-donor and the experiment was repeated, as described above. 
Determination of the concentration of eicosanoids and 5-HT 
Thitiy minutes after adding the highest concentration of platelets, a sample of I.S ml 
was drawn from the organ bath in a polypropylene tube and indomethacin (30 JlM) was 
added to stop cyclooxygenase activity. The samples were centrifuged at 570 g during 20 
min. The solution above the pellet was pipetted off and stored at -so °C until assay. The 
following eicosanoids were determined in this organ bath sample: TxB" PGE" and 6-keto 
PGF,o (stable metabolite of PGI,). Twenty microliter (TxB,) and 100 JlI (PGE, and 
6-keto-PGF,o) pOliions of the organ bath solution were used for radioimmunoassay 
(RIA) 16. Tritiated compounds lVere purchased from Amersham (U.K.), standards from 
Sigma Chem. Co. (St. Louis, Mo, USA) and antisera from Advanced Magnetics Inc. 
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(Cambridge, Ma, USA). The lower detection limits of the TxB" PGE" and 6-keto-PGF,a 
assays were 1.25, 2.5, and 5 pg pel' tube, respectively. Radioactivity was determined by 
counting scintillation using a Packard 1500 Tricarb. Calculations were performed with 
additional software using spline functions. 
5-HT was determined by high performance liquid chromatography (HPLC) with 
electrochemical detection. Organ bath solution (400 I!I) was mixed with an equal amount 
of mobile phase and 20 I!I samples were injected onto a reversed phase column (Bio-Sil 
CIS AlB, 5 I!m, 150 x 4.6 mm, Bio-Rad Laboratories, Bmssels, Belgium). The mobile 
phase consisted of 75 mM sodium acetate, 0.27 mM disodium EDTA, 2.13 mM heptane 
Sl"phonic acid and 20% methanol, pH 4.15 (flow rate: O.S mllmin; column temperature: 
40 "C). The detection system consisted of a model 5100A Coulochem detector equipped 
with a 5021 conditioning cell and a SOil high sensitivity cell (ESA, Bedford, MA). 
Potentials for the conditioning cell and detectors I and 2 were -0.20, +0.08 and +0.45 V, 
respectively (gain: 30xI00). Quantification was done by measuring peak heights. The 
lower detection limit for 5-HT was estimated at 5 nM. In samples in which the eicosanoids 
or 5-HT could not be detected, the concentration was assumed to equal the lower detection 
limit concentration. 
Histological examinalion 
Thirteen coronary artery segments obtained from 6 healis, which were used for a 
control concentration response curve by untreated platelets, were analyzed histologically 
to correlate the functional results to signs of early atherosclerosis. After the organ bath 
experiment the vessel segments were fixed in 10% formalin, and stained with 
haematoxylin-eosin and elastic-Van Gieson. Sections were examined microscopically, and 
signs of atherosclerosis were scored in two blind independent sessions in a semi-
quantitative fashion, modified from Ginsburg et at. (1984) 17. In brief, three vessel 
characteristics were scored: degree of luminal occlusion, fragnlentation of the intemal 
elastic lamina and intimal hypelproliferation. Each categOlY was scored on a scale from 
I to 3, with I being completely healthy and 3 being severely diseased. Thus, the mean 
Coronruy AlielY Disease Scale (CADS) was calculated for each vessel segment and 
correlated to functional parameters. 
Analysis of dolo 
All data are presented as mean ± SEM. Analysis of variance for multiple compari-
sons (Duncan) followed by a Student's I-test, for paired data where appropriate, were used 
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for comparison of mean contractile responses and organ bath concentrations. A conelation 
coefficient, 1', was calculated according to Pearson. A p value less than 0.05 was assumed 
to denote a significant difference. 
Compounds used in the study 
The following compounds were used during the organ bath experiments: ketanserin 
tartrate (gift: Janssen Pharmaceutica, Beerse, Belgium); prostaglandin F'a (tris salt) and 
substance P acetate ( Sign," Chem. Co., St. Louis, USA); SQ30741 (I S-[ I <a,2<a(Z),3<a, 
4<a]-7-[3-[[[[( l-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]- 5-
heptenoic acid; gift: Bristol-Myers Squibb, Princeton, New Jersey, USA). All compounds 
were dissolved in distilled water except SQ30741, which was dissolved in ethanol. 
6.3 Results 
Responses of coronary or/elY segments 
Mean relaxation to substance P was 74 ± 8% of precontraction to PGF'a (1 11M), 
which is in accordance with previous studies on human coronary at1eries obtained from 
heart transplant recipients IS. Potassium (100 mM) caused a mean contractile response of 
55.5 ± 7.6 mN. No difference in the mean contractile response to potassium (100 mM) 
was observed in any of the groups compared. 
Platelets contracted the vessel segnlents in a concentration-dependent manner. No 
contractile or relaxant response was elicited by the citrate buffer itself in which the 
platelets Were suspended (data not shown). At the highest platelet concentration tested, the 
concentration response curve had not reached the maximum response (Figure I). Since one 
is restricted by the amount of blood that can be drawn from platelet-donors, higher platelet 
concentrations were not used. The maximal response at 3.10" plateletsll reached 28.4 ± 
7.1% of the response to potassium (100 mM). Both ketanserin (111M, a 5-HT, receptor 
antagonist) and SQ30741 (0.0 111M, a TxA, receptor antagonist) reduced (p<0.05) the 
maximal response to platelets to 8.8 ± 2.3% and 3.2 ± 2.2% of potassium-induced 
responses, respectively. A combination of these two compounds practically abolished the 
contractile response and even caused platelets to evoke small relaxations in some vessel 
segments (relaxation: 0.9 ± 1.9% of potassium-induced responses, Figure I). 
During the period in which the platelet-donors took aspirin (range 7-13 days) no 
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Figure 1. Contraction of the human isolated coronary artery to activated platelets. Control 
concentration response curve:o , curve in the presence of ketallserin {I pM):t. ; curve in the 
presence of SQ30741 (0.01 flM):O ; curve in the presence of the combination of ketanserin (I 
flM) and SQ30741 (0.01 fIM):v ; n=6 each. *: different (p<0.05) from control response, #: 
different (p<O.05) from the control response and also from the response to platelets in the presence 
of ketanserin alone. At a concentration of 1010 platelets/I, the response to platelets in the presence 
of SQ30741 alone was found to be different (p<O.05, *) from the control curve, whereas the 
contractile response to platelets in the presence of the combination ofketanserin and SQ30741 was 
different (p<O.05, #) from both the control response and from the response in the presence of 
ketanserin alone. Where no error bar is visible, error falls within the limits of the symbol. 
adverse effects were observed. The contractile response to platelets obtained after aspirin 
treatment was significantly decreased reaching only a maximum of 7.6 ± 2.7% of 
potassium-induced contraction (Figure 2). Although SQ30741 (0.01 flM) was more potent 
than ketanserin (I [.1M) against untreated platelets (Figure I), ketanserin appeared to be 
more potent than SQ30741 against platelets from aspirin-treated platelet donors. As 
depicted in Figure 3, .8Q3074I (0.0 I flM) no longer significantly reduced the residual 
contractile responses. Contractions to aspirin-treated-platelets were however significantly 
attenuated by ketanserin (I flM) (contraction: 0.9 ± 1.9% of potassium-induced 
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Figure 2, Contraction of the human isolated coronary artery to activated platelets, Concentration 
response curve of platelets obtained from subjects before aspirin treatment:o; concentration 
response curve of platelets obtained from the same subjects after treatment with 40 mg/day 
aspirin:. ; n=6 each. Contractions are expressed as a percentage of contraction induced by 100 
mM potassium. *, different (p<0.05) from 'non~treated' (control) response. Where no error bar 
is visible, it falls within the limit of the symbol. 
contraction). Pretreatment with a combination of ketanserin and SQ30741 now caused a 
clear concentration dependent platelet-induced relaxation of the coronary at1ery segments 
(-5.0 ± 1.8% of the potassium-induced contractile effect, Figure 3). 
COllcelltrations of eicosalloids alld 5-HT ill the orgall bath solutioll 
The concentrations of eicosanoids (TxB" PGE" 6-keto-PGF I.) and 5-HT in the organ 
bath solution are shown in Table 1. When citrate buffer without platelets was added to 
the organ bath, no PGE" 6-keto-PGF I. or 5-HT could be measured significantly different 
from the lower detection limits (Table I; Section A). The concentration ofTxB, in these 
organ baths however, was significantly higher than the lower detection limit. After 
addition of3.101O non-aspirin-treated-plateletsll (Table I; Section B) a significant increase 
of TxB" PGE" and 5-HT was measured. The concentration of 6-keto-PGF1• increased 
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Figure 3. Contraction of the human isolated c~ronary artery to activated, aspirin treated platelets. 
Control concentration response curve:.; curve in the presence of ketanserin (1 ~tM): A ; curve in 
Ihe presence of SQ3074I (0.0 111M): III ; curve in the presence of Ihe combination of kelanserin 
(I I,M) and SQ30741 (0.01 11M),. ; n=6 each. Contractions are expressed as a percentage of 
contraction induced by 100 mM potassium. *: different (p<O.05) from control response. #J 
different (p<O.05) from the control response and also from the response to platelets in the presence 
of SQ30741 alone. Where no errOl· bar is visible, it falls within the limit of the symbol. 
from below the lower detection limit to 0.29 ± 0.08 nM. Ketanserin or SQ30741 did not 
influence the amount of TxB" POE" 6·keto-POF'a or 5-HT in the organ baths. Platelets 
obtained from aspirin-treated platelet-donors (Table I; Section C) secreted significantly 
smaller amounts of TxA, in the organ baths, as measured by the concentration of TxB,. 
The amount of POE" 6-keto-POF,a or 5-HT in the organ bath was not significantly 
affected by the treatment with aspirin. 
Corollary Artery Disease Scale (CADS) and filnctional parameters 
Histological examination of the control vessel segments used for experiments with 
untreated platelets, revealed early signs of atherosclerosis: modest intimal 
hyperproliferation, internal elastic lamina fragmentation, and luminal occlusion. The mean 
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CADS varied from 1.15 in a vessel segment obtained from a 7 year old tissue donor, to 
2.00 in a segment obtained from a 47 year old tissue donal'. The CADS correlated 
positively with age (t=0.84, p~O.OOO), but negatively with the percentage of relaxation to 
substance P (I nM) after precontraction with prostaglandin F,« (I ~IM) (1=-0.67, p~0.006). 
The CADS also cOiTelated negatively with the contractile response to untreated platelets 
(3.10 10/1), both when expressed as a percentage of potassium (100 mM)-induced 
contractions (1=-0.60, p~O.OI) and also when expressed as contraction in mN (1=-0.63, 
p~O.OI). 
6.4 Discussion 
In the present study we showed that both a TxA, receptor antagonist and a S-RT, 
receptor antagonist or low dose aspirin, taken by the platelet-donors, can attenuate 
platelet-induced contractions of human isolated coronary arteries. A S-RT, receptor 
antagonist caused a significant fullher reduction ofthe residual contractile response caused 
by aspirin treated-platelets. A TxA, receptor antagonist caused only minor, non-significant 
fUtlher attenuation of contractions induced by the aspirin treated-platelets. 
The effect of a TxA, receptor antagonist 
Platelets have been described to contract human isolated blood vessels by releasing 
S-RT and TxA" whereas platelet-derived ADP caused both the human coronruy artery and 
the intemal mammary mlelY to relax via the induction of endothelium-derived relaxing 
factor (nitric oxide, NO) '. 4. The thromboxane synthase inhibitor dezmegrel, however, only 
slightly enhanced platelet-induced relaxations of the precontracted (POF,o) human 
coronary mlery. The blockade of thromboxane synthase by dezmegrel resulted in an 
increased synthesis by platelets of both POF,. and POE" which were found to take over 
a pml of the contractile effect of TxA,. This seemed to be a major limitation to the 
clinical efficacy of tlu'omboxane synthase inhibitors '. More potent antagonism of 
platelet-induced contractions was achieved with the TxA, receptor antagonist SQ30741 19, 
which, in a concentration of 0.01 ,..M, caused marked inhibition of platelet-induced 
contraction of the human intemal mammmy artelY and the human saphenous vein 4. The 
present experiments show this to be valid also for the effect of untreated platelets on the 
human isolated coronmy rulelY (Figure I). Although another TxA, receptor antagonist 
(OR3219IB) has been shown to be ineffective in the prevention of coronary restenosis 
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Table 1. Concentration of TxB" POE, and 6-keto-POF,a and 5-HT (all in nM), measured in 
samples taken from the organ bath, 30 min after adding citrate buffer with (8 and C) or without 
(A) platelets. 
TxB, POE, 6-keto-POF'n 5-HT 
A. Citrate buffer, no platelets 0.39 (0.0 I)t 0,07 (0.00)* 0.14 (0.00) 5.90 (0.48)' 
B. Platelets from non-treated platelet-donors 
Control 2.19 (0.43) 0.42 (0.16) 0.29 (0.08) 65.17(9.94) 
Ketanserin, I ftM 2.30 (0.43) 0.44 (0.13) 0.23 (0.05) 76.32(12.38) 
SQ30741, 0.01 ftM 2.15 (0.59) 0.46 (0.14) 0.19 (0.03) 56.25 (7.09) 
Ketanserill, I J-lM, 1.70 (0.26) 0.42 (0.16) 0.23 (0.06) 79.00(12.77) 
and SQ30741, 0.0 I ftM 
C. Platelets from aspirilHreated plateietMdollors 
Control 0.66 (O.05)t 0.33 (0.17) 0.54 (0.26) 64.03 (8.98) 
Ketanserin, I ftM 0.56 (0.07) 0.40 (0.30) 0.40 (0.24) N.D. 
SQ30741, 0.01 ftM 1.04 (0.55) 0.42 (0.27) 0.81 (0.37) N.D. 
Ketanserin, I pM, 0.42 (0.05) 0.18 (0.08) 0.34 (0.19) N.D. 
and SQ30741, 0.01 ftM 
N.D.: Not determined; For statistical evaluation, the measured concentrations in the presence or 
absence of an antagonist or platelets (buffer, A) were compared to the respective (aspirin-untreated 
(B) or -treated (C» control situation where no antagonist was present. *': significantly different 
from the concentration measured for control platelets; t: as *' but also significantly different from 
the detection limit for this compound; The aspirilHreated control situation was compared to the 
nonatreated situation: t:significantly different from the untreated control situation. In samples in 
which the eicosanoid or 5-HT could not be detected, the concentration was assumed to equal the 
lower detection limit concentration. 
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after percutaneous trans luminal coronary angioplasty (PTCA) ", inhibition of the TxA, 
receptor may still have clinical perspective in the prevention of coronary vasospasm since 
they undoubtedly have potent receptor antagonist activity and do not affect the production 
of POI, and PGE, 'I. On the other hand, high concentrations of TxA" which may be 
present close to the vascular smooth muscle cell, could displace a competitive TxA, 
receptor antagonist, limiting the clinical efficacy of this potentially new class of 
anti-platelet d11lgs 22. 
The effect of 5-HT receptor antagonislIl 
Ketanserin (111M), a 5-HT, receptor antagonist, caused significant attenuation of 
platelet-induced contractions, indicating that the 5-HT, receptor plays an important role 
in the contractile response, as was found previously for both the human isolated internal 
mammaty artery and the saphenous vein 4. The contractile response to exogenous 5-HT 
is mediated by a mixed population of 5-HTI-like and 5-HT, receptors, but predominant 
mediation by 5-HT, receptors has been repOlted 23. ". It is quite likely, however, that the 
5-HTI -like receptor also plays a significant role. First, ketanserin alone was not found to 
be effective in the prevention of vasospastic angina ". Secondly, one may expect that 
5-RT in low concentrations (less than 1 !tM) activates especially 5-HTI -like receptors 
since it has significantly higher affinity for the different 5-HT1 receptor subtypes than for 
the 5-RT, receptor 26. Indeed, several authors have suggested that a mixed 5-HTI-like -
5-RT, receptor antagonist may be more effective in the treatment of coronaty 
vasospasm 27-30, 
The effect of low dose aspirin 
The mechanism by which aspirin decreases the morbidity and mOitality to 
cardiovascular disease is believed to be a generalized inhibition of production of 
contractile cyclooxygenase products, such as PGH" TxA, and PGE,. This process can be 
counteracted by a concurrent aspirin-induced decrease of the production of vasorelaxant 
and antiaggregatory POI, 'I, 31. The present experiments show that the systemic use of low 
dose aspirin results in a relatively selective decrease of TxA, production. The production 
of PGE, was left almost unaltered (Table I). Although the vessel segments in our study 
had not been exposed to aspirin, this same dose has previously been shown to preserve 
prostacyclin production in humans in vivo 5. '. 6-Keto-PGFla could only be detected after 
addition of platelets to the organ bath, indicating a, presumably endothelial, response to 
platelets or platelet products and the absence of a basal prostacyclin production in vitro 32. 
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TxB, was detected in the organ bath even when no platelets had been added, indicating 
basal vascular production of TxA" although TxA, derived from leftover tissue-donor 
platelets cannot entirely be excluded. The concentration of 5-HT was left unchanged by 
the treatment with low dose aspirin. Apart from HPLC meaSUl'ements this could also be 
reasoned from the fact that ketanserin was stiU significantly active as an antagonist after 
treatment of the platelets with aspirin (Figure 3), whereas SQ30741 caused only minor, 
non-significant additional attenuation of the residual contractile response. This was 
presumably due to a decrease of the TxA,-induced pml of the platelet-induced contractile 
response caused by treatment with aspirin. 
Correlatioll of Corollary ArMy Disease Score (CADS) alld jimctiollal parameters 
Despite the fact that the coronary arteries were obtained fi'om relatively young, 
apparently healthy organ donors, most vessel segments showed modest, age related signs 
of atherosclerosis: intimal hyperproliferation, internal elastic lamina fragmentation and 
luminal occlusion. It has to be kept in mind, however, that we avoided the use of vascular 
segments with distinct, macroscopically visible, atherosclerotic lesions. This analysis 
therefore refers to em'ly atherosclerotic development only. On the other hand, the present 
CADS appears to be in line with Ginsburg et a!. (1984) ", who found that CADS in 
coronary mleries ranged from 1.5 between 10 and 20 years of age, up to 2.2 between 40 
and 50 years of age. We observed that relaxation to substance P was inversely cOlTelated 
with the development of early atherosclerosis, confirming earlier repOlls concluding that 
atherosclerosis reduces the endothelium dependent, nitric oxide-mediated, relaxant response 
to substance P in the human isolated coronary mlery IS.33. 
In contrast to some animal models 34. ", we observed a tendency towards a decreased 
platelet-induced contractile response in mildly diseased vessel segments. In the present set-
up, both the luminal and serosal side were exposed to the platelet products. Kaul and co-
workers (1992) studied a perfusion model in which platelets were added on either the 
luminal or the serosal side. Indeed, only intraluminal, and not abluminal activation of 
platelets resulted in different responses of atherosclerotic and normal perfused atleries 34. 
It would therefore be of great interest to develop a similar model for the human isolated 
coronary artery. FlIlthermore it has to be noted that different platelet-stimulating agonists 
may induce the release of a somewhat different spectrum of platelet products II. In this 
model, as well as in previously adopted models 3.4. 10, platelets are apparently activated 
upon exposure to tissue collagen and Ca" in the Krebs solution. Thus, despite the human 
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nature of both platelets and coronary arteries, and ill vivo application of low dose aspirin, 
care has to be taken when extrapolating results obtained in vitro, to the ill vivo situation. 
Interactions betweell platelet products 
5-HT and TxA, are known to take part in an amplifying interaction at the vascular 
smooth muscle level 36.". Therefore, it seems rational not only to counteract the contractile 
effects of both TxA, and 5-HT per se, but also to interfere with the amplifying interaction. 
Interestingly, the presence of the stable TxA, mimetic, U46619, increased the response 
mediated by 5-HTI-like receptors but not by 5-HT, receptors 39. ", emphasizing also in this 
respect the potentially beneficial effect of a mixed 5-HTI-like / 5-HT, receptor antagonist 
when compared to a selective 5-HT, receptor antagonist like ketanserin. 
Whether the effect of TxA, ill vivo could be counteracted more effectively by a 
thromboxane synthase inhibitor, TxA, receptor antagonists or a combined synthase 
inhibitor-receptor antagonist than by low dose aspirin still remains to be proven ", since 
low dose aspirin is clinically very effective at low cost 1.8. '. In coneiusion, the present 
study shows that additional antagonism of the coronary artery contractile 5-HT receptors 
may increase the efficacy of low dose aspirin ill vivo. 
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Chapter 7 
Endothelin receptors in the humau coronary 
artery, ventricle and atrium; a quantitative 
alltoradiographic analysis* 
Summary - In the present experiments we investigated endothelin (ET) receptors in 
the human coronary artery, and in ventricular and atrial muscle using quantitative 
receptor autoradiography. Displacement of ['25IjSf6b (Sarafotoxin S6b) (30 pM)- and 
[' 25IjET_I (30 pM)-labelied binding sites was studied using ET-I, the ETA receptor 
selective ligand BQ-123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-]), and the ET. 
receptor selective ligand [Ala'·3·1I·l5jET-1. 
Specific binding was more dense in atrium and coronary artery (relative optical 
density (r.o.d.): 0.14 ± 0.01 and 0.16 ± 0.01, respectively) than in ventricular muscle 
(r.o.d.: 0.10 ± 0.01). In the coronary .. tery, binding was especially dense in the 
media. ET-I displaced [' 25IjET-1 and [' 25IjSf6b monophasically in atrium, ventricle 
and coronary artery. [Ala'·3·1I·l5jET_1 and BQ-123 displaced [' 25IjET_I and 
[' 25IjSf6b-labelled sites biphasically in the ventricle and in the atrium. In the human 
coronaIY mtelY, [Ala'·3·1I·l5jET_1 and BQ-123 displaced [' 25IjET-I-labelied sites 
monophasically (pIC,,: ET-I (9.72 ± 0.12) > BQ-123 (6.84 ± 0.08) > 
[Ala'·3·1I·l5jET_1 (6.40 ± 0.12». By contrast, [Ala'·3·1I·l5jET-1 and BQ-123 displaced 
["'IjSf6b-labelied coronary mte,y sites biphasically (high affinity pIC,,: BQ-123, 
9.03 ± 0.25; [Ala'·3·1I·l5jET_I, 8.40 ± 0.14; low affinity pIC,,: BQ-123, 7.24 ± 0.14; 
[Ala'·3·1I·l5jET_I, 6.99 ± 0.09). These data indicate that both ['''I]ET-I and 
[I2'IjSf6b-Iabelied ETA and ET B binding sites in human ventricular mId atrial muscle. 
In the human coronary artery, both radioligands labelled ETA binding sites, but 
[12'IjSf6b also labelled a non-ETA> non-ET. binding site with relatively high affinity 
for both BQ-123 and [Ala'·3·1I·l5jET_1. 
*, Based all: Bax, W.A., Bruinvels, A.T., Van Suylen, R.J., Saxena, P.R. and Hoyer, D. (1993) 
Endothelin receptors in the human coronary artery, ventricle and atrium; A quantitative auto-
radiographic analysis. NaullYIl Schmiedeberg's Arch. Pharmacal. 348, 403-410. 
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7.1 Introduction 
Endothelin (ET) was originally described as a potent vasoconstrictor peptide I. In 
addition, Wright and Fozard described a vasodilatory effect 2, later found to be mediated, 
at least partially, by an endothelium-dependent mechanism involving the release of nitric 
oxide (NO 3) and/or prostacyclin (PGl2 4). In the heart, endothelin has been repOlled to 
elicit both positive inotropic '·7 and chronotropic' effects, Furthermore, endothelin induced 
mitogenesis of vascular smooth muscle cells 9, 10 and hypertrophy of myocardial cells II 
indicating that endothelin may play a role in the development of atherosclerosis and 
cardiac hypertrophy. 
Two distinct endothelin receptor subtypes (ETA 12 and ET D 13) have been cloned, In 
radioligand binding studies, the ETA receptor has somewhat higher affinity for ET-I in 
comparison with isopeptides like ET-3 or sarafotoxin S6b, The ET u receptor has almost 
equal affinity for all endothelins and sarafotoxin S6b 12.14. The development of selective 
ligands that distinguish between these receptors has helped to characterize the receptors 
present in various tissues such as the lungs I', kidneys 16 and the myocardium 17. In the 
diseased human heart obtained from heart transplant recipients, both ETA and ET D 
receptors have been described in the atrium and ventricle, and in the atrioventricular 
conducting system, using in situ hybridization and radioligand binding applying the ET B 
receptor selective [125IlBQ3020, C25Ij[Ala l ,3,II,I'lET-I, and the relatively nonselective 
[125IlET-I as radioligands 17.1'. 
In the present study we characterized endothelin receptors in the human coronary 
artery obtained from healthy and diseased heallS, For comparison we also studied 
endothelinreceptors in the human ventricle and human atrium, We used the ETA receptor 
selective ligand BQ-123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-]) 20, and the ETu 
receptor selective ligand [Ala l ,3,II,I'lET-l I', and ET-I, to displace binding of the relatively 
non-selective ligands [125IlET-l and [125IlSf6b. A pall of this study was presented to the 
British Pharmacological Society 21, 
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7.2 Materials and methods 
Preparation of the tissue 
A total of 16 human heatts was used in the present investigation. All experiments 
were approved by the Ethical Committee of the University Hospital Rotterdam 'Dijk:zigt', 
The Netherlands. The heat·ts were provided by the Rotterdam Heart Valve Bank (Bio 
Implant Services / Eurotransplant Foundation, Leiden, The Netherlands) after removal of 
the aortic and pulmonary valves for valve transplantation. Twelve of the hearts were 
obtained from patients who had died of non-cardiac disorders (6 cerebrovascular accident, 
6 poly trauma; 7 male, 5 female; age 7-55 yrs). These heatts were stored at 0-4 °C in a 
sterile organ protecting solution immediately following circulatory arrest and arrived in 
the laboratory within 20 h after cardiac arrest. Four hearts viere obtained from patients 
undergoing cardiac transplantation (2 dilating cardiomyopathy, included in the groups of 
cardiac atrium and ventricle and 2 end-stage coronary artery disease, included in the 
coronary artery group; all male; age 41-55 yrs). After arrival in the laboratory, the right 
and left descending coronary "'tery and samples of free wall of right atrium and left 
ventricle (± 1.5 cm') were removed and the vessels were cleaned of fat and connective 
tissue. All samples were embedded in M-I embedding matrix (Upshaw, Pittsburgh PA, 
USA) and frozen in liquid nitrogen. The tissue lVas kept at -70 'c until further use. Serial 
sections of 10 !1m were cut on a micro-cryostat and thaw-mounted on gelatin-coated glass 
slides and kept at -20°C until binding experiments. 
Autoradiographic protocol 
The slides were thawed and subsequently preincubated for 15 min in a Tris-BSA 
buffer, pH: 7.4. (Tris: tris(hydroxymethyl)-aminomethan); BSA: Bovine Serum Albumin 
(both from Sigma Chemical Co., St. Louis MO, USA). The tissue was then incubated, at 
room temperature, for 120 min in 10 ml Tris-BSA buffer containing either 30 pM 
[ 125IjET -lor 30 pM [125I]Sf6b. The incubation buffer also contained chymostatin (2 mg/I; 
Bachem, Bubendorf, Switzerland), leupeptin (4 mg/I; Sigma Chemical Co., St. Louis MO, 
USA), bacitracin (40 mg/I; Sigma, Buchs, Switzerland) and 5 mM MuCI,. Non-specific 
binding was assessed in the presence of 0.3 !1M unlabelled ET-1. Displacement of 
radioligand binding was studied by adding unlabelled ET-I (concentration range 1 pM -
0.3 !1M), [Alal .'.II.l5jET-1 (concentration range 30 pM - 10 !1M) or BQ-123 (concentration 
range 3 pM - 30 !1M) to the radioligand containing buffer. After incubation, the slides 
were rinsed twice in ice-cold buffer for 5 min. The slides were then rapidly dried by 
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exposing to a stream of cold ail' and subsequently apposed to ['HjHyperfilm (Amersham, 
Buckinghamshire, UK) for 6 h. After exposure the films were developed (Kodak D19, 
Rochester, New York, USA), fixated and dried. In addition, we performed high resolution 
autoradiography by placing emulsion-coated (Kodak NTB
" 
Rochester, New York, USA) 
glass coverslips to the slides and exposed for 18 h. The coverslip slides were developed 
(Kodak D 19, Rochester, New York, USA) and fixated. Subsequently the tissue was stained 
with elastic-Van Gieson. Experiments (n=7-14) were performed in two separate sessions. 
Analysis of the data 
Binding on film was quantified densitometrically using a computerized image 
analysis system (MCID Imaging Research, St Catherines, Ontario, Canada). Displacement 
curves were analyzed for individual segments, generating competition curves for a one or 
two site-model, depending on the best fit (based on the X' values, Grafit, Erithacus 
Software Ltd., Staines, UK). The slope factor of the displacement curves by 
[Alal.l.II.ISjET_1 and BQ-123 in the coronary at1ery were calculated according to Ref. 22, 
by fitting the curve in a one-receptor model. 
Compounds 
[ 12SIjET_I and [12SIjSf6b (both with specific activity of2200 Cilmmol) Were purcha-
sed from ANAWA (Zurich, Switzerland). ET-I, [Alal.l.II.ISjET_1 and BQ-123 were pur-
chased from Neosystem S.A. (Strasbourg, France). 
7.3 Results 
Specific binding of [12SIjSf6b and [12SIjET_I in ventricular and atrial muscle was 
homogeneously distributed over the tissue and specific binding was more dense in the 
atrium and the coronary artery (relative optical density (r.o.d.): 0.14 ± 0.01 and 
0.16 ± 0.01 respectively) than in the ventricle (r.o.d.: 0.10 ± 0.01; Figure I). In the 
coronary mery, binding on film consisted exclusively of binding to the media, but 
coverslip high resolution autoradiography revealed also a sigual in a thin adventitial layer 
and between media and the intimal hyperplasia. Labelling in the latter two regions of the 
vessel consisted mainly of non-specific binding, and did not show on ['HjHyperfilm 
(Figure 2). 
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A 
Figure 1. Autoradiographs of total (A and B) and non-specific binding (C and D) of 
["'IJET-I-Iabelled ventricular segments (three difTerent patients, A and C) and one 
[ l15IJET-I-labelled atrial segment (8 and D). Note differences in receptor density between 
ventricle on one hand and atrium and coronary artery (embedded in fat attached to the left 
ventricle: A and C, arrow) on the other hand. Scale bars: panel C, 4 mm; panel OJ 0.5 mm. 
ET-l displaced ["'IlSf6b and ["'IlET-l monophasically in the ventricle (Figure 3; 
pIC" values of the curves are shown in Table I). [Ala
"
l.II.lSlET-1 and BQ-123 displaced 
['2SI]ET_I and ['2SIlSf6b-labelled sites biphasically in the ventricle. Assuming a two 
receptor model to be present, the propOl1ion of high-affmity sites of BQ-123 (which 
should equal the proportion of low affinity sites of [Ala
"
l,II.lSlET-I) as compared to the 
high affinity sites of [Ala
"
l,II,lSlET-1 (which should equal the propol1ion of low affinity 
sites ofBQ-123) was 53 ± 3% : 47 ± 3% in the ventricle (percentages for separate curves: 
see Table I). 
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Figure 2, Left panels: Autoradiography film of total (A) and non-specific (C) binding of one 
[IHI]ET-I-Iabelled coronary artery segment, obtained from a patient undergoing a cardiac 
transplantation for ischaemic coronary 811ery disease. Right panels: High resolution 
autoradiography (C) and light microscopy (elastic-Van Gieson staining, 40x, D) of the same 
coronary artery segment. Int) intima: a combination of intimal hyperplasia and intimal fibrosis; 
M) media. 
Also in the atrium ['''IlSf6b and [I2'IlET-! were displaced monophasic ally by ET-!, 
but biphasically by [A!a,,3,II, i5lET_! and BQ-!23 (Figure 4; pIC" values of the curves are 
shown in Table 2), In the atrium, the prop0l1ion of high affinity sites of BQ-!23 as 
compared to the high affinity sites of [Ala,,3,II, i5lET-! was 68 ± 3% : 32 ± 3% 
(percentages for separate curves: see Table 2), 
In the human coronary at1ery, ET-! displaced both ['''IlSf6b and ['''IlET-! in a 
monophasic manner, [Ala,,3,II, i5lET-! and BQ-!23 displaced ['''IlET-I-labelled sites 
monophasically in 6 and 7 segments respectively, out of 7 individually analyzed tissue 
segments, In contrast, [Ala,,3,II'''lET-! and BQ-!23 displaced [12'IlSf6b-labelled sites 
biphasically in 9 segments each, out of !4 individually analyzed coronary artery segments, 
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Figure 3. Human left ventricle. Displacement (% oftotal specific binding) of[IlSI]ET-1 (panel A) 
and [121I]Sf6b (panel B) by ET-l (~), BQ-123 (l1li) and [Ala1),11,15]ET_1 (0), 
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Figure 4, Human right atrium, Displacement (% of total specific binding) of [12SI]ET_1 (panel A) 
and [125[]Sf6b (panel B) by ET-l (CII), BQ-123 (l1li) and [Ala1),1l,15]ET_l (0), 
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Figure 5. Human coronary arlery. Displacemenl (% of lolal specific binding) of ['''I]ET-I 
(panel A) and ['15[]Sf6b (panel B) by ET-I (€I), BQ-123 (l1li) and [Ala,),ll'''jET-1 (A). 
Also analysis of the mean curves in the coronary rniery revealed a monophasic curve as 
the best fit for the displacement of ['''IlET-l by [Ala,,3,ll'''lET-l and BQ-123, whereas 
the displacement of [125IlSf6b by [Ala,,3,ll'''lET-l and BQ-123 were both best described 
by a biphasic curve (Figure 5), In addition, the slope factor (or pseudo Hill number) of 
the displacement curve of ['15IlSf6b by [Ala,,3,ll,15lET_l or BQ-123, when fitted to a 
monophasic model according to De Lean et a1. (1978), was significantly lower 
(0,64 ± 0.09 and 0,69 ± 0.11 respectively) than the slope of the displacement curve by 
[Ala,,3,l1,15lET_l or BQ-123 of [125IlET-1 (0,95 ± 0,08) and !.27 ± 0,14 respectively), The 
['''IlSf6b-labelled propOliion of receptors with high affmity for both BQ-123 and 
[Ala,,3,l1'''lET-l was 49 ± 4% : 51 ± 4% when compared to the proportion of 
['''IlSf6b-labelled- sites with 'low' affmily for BQ-123 and [Ala,,3,l1'''lET-!. We 
observed no differences in receptor density, affinity values or slope factors between 
healthy and diseased heatis, Therefore, the data refer to the mean of all ventricle, atrium 
or coronary atiery samples, 
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Table }, Hlllllan ventricle, pIC" (-Log IC,,) for the monophasic displacement by ET-I, and in 
case of biphasic displacement the high (pIC" high) andlor low (pIC" low) affinity value and pro-
portion (% high, % low) of the affinity phases of [Ala"l,ll'''lET-1 and BQ-123, 
["'I1ET-I ['''I1Sf6b 
ET-I pIC,,' 10,16 ± 0,08 9.49 ± 0,08 
[Ala'~·ll·"lET-1 pIC" high 9.59 ± 0,34 9.48 ± 0.16 
% high 39,7 ± 5,1 50,6 ± 5,1 
pIC" low 6,05 ± 0,20 6,54 ± 0,12 
% low 60,3 ± 5,1 49.4 ± 5.1 
BQ-123 pIC" high' 7,04 ± 0,24 7.49 ± 0,10 
% high2 50,1 ± 5.6 49.4 ± 14.3 
I J Monophasic complete displacement; 
2, Lower affinity phase could not be analyzed because plateau was reached. 
Table 2, Hlllllan alrilllll, piC" (-Log IC,,) for the monophasic displacement by ET-I, and in case 
of biphasic displacement the high (pIC" high) andlol' low (pIC" low) affinity value and 
proportion (% high, % low) of the affinity phases of [Ala'~·ll·"lET-1 and BQ-123, 
['''I1ET-I ["'11Sf6b 
ET-I pIC,,' 9,61 ± 0,04 8,95 ± 0,07 
[Ala'J·ll·"lET-1 pIC" high 9.05 ± 0.33 9.36 ± 0.09 
% high 27,9 ± 5,1 24,7 ± 2,7 
pIC" low 5,79 ± 0.17 6,91 ± 0,05 
% low 72.1 ± 5.1 75,3 ± 2,7 
BQ-123 pIC" high' 6,67±0,12 7.45 ± 0.40 
% high2 58,7 ± 5.5 48,3 ± 13,2 
I, Monophasic complete displacement; 
2, Lower affinity phase could not be analyzed because plateau was reached. 
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Table 3, Humall co/'ollwya/'Ie!y, pIC" (-Log IC" (molll» for the monophasic displacement (pIC" 
mono) or, in case of biphasic displacement, the high (pIC" high) and low (pIC" low) affinity 
value and proportion (% high, % low) of the affinity phases of [Alaw1'''JET-1 and 8Q-123, 
Slope factor of the curves (or pseudo Hill number), see Ref. 22, 
Slope factor 
ET-I pIC" 9,72 ± 0,02' 
[Alal~,ll'''JET-1 pIC" mono 6.40 ± 0,12
' 
0,95 ± 0,08 
8Q-123 
piC" high 
% high 
pIC" low 
% low 
pIC" mono 6,84 ± 0,08 ' 1.27 ± 0,14 
pIC" high 
% high 
pIC" low 
% low 
I, Monophasic complete displacement; 
9,35 ± 0,04 
7,66 ± 0,06' 
8.40±0,14 
47,3 ± 4,8 
6,99 ± 0,09 
52,7 ± 4,8 
7,82 ± 0,13' 
9,03 ± 0,25 
50,1 ± 6,1 
7,24±0,14 
49,9 ± 6,1 
Slope factor 
0,64 ± 0,09 
0,69 ± 0,11 
2, pICso value when fitted to a monophasic model to calculate the slope faetol' of the curve, 
7.4 Discussion 
Both ['25I]ET_I and [125I]Sf6b were found to label a mixed population of binding sites 
in human ventricle and atrium, Using ['25I]ET-I, we found an apparently single receptor 
population in the human coronary m1ery with chm'acteristics similar to one of the two 
receptors in the ventricle and atrium, However, the radioligand [125I]Sf6b also seemed to 
label a coronary m1ery site with binding characteristics different from the atrial and 
ventricular endothelin receptors, It is to be noted that non-specific binding was defined 
using unlabelled ET-l. In general, non-specific binding should preferably be determined 
using a cold ligand, different from the radioligands [125I]ET-I and [125I]Sf6b, However, 
little is known about truly non-selective endothelin receptor ligands, Furthermore, the 
maximum displacement by [Ala,,),ll''']ET-1 and ET-I was similar for both [125I]ET_I_ and 
[ 125I]Sf6b- binding in atrium and in ventricle (Figure 3, Figure 4), In the coronaty m1ety, 
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all three cold ligands (ET-I, [Ala l ,3,11,1']ET-I, and BQ-123) caused a similar amount of 
total displacement both for [J25I]ET_1 and [12SI]Sf6b (Figure 5), Taken together, this would 
indicate that the use of ET-I to define non-specific binding is appropriate, 
Endothelin receptors in the ventricle and Ihe ah'it/111 
Endothelin has been shown to cause positive inotropic and / or chronotropic effects 
in the ventricle and atrium of several animal species 6, 8, 23 and man 5, 24, 2S. In the rabbit 
isolated papillary muscle, the positive inotropic response appeared to be mediated by the 
ET B receptor " but the nature of the receptor involved in endothelin-induced rat myocyte 
hypel1rophy and secretion of natriuretic peptide from rat myocytes II thus far remains 
unknown, The human ventricle has recently been shown to contain both ETA and ET B 
receptors, e,g, by using BQ-123 and BQ-3020 (an ETB receptor selective compound) to 
displace [12'I]ET-I-labelled sites and also by showing the presence of mRNA strands for 
both the ETA and the ETB receptor 17, These authors also found a (free wall) ventricular 
population of both ETA and ET B receptors in an approximate percentage of 60 and 40 
percent, respectively (present study 53 and 47 percent, respectively), In our study the pIC,o 
values ofET-I, [Ala l ,3,1I,i5]ET-l and BQ-123 also fitted with a mixed ETA / ETB receptor 
population, The high affinity ofBQ-123 (PKD",9), presumably for the ETA receptor, was 
however clearly higher in the study by Molenaar and colleagues 17 than in our study 
(PIC"",7), Other ETA receptor assays, however, have rep0l1ed pIC" values for BQ-123 of 
approximately 7 i5 or 8 20, 
Also in the atrium we observed a mixed receptor population that appeared to consist 
of both ETA and ETB receptors, In the right atrium, the proportion of ETA receptors (68% 
ETA vs, 32% ET B receptors) was somewhat higher than in the ventricle, This was possibly 
due to a higher density of atrial ETA receptors and similar density of ET B receptors, since 
the overal ET receptor density was higher in the atrium, Endothelin has previously been 
shown to elicit positive inotropic responses in the human isolated atrium 24,25, By contrast, 
ET-I did not cause positive inotropic affects in six strips obtained from the human 
ventricle, that responded normally to (-)-isoprenaline 24 and caused only very small 
inotropic effects in another study', In this respect, it is of interest that the receptor density 
in the ventricle of several animal species was previously found to con'espond to the 
effectiveness ofET-l in producing a positive inotropic effect', Functionally differential 
effects on human atrial and ventricular tissue were also observed for 5-hydroxytryptamine, 
which produced a positive inotropic effect on the isolated atrium 26, that could not be 
shown in the ventricle 27-29, Therefore, one should be careful to extrapolate the positive 
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inotropic response, elicited by endothelin in the rabbit papillary muscle 7 and in the human 
atrium 24,25, to the human ventricle until further functional experiments in the human 
ventricle are performed, 
Elldothelill receptors ill the corollmy artery 
Endothelin was originally described as a vasoconstrictor peptide I, Since then, various 
rep0l1s have appeared on the nature of the receptor mediating contraction, An ETA 
receptor appeared to be involved in the porcine coronary artery contractile response to 
ET-I 30, but a non-ETA> non-ET. receptor seemed to be involved as well ", This contention 
was based on the observation that ET-3 recognized a sarafotoxin S6c sensitive receptor 
(sarafotoxin S6c is ET. receptor selective 32), which was not recognized by ET-I, thus 
mling out the ET. receptor, ET-I was also shown to cause potent contractions of the 
human isolated coronary artery 24, 3l, 34, but until now the nature of this pat1icular 
endothelin receptor has remained unknown, 
The present results indicate that a receptor is present in the human coronary artery, 
which showed similar affinities for ET-I, [Ala
'
,3,II'''jET-1 and BQ-123, when compared 
to one of the two endothelin receptors in the human ventricle and atrium, Using in 
situ-hybridization to show the presence of mRNA for the receptor, Molenaar and 
colleagues provided finther evidence that this endothelin receptor in the human ventricle 
and atrium is of the ETA receptor type 17, Considering the biphasic and shallow 
displacement curves (Figure 5), [125IjSf6b also appeared to label another binding site with 
high affinity for both [Ala,,3,II'''jET_1 and BQ-123 (Table 3), Apparently, this binding site 
does not relate to any of the thus far discovered endothelin receptors, Interestingly, 
unlabelled ET-I completely displaced [125IjSf6b binding with high affinity, and thus also 
appeared to have affinity for this 'unknown' binding site, On the other hand, iodinated 
ET-I did not bind to the 'unknown' binding site since ET-I, BQ-123 and [Ala,,3,II'''jET-1 
all caused monophasic displacement of ['25IjET_1. Whether indeed this ['25IjSf6b-Iabelled 
binding site - with high affinity for both BQ-123 and [Ala,,3,II,lSjET_1 - constitutes a new 
endothelin receptor in blood vessels, requires fill'ther investigation using other endothelin 
isopeptides like ET-3 and sarafotoxin S6c, in radioligand assays as well as in fimctional 
experiments, Also the existence of different affmity states for the same receptor, labelled 
by ['25IjSf6b, but not by ['25IjET_I, cannot be entirely excluded, This does however not 
apply to differences between high and low affinity phases for [Ala
'
,3,II'''jET-1 and BQ-123 
in the atrium and ventricle, since the differences of pICsQ values appear too high for 
different affinity states of the same receptor (Table I, Table 2), On the other hand, 
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vascular receptor heterogeneity was previously suggested by Sumner and co-workers, who 
observed that ET-3-induced contractions of the rabbit thoracic aorta were antagonized by 
BQ-123 with an estimated pKB value of 8.3, whereas BQ-123 antagonized ET-I-induced 
contractile responses of the same tissue with a (presumably ETA receptor-related) pA, 
of 6.9 ". 
Endatilelin receptors in the diseased heart 
When compared to healthy cardiac tissue (Bio Implant Services / Eurotransplant 
organ donor tissue), we observed no differences in atrial and ventricular endothelin 
receptor characteristics in diseased hearts (dilating cardiomyopathy, obtained from heart 
transplant recipients). However, it must be kept in mind that the numbers of diseased 
heat1s investigated (n=2) is too small to note possible subtle differences. Other investi-
gators also failed to show a difference between healthy and diseased tissue in man (e.g. 
Eisenmenger's syndrome, ischemic heati disease 17). However, an experimentally induced 
congestive heart failure in dogs, was found to result in a downregulation of cat'diac 
endothelin receptors, possibly due to an increased plasma endothelin level 36. An increased 
plasma endothelin level has also been noticed in a variety of human cardiovascular (and 
nonMcardiovascular) diseases in man 37, 
In the human coronary artery obtained from cardiac transplantation patients for 
ischemic heati disease (n=2), we have neither observed a higher density of receptors nor 
different receptor characteristics. However, it must be stressed that the pathological 
changes in coronary artery diseased heat1s, obtained after transplantation, are the end-stage 
of a disease, present in the vasculature of many subjects who are generally considered 
healthy. 
In sununaty, we observed that both [125I]ET_I and [125I]Sf6b labelled a popUlation of 
ETA and ETa binding sites in the human ventricle and atrium. Using [125I]ET_I we found 
a single receptor population in the human coronaty atiery with similar characteristics as 
the ETA receptor in the ventricle atld atrium. However, the radioligand [125I]Sf6b also 
labelled a binding site with characteristics different from the atrial and ventricular 
endothelin receptors. FUl1her experiments are needed to demonstrate whether this binding 
site represents a new endothelin receptor in the human coronal), a11ery. 
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Heterogeneity of endothelin receptors mediating 
contraction of the human isolated saphenous vein* 
Summary - We investigated the effect of the endothelinA (ETA) receptor antagonist 
BQ-123 (0.1 and 1 ~lM) on contmction of the human isolated saphenous vein induced 
byendothelin-I (ET-I) or samfotoxin 86b. Contraction to ET-I was not affected by 
BQ-123. In contrast, BQ-123 biphasically attenuated contractions to sarafotoxin 86b. 
These data indicate that (i) ET-I induces contractions of the human saphenous vein 
via a BQ-123-insensitive receptor and (ii) contractions to sarafotoxin 86b are 
mediated in part via a receptor, different from the receptor mediating contraction to 
ET-l. 
8.1 Introduction 
The cloning of two endothelin receptors, denoted ETA and ETB I. " has encouraged 
the characterization of endothelin receptors that mediate contraction in the vascular bed 
of several species (e.g. Ref. 3). This was facilitated by the introduction of compounds with 
selectivity for one of these two receptors. BQ-123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-
Trp-J), for instance, has extensively been used as a selective antagonist with high affinity 
for the ETA receptor 4. '. Although the ETA receptor was originally believed to be the most 
important in mediating vascular smooth muscle vasoconstriction 6, several investigators 
concluded that the ET. receptor 3, or a non-ETA> non-ET B receptor 7 also playa role in 
vasoconstriction. For this reason, and because little information is available on human 
vascular tissues, we investigated the effect ofBQ-123 (0.1 and I 1lM) on contractions of 
the human saphenous vein induced by endothelin-I (ET-I) or sarafotoxin 86b. 
*, Based on: Bax, \V.A., Bas, E. and Saxena, P.R. (1993) Heterogeneity of endothelin / sarafo~ 
toxin receptors mediating contraction of the human isolated saphenous vein. EliI'. J, Pharmacal. 
239, 267-268. 
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8.2 Materials and methods 
Leftover human saphenous vein was obtained intraoperatively from 9 patients (B 
males, I female; age: 53 to 75 years), undergoing coronary bypass surgery. The tissue was 
innnediately placed in a cold, oxygenated Krebs' bicarbonate solution of the following 
composition: liB mM NaCI, 4.7 mM KCI, 2.5 mM CaCI" 1.2 mM MgSO" 1.2 mM 
KH,PO" 25 mM NaHCO" and B.3 mM glucose; pH 7.4. The vein was cleaned of 
adhesive fat and connective tissue, and the endothelium was removed, using a cotton swab. 
Ring segments (4 mm) were suspended in 15 ml organ baths to measure isometric tension. 
The absence of the endothelium was verified by observing lack of relaxation to 
acetylcholine (I flM) or bradykinin (I flM) after precontraction with noradrenaline (0.1 
flM). After measuring the contractile response to K+ (100 mM), the segments were either 
incubated with BQ-123 (0.1 or I flM) for 30 min, or remained untreated as a control 
segment. Subsequently, a concentration response curve to ET-I or sarafotoxin S6b was 
obtained in all vessel segments. Contraction was expressed as a percentage of K+ (100 
mM)-induced contractions. 
ET-I, sarafotoxin S6b and BQ-123 were purchased from Neosystem S.A., Strasbourg, 
France; all other drugs from Sigma Chemical Co., st. Louis, USA. 
8.3 Results 
Both ET-I and sarafotoxin S6b caused concentration dependent contractile responses 
of the vessel segments (pD,: B.06 ± 0.10 and B.13 ± 0.05, respectively; ~'AX: 123 ± 7% 
and 135 ± 6% ofK+ (100 InM)-induced contractions, respectively; n~7-9). BQ-123 (0.1 
and I flM) did not affect ET-I-induced contraction. The contractile responses, induced by 
sarafotoxin S6b in concentrations not higher than I nM, also remained unaffected by 
BQ-123. However, contractions induced by higher concentrations ofsarafotoxin S6b were 
concentration-dependently attenuated by BQ-123 (0.1 and 111M; Figure I). 
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Figure 1. Contractions of the human isolated saphenous vein to endothelin-l (panel A) or 
sarafotoxin S6b (panel B), without (0, control) or in the presence of BQ·123 (0.1 11M, «3; 1 f.M, 
A). The concentration refers to moUI. Contractions are expressed as a percentage ofK + (I 00 mM)u 
induced contractions. n=7-9. 
8.4 Discussion 
We conclude that ET·I contracts the human isolated saphenous vein via a 
BQ-123-insensitive receptor. Since BQ-123 has high affinity for ETA receptors 4. 5 it 
appears unlikely that ETA receptors are involved. On the other hand, BQ-123 caused a 
biphasic inhibition of sara fat ox in S6b-induced contractions, indicating heterogeneity ofthe 
receptor population mediating the contractile response to sarafotoxin S6b. It appears 
reasonable to assume that the BQ-123-insensitive receptor, which mediates the contractile 
response to low concentrations of sarafotoxin S6b, is similar to the receptor that mediates 
the contractile response to ET-l. The exact nature of this receptor remains to be 
determined. The BQ-123-sensitive receptor, which mediates the contractile response to 
higher concentrations of sarafotoxin S6b, appears to be different Ii'om the ETA receptor; 
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since ET-J has higher affinity than sarafotoxin 86b for the ETA receptor I, one would 
expect that the contractile response to ET-l would also be attenuated by BQ-123. 
Therefore, the present data indicate that BQ-123 may have relatively high affinity for a 
non-ETA' non-ETB receptor. Interestingly, a previous study using quantitative receptor 
autoradiography in the human coronary artery, also indicated that [I"llsarafotoxin 86b but 
not C"llendothelin-l labeled a non-ETA' non-ET B receptor with high affinity for BQ-123 '. 
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Different endothelin receptors involved in 
endothelin-l- and sarafotoxin S6b-induced contractions 
of the human isolated coronary artery 
Summary - Endothelin receptors, that mediate contraction of the human isolated 
coronary artery, were characterized using a number of agonists and antagonists. 
Contraction induced by the non-selective agonists endothelin(ET)-1 and sarafotoxin 
86b, was compared in endothelium-intact and endothelium-denuded ring segments. 
The effects ofET-1 and BQ-123 (an ETA receptor antagonist) were investigated both 
in ring segments and in spirally cut strips. Lastly, the effect of phospho rami don was 
studied on contraction induced by big-ET-l. 
The order of agonist potency (pD,) in endothelium-intact coronaty alielY ring 
segments was: ET-I (8.27) '" sarafotoxin 86b (8.16) > big-ET-I « 7.1) '" ET-3 « 
6.9). [Alal.3•1l,lSlET_1 (ETa receptor agonist) caused significant contraction at I flM 
only, whereas 0.3 flM big-ET-3 had no effect. Removal of the endothelium in ring 
segments did not affect the contractile response to ET-I or to sarafotoxin 86b. 
After a full concentration response curve with ET-I or sarafotoxin 86b, further 
contractions of the endothelium-intact coronary atiClY segments could only be 
achieved by applying ET-I in segments exposed to sarafotoxin 86b, and not the 
reverse. 
0.1 flM BQ-123 antagonized contractions of endothelium-intact ring segments 
induced by sarafotoxin 86b (PKa: 7.86). Only 10 flM BQ-123 antagonized 
contractions induced by ET-I (PKa: 5.75). Also FRI39317 was more potent against 
sarafotoxin 86b (PKB: 8.24-8.47) than against ET-I (PKa: 6.11). [Alal•3•1l •lSlET_1 
(I flM) had no effect on the contractile response to ET-I or to sarafotoxin 86b. 
"', Based on: Bax, W.A., Aghai, Z., Van Tricht, C.L.J., Wassenaar, C. and Saxena, P.R. (1994) 
Different endothelin receptors involved in enclothelin-I- and sarafotoxin S6b-induced contractions 
of the human isolated coronary artery. Br. J. Pharmacal. 113, 1471-1479. 
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In strip preparations with intact endothelium, the pD, of ET-I increased to 
9.04 ± 0.16 (vs. 8.50 ± 0.07 in rings), and 1 ~(M BQ-123 caused a rightward shift 
of the ET-I-induced concentration response curve (PK.: 6.62 vs. 5.75 in rings). 
Contractile responses to big-ET-I of endothelium-intact coronary artery segments 
were attenuated in the presence of 100 11M phosphoramidon, indicating conversion 
of big-ET-I to ET-I within the coronary artery segment. 
The present study indicates that ET-I and sarafotoxin S6b contract the human 
isolated coronary artery via different receptors, which can probably be best 
characterized as subtypes of the ETA receptor. FlUihermore, it is demonstrated that 
the type of preparation (ring or strip) may affect the potency ofET-1 as an agonist, 
and of BQ-123 as an antagonist. 
9.1 Introduction 
The cloning of endothelin ETA I and ETo 2 receptors, and the subsequent development 
of relatively selective receptor agonists and antagonists, have stimulated the charac-
terization of functional receptors, mediating vascular smooth muscle contraction to 
endothelin isopeptides. For instance, ETA receptors have been shown to mediate contractile 
responses in the rat aorta 3, whereas ETB receptors were found to mediate contraction of 
the rabbit saphenous vein 4. Other smooth muscle preparations were found to contract via 
a mixed receptor population, or via non-ETA> non-ETB receptors (e.g. the pig coronary 
artery s. 6. In Paliicular, the putative ETA receptor antagonist BQ-123 (cyclo[D-Asp-L-Pro-
D-Val-L-Leu-D·Trp-]) 7 was found to discriminate between contractions induced by 
endothelin(ET)-1 and contractions induced by endothelin(ET)-3 or sarafotoxin S6b in rat 
aorta 3, rat vas deferens 8.9 and goat cerebral artelY 10. Also in the human saphenous vein 
it was found that BQ-123 antagonized sarafotoxin S6b-induced contractions with higher 
affinity than ET-I-induced contractions ". Similar data were obtained in the human 
umbilical miery ". These apparently heterogeneous receptor populations could not be 
readily characterized as 'typical' ETA or ET. receptors. 
In the human isolated coronary aliery, Godfraind 13 observed differential effects of 
BQ-123 against ET-I- and ET-3-induced contractile responses. Furthermore, the nature 
of the contractile endothelin receptors varied between proximal and distal coronmy miery 
segments; distal segments were more sensitive to both the agonist effect ofET-1 (as was 
also observed by Chester and co-workers 14) and the antagonist effect of BQ-123. It was 
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therefore concluded that distal parts of the artery contract via ETA receptors only, but that 
other receptors are involved in the contractile response of proximal segments ", Using 
quantitative receptor autoradiography in the human coronary artelY, it was previously 
shown that ["'IlET-I labelled a homogeneous receptor population in the media of 
proximal segments of the human coronary artery, [I2'IlSarafotoxin S6b labelled a similar 
receptor, but also labelled a non-ETA' non-ETB receptor with relatively high affinity for 
BQ-123 and [Alai,l,Il,i'lET_1 16 (ETB receptor selective 15), 
In the present study, we fiuiher characterized endothelin receptors that mediate 
contraction of the human isolated coronary ariery, using BQ-123 and FRI39317 (ETA 
receptor selective 17) as antagonists, We also examined whether the response to ET-I or 
to sarafotoxin S6b is altered in the presence or absence of functionally intact en-
dothelium ", We hypothesized that pari of the previously found differences between lar'ge 
proximal and small distal coronary artelY segments ", 14, could be due to facilitated 
diffusion of the large peptide molecules to the receptors in distal coronalY artery segments, 
rather than to a different receptor profile, To verify this hypothesis we compared the effect 
ofET-1 and BQ-123 on ring segments and on spirally cut coronary artery strips, Lastly, 
we investigated whether local conversion of big-ET-I to ET-I i9,20 is involved in the 
contractile response to big-ET-I, A pari of this study was presented to the joint meeting 
of the British Pharmacological Society and the Societ. Italiana Farmacologia ", 
9,2 Methods 
Tissue preparation and experimental procedure 
The right epicardial coronary artelY was obtained from 43 hearts of organ donors, 
who had died of non-cardiac disorders less than 24 hours before the tissue was taken to 
the laboratory (25 cerebrovascular accident, 16 polytrauma, 2 cerebral hypoxia; 24 male, 
19 female; age I-54 years), The hearts were provided by the Rotterdam Heart Valve Bank 
(Bio Implant Services Foundation I Eurotransplarlt Foundation) after removal of the aortic 
and pulmonary valves for homograft valve transplantation, The study was approved by the 
Joint Medical Ethics Committee of the Erasmus University Rotterdam arld the University 
Hospital Rotterdam 'Dijkzigt', The hearts were stored at 0-4 °C in commonly used sterile 
organ protecting solutions (University of Wisconsin (UW) solution, HTK-Bretschneider 
solution, or EuroCollins solution, see Ref, 22), itmnediately following circulatory an'es!. 
After arrival in the laboratory, the right coronary artery was removed and placed in a cold, 
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oxygenated Krebs bicarbonate solution of the following composition: liB mM NaCI, 4.7 
mM KCI, 2.5 mM CaCI" 1.2 mM MgSO" 1.2 mM KH,PO" 25 mM NaHCO, and B.3 
mM glucose; pH 7.4. Segments 2 (mid segment) and 3 (distal segment) 2l of the coronary 
artery were cut into rings with similar diameter and approximately 4 mm of length. The 
rings were suspended on stainless steel hooks in 15 ml organ baths containing the Krebs 
bicarbonate solution, aerated with 95% 0, and 5% CO, and maintained at 37' C. Vessel 
segments containing macroscopically visible atherosclerotic lesions were not used. In some 
ring segments, the endothelium was removed, using a cotton swab and a watclnnakers' 
forceps. However, if not mentioned otherwise, results refer to ring segments with intact 
endothelium. For the comparison of ring and strip segments, we made two such pairs from 
adjacent portions of the coronary artery with intact endothelium. The 4 mm rings were 
prepared as described above, while the strips were cut in a spiral marmer (diameter I mm) 
and attached to silk threads. 
All segments were allowed to equilibrate for at least thirty min and were washed 
every fifteen min. Changes in tension were recorded using a Harvard isometric transducer. 
Preparations were stretched to a stable tension of approximately 20 mN. The tissue was 
exposed to K+ (30 mM) twice. Subsequently, the functional integrity of the endothelium 
was verified by observing relaxation to substance P (I nM) after precontraction with 
prostaglandin F,o (PGF,«, I 11M). After washout, the tissue was exposed to 100 mM K+ 
to determine the maximal contractile response to K+, which was expressed as mN. The 
tissue was allowed to equilibrate in the Krebs solution for a period of thirty min. 
Determination of agonist and antagonist potency 
After this period of equilibration, some segments were treated with vehicle only 
(controls), whereas others were incubated with an antagonist for thitty min. After that, a 
cumulative concentration response curve was obtained on every segment. Responses were 
expressed as a percentage of the contractile response to 100 mM K+. Curves obtained in 
the presence of a receptor antagonist were compared to the control curves. All curves were 
obtained in a paired, parallel experimental set-up. Some concentration response curves 
were obtained in duplicate or triplicate. These curves were averaged and considered as a 
single curve in further analysis. 
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Analysis of Dala 
Curves were analyzed by means of a computerized curve fitting technique 24 to obtain 
E"IAX (maximal response), and pD, (-Log of the molar concentration of an agonist needed 
to reach half of its maximal effect, i.e. -LogEC,,) values, which were averaged for the 
respective agonists. For antagonists against ET-I or sarafotoxin S6b, a pKn value was 
calculated, assuming the nature of antagonism to be competitive, using the equation 
described by Furchgott ": 
pKn ~ -Log[B] + Log{([A,]/[A,D-I}, 
where [B] is the antagonist concentration and [A,] and [A,] are, respectively, the EC" 
values of the agonist in the absence and presence of the antagonist. For calculation of 
pKB values, only paired experiments were taken into account. pKB values are given only 
when a more than 2-fold shift of the EC" was obtained. All data are presented as mean 
± s.e.mean. pD, and EMAX of agonist-induced contractions without or in the presence of 
an antagonist were compared using a paired Student's I-test. Mean contractile responses 
were compared using an Analysis of Yariance (ANDY A) followed by a Student's I-test, 
for paired data where appropriate. A correlation coefficient, r, was calculated according 
to Pearson. A P value less than 0.05 was assumed to denote a significant difference. 
Compounds 
The compounds used in this study were purchased from the sources indicated: 
Prostaglandin F'a (tris salt), substance P acetate and phosphoramidon: Sigma Chemical Co. 
(St. Louis, USA); ET-l: Saxon Biochemicals GMBH (Hannover, Federal Republic of 
Germany); ET-l, sarafotoxin S6b, FRI39317 and BQ-123 (sodium salt): Neosystem S.A. 
(Strasbourg, France); sarafotoxin S6b, ET-3, big-ET-I and BQ-123 (sodium salt): 
Novabiochem AG (Laufelfingen, Switzerland); sarafotoxin S6b, big-ET-3, and 
[Ala,,3,1I''']ET-l: Peninsula Laboratories (Belmont, USA). It should be noted that due to 
non-availability of the compounds andlor cost factors, we had to order ET-I, sarafotoxin 
S6b, and BQ-123 from more than one source. Although direct comparisons were not 
made, the compounds obtained from different sources did not differ in potency. Stock 
solutions for [Ala,,3,1I''']ET-l, and ET-l (Saxon) were prepared in 0.1 % acetic acid. Other 
compounds were dissolved in water. 
161 
Endothelin receptors in the human isolated corOl/my artery 
9.3 Results 
Basic properties of the preparations 
All ring segments, where endothelium was left intact, relaxed to I nM substance P 
after precontraction to 1 ~lM PGF,. (73 ± 5% of the contractile response to PGF,.; n=43). 
This is in accordance with previous findings with substance P in the human isolated 
coronary atiery obtained from patients undergoing cardiac transplantation ". 100 mM K+ 
caused a mean contractile response of 45 ± 3 mN (n=43). Where the endothelium had 
been removed from the ring segments, the relaxant response to substance P was vit1ually 
abolished (2 ± 1% of the contractile response to 111M PGF,.; n=13), and the contractile 
response to potassium was decreased from 37 ± 5 mN to 21 ± 3 mN (n=13; P<O.OI). In 
strip preparations (n=5), the relaxant response to substance P was 31 ± 12% of the 
contractile response to 1 11M PGF,., and the contractile response to 100 mM K+ was 
20 ± 6 mN. 
Effict of agonist peptides 
In endothelium-intact coronary atiery segments, sarafotoxin 86b, ET-l, big-ET-I, and 
ET-3 caused concentration dependent contractions. [Alal.l·Il ·"lET-l caused a small 
contractile response at the highest concentration used (l 11M), whereas big-ET-3 had no 
effect at 0.3 11M (Figure 1). For big-ET-l, ET-3 and [Alal.l.ll.lslET-l the highest 
concentration tested (l 11M) may not have reached the maximal contractile response, which 
could affect the given approximate pD, and ~'AX values. The order of potency of the 
agonists tested was: ET-I '" sarafotoxin 86b > big-ET-I '" ET-3 > [Alal.l.Il.lslET-l ;:, big-
ET-3 (for EMAX and pD" see Table 1). The contractile response to ET-l or sarafotoxin 86b 
in ring segments was not affected by removing the endothelium (Figure 2). Comparison 
of the EMAX of 21 paired vessel segments, in which a concentration response curve with 
both ET-I and sarafotoxin 86b was constructed, revealed that the EMAX but not the pD, 
of sarafotoxin is slightly but significantly different from that of ET-l (105.7 ± 4.9% vs. 
95.2 ± 3.9%, respectively, P=O.OI). No age-related variation was observed for the pD, of 
ET-I (n=37) and sarafotoxin 86b (n=26) (correlation age - pD,: 1=-0.12 and -0.05, P=0.24 
and 0.40, respectively). Only the ~lAX of ET-I, but not of sarafotoxin 86b, was found to 
be somewhat higher in younger patients (correlation age - ~lAX' ET-I: 1=-0.36, P=0.02; 
sarafotoxin 86b: 1=0.07, P=0.37). 
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Table 1. Potency (PD, (-Log [Ee", maUl])) and maximal effect (EMAX' expressed as a percentage 
of the contractile response to 100 mM K+) of endothelin receptor agonists. 
Agonist Concentration n pD, EMAX 
range studied 
ET-I 30 pM - 0.3 ~M 37 8.27 ± 0.06 102.7 ± 5.4% 
Sarafotoxin S6b 30 pM - 0.3 ~M 26 8.16 ± 0.05 104.5 ± 5.4% 
Big-ET-I 0.1 nM - I ~M 4 <7.1 ± 0.02' > 124.3 ± 12.4%' 
ET-3 0.1 nM - I ~M 4 < 6.9 ± 0.1' >84.4 ± 9.6%' 
[Ala,,3.II'''jET-1 0.1 nM - I ~M 7 n.c.! >11.4 ± 3.6%' 
Big-ET-3 0.1 nM - 0.3 f,M 3 No Effect No Effect 
11, Number of segments tested; 
n.c., Not calculated; 
" Maximal effect possibly not reached at I pM. 
Figure 3 shows experimental recordings of responses obtained with ET-I and 
sarafotoxin S6b in endothelium-intact coronary altery segments. The addition of 0.1 pM 
sarafotoxin S6b at the end of a full concentration response curve with ET-I did not result 
in a flU1her increase of tension (Figure 3A). However, in a parallel vessel segment, the 
addition of 0.1 J.lM ET-I after a full concentration response curve \vith sarafotoxin 86b, 
caused a further increase of tension (Figure 3B and also 3D). Figure 3C shows that the 
maximal contractile response to sarafotoxin 86b (but also to ET -I: not shown) slowly 
faded after the highest concentration of agonist had been added. The mean contraction (as 
a percentage of contraction induced by 100 mM K+), directly and sixty min after adding 
0.3 11M ET-I or 0.3 pM sarafotoxin 86b was: 84.0 ± 5.2% and 26.2 ± 3.5%, respectively, 
for ET-I (n~18 segments from 10 hearts), and 90.7 ± 10.0% and 56.3 ± 11.8%, 
respectively, for sarafotoxin 86b (n~IO segments from 5 hear1s). 8ixty min after the 
maximal concentration of sarafotoxin 86b had been added (not shown in Figure 3), the 
subsequent addition of 0.03 pM ET-I resulted in an increase of contractile force (from 
33.0 ± 11.7% to 81.1 ± 6.0% of contraction induced by 100 mM K+, n~5), whereas the 
subsequent adding of 0.03 J.lM sarafotoxin 86b had no further effect (from 66.2 ± 3.2% 
to 64.3 ± 4.0% of contraction induced by 100 mM K+, n~5). When 0.1 ~M ET-I lVas 
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Figure I. Contractions of the endothelium· intact human isolated coronary artery to endothelin 
receptor agonists. III, ET-I (n=37); 0, sarafotoxin S6b (n=26); +, big-ET-I (n=4); " ET-3 (n=4); 
A, [AI.'~·Il·"JET-1 (n=7); A, big-ET-3 (n=3). Agonist concentration refers to moili. pD, and EMAX 
are mentioned in Table I. Where no error bar is visible, it falls within the limits of the symbol. 
added after this failure of 0.03 !1M sarafotoxin S6b to produce further contraction, an 
increase of contractile force to 99.6 ± 3.1 % of contraction induced by 100 roM K+ was 
observed (n=5; P<O.OI). Sixty min after the maximal concentration of ET-I had been 
added, subsequent addition of neither 0.03 !1M ET-I nor 0.03 !1M sarafotoxin S6b resulted 
in a further increase of contraction (from 22.1 ± 4.9% to 22.6 ± 5.0% (n=IO) and 
31.3 ± 6.2% to 32.1 ± 6.1 % (n=8) of contraction induced by 100 roM K+, respectively). 
Antagonist effects 
In endothelium-intact coronary artery segments 0.1 !1M BQ-123 antagonized 
contractions induced by sarafotoxin S6b reSUlting in a pK. of 7.86 ± 0.08 (n=6). This 
same concentration of BQ-123 caused a small increase of contraction induced by ET-I 
(n=7). Only 10 !1M BQ-123 antagonized contractions induced by ET-I (PK.: 5.75 ± 0.18; 
n=4). FRI39317 was also more potent against sarafotoxin S6b than against ET-1. This 
resulted in pKB values for FRI39317 against sarafotoxin S6b of 8.47 ± 0.17 (3 nM) and 
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Figure 2. Left panel: Contractions of the human isolated coronary artery to ET-l in endothelium 
intact (.). or endothelium denuded (.) ring segments (n~8). Middle panel: Contractions of the 
human isolated coronary artery to sarafotoxin S6b in endothelium intact (0), or endothelium 
denuded (.) ring segments (n~5). The concentration ofET·1 and sarafotoxin S6b refers to moili. 
Right panel: Relaxant responses to 1 nM substance P in the same segments expressed as a 
percentage of pre contraction with 1 ~lM PGF2(l' E+, endothelium intact; E-, endothelium denuded. 
Where no error bar is visible, errOl' falls within the limits of the symbol. 
8.24 ± 0.08 (0.3 11M) (both n~5). By contrast. 311M FR139317 applied against ET-l-
induced contractions resulted in a pKB of 6.11 ± 0.16 (n~6). The small contractile response 
induced by I 11M [Ala'·3·1I·"jET_1 faded during the thirty min incubation when tested as 
an antagonist. [Ala'.J· lI·"jET-l (111M) did not affect the contractile response to ET-l or 
to sarafotoxin S6b (n~6) (Figure 4). 
Comparison with strip preparations 
ET-l was more potent as an agonist on endothelium-intact strip preparations than on 
endothelium-intact ring segments (pD,: 9.04 ± 0.16 in strips vs. 8.50 ± 0.07 in rings; n~5). 
The pKB ofBQ-123 (111M) against ET-I-induced contractions of strips was 6.62 ± 0.18 
(Figure 5) vs. 5.75 ± 0.18 in rings (10 11M BQ-123). 
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Figure 3, Experimental recordings of concentration response curves, preceded by the reference 
contractile response to 100 mM K+, in four endothelium-intact coronary artery segments obtained 
from a 41 year old male (A and B) and a 25 year old female (C and D). A. After reaching the 
~ in a concentration response curve with ET-I, the addition of 0.1 ~tM sarafotoxin S6b (arrow) 
does not calise an additional response. n, After reaching the ~lAX in a concentration response 
curve with sarafotoxin S6b, the addition of 0.1 J-lM ET-I (arrow) does cause an additional 
contractile response, C. After reaching the EMAX of a concentration response curve to sarafotoxin 
(but also to ET-I: not shown) contraction slowly faded away (also A and B). D. Addition of a 
concentration sarafotoxin S6b, causing a submaximal effect in a parallel segment, resulted in a 
sustained contractile response. After subsequently completing the concentration response curve in 
this particular segment, a further contractile response could be induced by adding 0.1 JlM ET-l 
(arrow). 
Big-ET-l and phosphoramidon 
The concentration response curve to big-ET-I was remarkably steep in comparison 
with the other endothelin isopeptides (Figure I). As shown in Figure 6, the pretreatment 
of the vessel segment with phosphoramidon (100 J-lM) resulted in significant attenuation 
of the contractile responses, and in a non-parallel shift of the big ET-I-induced 
concentration response curve. 
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Figure 4. Contractions of the endothelium-intact human isolated coronary artery to ET-l (top 
panels), and sarafotoxin S6b (bottom panels) in the absence (control ET-l: .,; control sarafotoxin 
S6b: 0) or presence of the endothelin receptor antagonist BQ-123 (n~4·13), FR139317 (n~5-6), 
or [Ala,),II'''jET-1 (n~6)_ Concentrations of receptor antagonists were 3 nM (+), 0,03 11M (0), 
0.1 ~M (0), 0,3 ~M (v), 1 ~M (0), 311M (0) or IO ~M (III), Concentrations of ET-I and 
sarafotoxin S6b refer to molli. pKs values are mentioned in the text. Where no error bar is visible, 
error falls within the limits of the symbol. 
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Figure 5, Contractions of the human isolated coronary artery to ET -1 in endothelium-intact ring 
preparations (closed symbols, u==12) and endothelillln-intact spiral strip preparations (open 
symbols, n=5), in1he absence (contro[, ~ and 0) or presence of I flM BQ-[23 (II and 0). For 
pD2 and pKB values, see text. The concentration ofET-1 refers to moUI. Where no errol' bar is 
visible, errol' falls within the limits of the symbol. 
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Figure 6, Contractions of the endothelium-intact human isolated coronary artery to big-ET -1 in 
the absence (contro[, +) and presence of 100 flM phosphoramidon (T). n=4; *, p < 0.05 vs. 
control response. The concentration of big-ET-l refers to moUI. Where no error bar is visible, 
error falls within the limits of the symbol. 
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9.4 Discussion 
The main findings of the present study are the observed differences between 
contractions induced by ET-I and sarafotoxin S6b. The ETA receptor antagonists BQ-123 
and FRI39317 were clearly more potent against sarafotoxin S6b than against ET-l. ET-I 
and sarafotoxin S6b induced similar contractile responses in endothelium-intact and 
endothelium-denuded vessel segments. After a full concentration response curve with ET-I 
or sarafotoxin S6b, fuliher contractions ofthe endothelium-intact coronary ruielY segments 
could only be achieved by applying ET-I in segments exposed to sarafotoxin S6b, and not 
the reverse. 
It is to be noted that most concentration-response curves were obtained in vessel 
segments in which the endothelium was left intact, in view of the more frequent 
occun'ence of spontaneous phasic oscillations in the absence of endothelium. These 
spontaneous rhythmic contractions would hinder detailed analysis of concentration 
response curves 21. Destruction of the endothelium in a perfused rat mesenteric mierial bed 
increased the contractile response to ET-I, sarafotoxin S6b, ET-3 and big-ET-I ". We 
established for ET-l and sarafotoxin S6b that removal of the endothelium in coronmy 
artelY segments in our model does not alter the contractile response (Figure 2). It can 
however not be ruled out that contractile responses to the other agonists are modulated by 
the presence of endothelium. 
Heterogeneity o/receptors involved in Ihe response to ET-J and sara/oloxin S6b? 
The present data supply evidence for heterogeneous mechanisms mediating the 
contractile response to ET-I and sarafotoxin S6b. First, the ETA receptor antagonists 
BQ-123 and FR139317 had significantly different potencies against ET-l- and sarafotoxin 
S6b-induced contractile responses. Secondly, after a full concentration response curve 
ending with 0.3 J.lM ET-I or 0.3 J.lM sarafotoxin S6b, fuliher contractions could only be 
achieved with ET-l in segments that had been exposed to sarafotoxin S6b and not in those 
exposed to ET-l. Also in view of the EMAX of sarafotoxin S6b being slightly, but 
significantly, higher than that of ET-I, it is difficult to explain why ET-I, but not 
sarafotoxin S6b, caused further contraction of segments exposed to the other compound. 
Possibly, ET-l caused desensitization of events beyond activation of the receptor for 
sa .... fotoxin S6b, without affecting this receptor itself. The latter was also suggested by 
Cardell and co-workers ", who made similar observations in the guinea-pig pUlmonmy 
miery, using ET-3 instead of sara fat ox in S6b. Hiley and colleagues 30 observed analogous 
cross-desensitization using ET-I and ET-3, but suggested that ET-3 interacted with an 
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ET-I-insensitive acceSSOlY binding site on·the receptor used by ET-I itself. Similarly, this 
explanation of two agonists binding to different binding-sites on the same receptor cannot 
be lUled out to account for the differences in antagonist potency observed against ET-I 
and sarafotoxin S6b. 
To characterize endothelin receptors in the present study, several complicating factors 
have to be kept in mind. First, we have no knowledge of possible differential metabolic-
or uptake mechanisms of any of the endothelin receptor ligands. Indeed, contractile 
responses to high (EMAX) concentrations ofET-1 or sarafotoxin S6b (with a magnitude of 
over 100% of the contractile response to 100 mM K+) fade away partially. However, this 
decline is apparently not due to metabolic breakdown, since ill oUl' study the contractile 
response to lower concentrations of the peptides was sustained (Figure 3). Secondly, one 
may argue that receptor pharmacodynamics are not conventionally straightforward in 
interactions with endothelin receptors. After activating the receptor in human and porcine 
smooth muscle cells, the endothelin receptor-ligand complex was found to be intetnalized 
and, thus, possibly unavailable for competition 31. It has also been reported that an 
endothelin receptor antagonist like BQ-123 may act eitller as a competitive or non-
competitive antagonist 32, depending on whether or not equilibrium conditions are 
present 33. Lastly, the ligand-receptor kinetics for endothelins (e.g. different association! 
dissociation rates for different endothelin isopeptides 34) could have implications for 
functional studies investigating the receptors involved. On the other hand, these 
conceivable, but yet theoretical pitfalls should not preclude comparison of the present 
observations with endothelin receptor characterizations in smooth muscle preparations as 
reported in previous studies. Furthermore, the involvement of heterogeneous receptors is 
suppOlied by the observation of an additional non-ETA> non-ETa binding site in human 
coronary atieries labelled by [125I]sarafotoxin S6b, but not by [I25I]ET-I, with patiicularly 
high affinity for BQ-123 16. Also in suppOli of the involvement of heterogeneous receptors 
are previous studies in human isolated saphenous veins in which BQ-123 biphasically 
inhibited sarafotoxin S6b-induced contractions. BQ-123 was more potent against high than 
against low concentrations of sat'afotoxin S6b II. 
Are ETA receptors involved in the contractile responses to ET-J and sara/otoxl" S6b? 
Originally, ETA receptors Were differentiated fi'om ET D receptors by a high affinity 
of ETA receptors for ET-l compared to ET-3 I.)S. ETB receptors, however, have similar 
affinity for ET-l and ET-3 2.)S. Considering the difference in potency of ET-I atld ET-3 
in the present study, it may be concluded that ET-I-induced responses in the present study 
are mediated by ETA receptors. In addition, this order of potency vit1ually lUles out the 
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involvement of the putative ETc receptor, which has higher affmity for ET-3 than for 
ET-I ". The presently observed agonist order of potency is similar to that in the rat 
thoracic aorta " the rabbit carotid artery 37, and the guinea-pig aorta '. In all ofthese animal 
preparations, it was concluded that ETA receptors mediate the contractile response. 
However, the fact that in the present study BQ-123 antagonized ET-I-induced contractions 
only at 10 JlM (PKB = 5.75) would argue against involvement of the ETA receptor, since 
BQ-123 has submicromolar 7.35 to nanomolar 38. 39 affinity for ETA receptors in binding 
studies. In oUl' experiments 0.1 JlM BQ-123, if anything, caused a small potentiation of 
the contractile response. The pKB value of BQ-123 against sarafotoxin 86b appears in 
better agreement with ETA receptor involvement. It is however unlikely that sarafotoxin 
86b activates an ETA receptor, which is not activated by ET-I, since ET-I has an even 
higher affinity for ETA receptors than sarafotoxin 86b I. 
The pKB value (6. II) of FRI39317 against ET-I is in reasonable accordance with 
an ETA receptor mediated mechanism. Previously found pA, values for FRI39317 include 
6.0 in the rabbit femoral at1ery 40, 6.65 in the guinea-pig pulmonary artery 41 and 7.2 in the 
human coronary artery 42 and rabbit aorta 17. A pKB value ofFRI39317 as high as 8.2-8.5 
against sarafotoxin 86b-induced responses (present results) has not yet been described for 
an ETA receptor-mediated functional response in organ bath experiments, and appears too 
high to point towards a 'typical' ETA receptor-mediated mechanism. 
Recent studies assessing the antagonist effects of BQ-123 against ET-I-induced 
contractions of human coronary aI1ery rings (2 mm) report that, even at 0.1 JlM, BQ-123 
antagonized contractile responses to ET-I, resulting in pA, values of 6.4-7.5 13. ". Both 
these studies concluded that ETA receptors mediate the contractile responses to ET-l. It 
may be hypothesized that the difference of the potency of BQ-123 in those studies and our 
study, and also the discrepancies within other studies between large proximal and small 
distal COl'Onary artery segments 13, 14, could be due to differential diffusion of the large 
peptide molecules to the receptors in these two types of arterial segments. Indeed we 
found in the present study that the type of preparation (4 nun ring or I nun spiral strip) 
made a difference in the observed potency of both ET-I as an agonist and BQ-123 as an 
antagonist (Figure 5). Although the influence of the applied resting tension on strips and 
rings can not be excluded, the observed discrepancy may be due to different dntg 
concentrations in the receptor compartment, caused by differences in the diffusion barrier 
of lat'ge molecules 43, such as the endothelins., This could playa role in the observed 
divergence found between proximal and distal human coronary artery segments 13. 14, 
possibly in addition to a different receptor profile, One may argue that pa11ial endothelial 
damage of the strip preparation affected the present results, However, it must be kept in 
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mind that even a complete removal of the endothelium in ring segments did not affect the 
contractile response to ET-l or sarafotoxin S6b (Figure 2). Similar diffusion-related 
differences may also playa role in the recently observed 3-fold leftward shift of the ET-l 
concentration response curve of human vertebral mieries of infants, when compared to 
vertebral arteries of adults (0-2 years vs. 38-71 years) 44. Our data in human coronary 
mieries do not support such age-dependent differences in the response to ET-l or 
sarafotoxin S6b. 
The pK. value of 6.62 ± 0.18 for BQ-123, presently obtained in strip preparation 
against ET-I, would not seem out of line when compared to pA, values of 6.93 in the rat 
aorta', of6.5 in the rabbit femoral miery 40, of6.8 and 6.9 in the rabbit carotid miery and 
thoracic aorta, respectively", and even compared to pA, values of 6.8 - 7.5 in the more 
distal parts of 2 Illlll humml coronary artery rings 13. In all of these preparations the 
response was characterized as being mediated via ETA receptors. Interestingly, Schoeffter 
and Randriantsoa', using 3 mm ring preparations, found that ET-l-induced contractile 
responses of the porcine coronary artery were vh1ually insensitive to BQ-123 (PK.: 5.21), 
and concluded that these contractions were mediated by non-ETA receptors. By contrast, 
an em'lier study in the porcine coronary artery, applying spiral strips (diameter I mm), 
found an apparently ETA receptor-linked pA, value of 7.4 7. Also in the porcine coronary 
artery, the agonist potency ofET-1 in the strip prepm'ation 7 was clearly higher (pD,: "'10) 
than in the ring preparation studied by Schoeffter and Randriantsoa 6 (pD,: 8.3). 
The presence of mRNA encoding for ETA receptors was demonstrated in smooth 
muscle cells of the human coronary aliery 39. ". In a receptor autoradiography analysis of 
endothelin receptors in the human coronary artery, it was shown that 30 pM ['2SI]_ET_l 
labelled a homogeneous receptor population in the human coronmy artery with similar 
characteristics as the ETA receptors identified in atrium and ventricle ". Also DavenpOli 
and colleagues 46, studying binding displacement of 100 pM ["'I]-PDI51242, concluded 
that ETA receptors were present in the media of (atherosclerotic) human coronary artery. 
Taking into account (i) the higher potency of ET-l compm'ed to ET-3, (ii) the 
presently found pK. value (6.62 ± 0.18) for BQ-123 against ET-I in strip preparations, 
(iii) the potency of FRI39317 in coronary artery rings, and (iv) the previously obtained 
evidence from radioligand binding and molecular biology experiments for the presence of 
ETA receptors in the human coronary m1ery, we have to conclude that contractile 
responses to ET-I were most likely mediated via an ETA receptor, despite a pKB value of 
only 5.75 for BQ-123 against ET-I-induced responses in 4 mm coronary miery rings. We 
showed that the type of preparation can affect the potency of both ET-I and BQ-123, 
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which may have significant implications for the use of these compounds in other studies 
involving endothelin receptor characterization, Considering the associated high pK. values 
ofBQ-123 and especially FR139317, we propose that contractions to sarafotoxin S6b are 
mediated via another subtype of ETA receptors, A similar suggestion has been made by 
Salom and co-workers 10 for the effects of sarafotoxin S6b in the goat cerebral at1ery, 
Possibly, the effects of ET-3 (also extremely potently antagonized by BQ-123) are 
mediated via the same receptor, not only in the human isolated coronary artery 13, but also 
in the human small omental vein 41, in the rat vas deferens 8, " and in the guinea-pig left 
atrium ", Although the above mentioned complicating receptor dynamics or kinetics can 
not entirely be mled out, no evidence is available for such mechanisms yet. 
Are ETB receptors involved in contractile responses? 
The very small contractile response elicited by high concentrations of[Alal,l,II,I'jET-l 
in the human isolated coronary at1ery would argue against the involvement of ET. 
receptors, DavenpOl1 and co-workers" found a complete lack of agonist effect in the 
human coronary artery of both [Alal",JI,15jET_l and BQ-3020, another ETB receptor 
selective agonist ", In the pig coronary artery [Alal,l,JI,15jET_l acted as a partial agonist 
with a pO, of 7.4', Furthermore, [Alal,3,11,15jET_1 induced phosphoinositol turnover in 
human ET. receptor-transfected COS-7 cells (KD 20 nM so), and caused relaxation of the 
porcine pulmonary artery (ED" 4.4 nM 15), To verify whether [Alal,3,11,15jET-l acted as 
a pat1ial agonist in this preparation, concentration response curves to both ET-l and 
sat'afotoxin S6b were constmcted in the presence and absence of I !1M [Alal,3,11,15jET_I, 
but no antagonism was observed (Figure 4), Thus, in the present study, no evidence was 
obtained to support functional involvement of contractile ET B receptors, Also in our 
radioligand binding study, in which either 30 pM [125Ij_ET_I or [125IJ-sarafotoxin S6b were 
used, no indication was found for the presence of ET B receptors on the smooth muscle of 
the human coronary artery I', However, in another investigation, where 100 pM [J25Ij_ET_I 
was used as a radioligand, it was concluded that a small propOl1ion (13%) of ET B 
receptors was present in the human coronruy artmy ", The presence of mRNA encoding 
for ET. receptors has been shown in human coronaty artery smooth muscle cells ",45, 
Possibly, these ET B receptors do not playa major role in endothelin-induced vasoconstric-
tion, but they may be involved in other yet unknown effects, However, recently it was 
shown in the human internal mammary artery and vein, that ET-I may induce contractions 
via a mixed ETAIET. receptor population 51, 
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Effects of big-ET-l and phosphoramidon 
The 21-amino acid peptide ET-I is formed after cleavage between Tlp21 and Val" 
of a 38 amino acid precursor peptide, big-ET-I 19.20. The contractile response of big-ET-I 
in isolated tissues may develop directly via binding of big-ET-I to vascular smooth muscle 
receptors" as well as indirectly via ET-I cleaved from big-ET-I by the endothelin-
convel1ing-enzyme (ECE), which is reflected by the steep nature of the concentration 
response curve. The activity ofECE was found to vary between different vascular beds 53, 
as shown by the ability of phosphoramidon, a metalloprotease inhibitor of ECE 20, to 
inhibit the contractile response induced by big-ET-l. Since in the present study, 
pretreatment with I 00 ~IM phosphoramidon partially reduced the contractile response to 
big-ET-I, we conclude that ECE, present in the coronary artery, contributed to the 
contl'actile response induced by big-ET-l. It has been suggested that ECE has substrate 
specificity for big-ET-I compared to big-ET-3 20. Apm1 from this explanation, the absence 
of contractile effects to big-ET-3 in the present study could also result from the lower 
contractile potency ofET-3 compared to ET-I (Table I), combined with, possibly, a low 
affinity of big-ET-3 itself for vascular contractile receptors. 
In conclusion, the present study showed that ET-l and sarafotoxin S6b contract the 
human isolated coronmy artery via different receptor mechanisms, which can probably be 
best characterized as subtypes of the ETA receptor. Responses to ET-I and sarafotoxin S6b 
are not modified by endothelial denudation. This study also showed that the type of 
preparation (ring or strip) may afrect the potency of ET-I as an agonist, and of BQ-123 
as an antagonist. Finally, the contractile response to big-ET-I is mediated in pmt by 
conversion to ET-I, taking place within the vascular wall of the human isolated coronary 
artery. 
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The current endothelin receptor classification: 
Time for reconsideration?* 
Summary - The possible involvement of endothelins in a variety of diseases has 
attracted the attention of many phannacologists in search of a novel therapeutic 
approach. The rapid development of endothelin (ET) research resulted in the 
molecular characterization and phannacological recognition of ETA and ET B recep-
tors, and in development of compounds selective for these receptors. However, the 
characterization of receptors in various assays showed that a number of effects is 
mediated by receptors, which do not fit the present criteria for ETA or ET B receptors. 
This review addresses endothelin receptors in general, and atypical receptors in 
particular. 
10.1 Introduction 
Endothelin (BT) was discovered and recognized as a potent vasoconstrictor peptide 
only 7 years ago '. Three distinct endogenous endothelin isoforms (ET-l, ET-2, and ET-3) 
are cleaved from the endothelin precursors big-ET-l, big-ET-2 and big-ET-3 by an 
endothelin converting enzyme. Increased concentmtions of endothelins have been observed 
after myocardial infarction, in atherosclerosis, (pulmonary) hypertension, migraine and 
many other diseases (review: see Ref. 2). Although recent advances towards the 
elucidation of the molecular structure of endothelin converting enzymes 3 will undoubtedly 
be followed by the development of endothelin converting enzyme inhibitors, efforts have 
so far primarily been directed to the development of endothelin receptor antagonists for 
clinical purposes. Indeed ETA and ET B receptors were cloned 4. " and selective ligands for 
these receptors have been recognized. 
*, Based on: Bax, \V,A. and Saxena, P.R. (1994) The current endothelin receptor classification: 
Time for reconsideration? Trends Phal'macoi. Sci. 15, 379-386. 
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10.2 The current criteria for endotheliu receptor classification 
Receptor classification in general should be based on three criteria 6, ': (i) structural 
(gene nucleotide and amino acid sequence of the receptor protein), (ii) transductional 
(receptor-effect coupling), and (iii) operational (receptor-(ant)agonist interaction), Endothe-
lin receptors are currently classified based on the consensus view of the subcommittee of 
lUPHAR, primarily according to endothelin isopeptide potency order, but also according 
to the potency of some antagonists, In so-called type I responses, ET-l is more potent than 
ET-3, whereas in type II responses both isopeptides have similar potency, In studies 
applying techniques to express cDNA for the currently known endothelin receptors, it was 
established that the type I and type II responses correspond to ETA and ET" receptors, 
respectively', 
Gene nucleotide and amino acid sequence of the receptor protein 
ETA and ET" receptors have approximately 63% amino acid homology, Southern 
blots of the human genomic DNA, using cDNA probes for the ETA and ET" receptor 
under low stringency, revealed only two signals, probably corresponding to human ETA 
and ET" receptor genes, Thus it appeared that other endothelin receptors, if existent, would 
probably have a considerably different amino acid sequence " It should however be noted 
that amino acid homology may be indicative of operational and functional similarity, but 
that this is not a general prerequisite, 5-HTID and 5-HTID' receptors, for instance, have a 
clearly different pharmacological profile for a number of compounds, despite a 96% amino 
acid homology in the transmembrane spanning region, In contrast, 5-HTID' and 5-HTlDa 
receptors are pharmacologically practically indistingnishable, but have a relatively 
moderate 77% amino acid homology in the transmembrane spanning region " 
Recently, the identification of cDNA for a receptor in xenopus dermal melanophores 
was reported, with relatively high affinity for ET-3, This receptor had approximately 50% 
amino acid homology with ETA and ET" receptors 10, It is however not yet celia in whether 
it actually represented the putative ETc receptor, highly selective for ET-3, which was 
reported in operational studies in e,g, bovine endothelial cells II, or whether it represented 
the xenopus variant of, for instance, ET B receptors, Because of the scarcity of fimctional 
correlates, and because oftlle lack of selective ETc receptor ligands other than ET-3, this 
review will not discuss ETc receptors in fiuiher detail. 
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Second messenger mechanisms 
Both ETA and ETa receptors have been described to be coupled to phosphatidyl-
inositol-biphosphate (PIP,) hydrolysis via G-protein-coupled phospholipase C, and to the 
generation of inositol phosphates (IP) and diacyl-glycerol, resulting in an increased 
concentration of intracellular Ca" '. In transfected Chinese hamster ovary cells it was 
observed that ETA receptors induced accumulation of cAMP, whereas ETa receptors 
inhibited forskolin-stimulated cAMP production. The stimulation of adenylyl cyclase, 
mediated by ETA receptors, was however less efficient than the stimulation of IP 
formation, which raises questions about the physiological relevance of adenylyl cyclase 
as a second messenger system in these cells ". 
Less is known about transduction of receptors that do not resemble the ETA or ETa 
type. Kumar and co-workers 13 observed endothelin receptors in the follicular membranes 
of xenopus laevis oocytes, resembling human ETA receptors in their affinity for ET-I, 
ET-3 and sarafotoxin 86c, but with an atypically low affinity for BQ123. Activation of 
this receptor, which was considered a subtype of ETA receptors (ETAX)' led to mobilization 
of Ca", which was blocked by treatment that uncouples gap junctions. In contrast, Ca" 
mobilization induced by expressed human ETA receptors was not sensitive to such 
treatment. In another study, [125I]_ET_I binding to human brain endothelial cells revealed 
a high and a low affinity binding site 14. The high affinity binding site had the order of 
affinity: ET-I > ET-2 > sarafotoxin S6b> ET-3, which resembled the ETA receptor, and 
also matched the order of potency for IP accumulation in these cells. The order of affinity 
for displacement of the unidentified low affinity [125I]_ET_I binding site (sarafotoxin S6b 
> ET-2 > ET-I~ET-3) did not match the order of potency for IP accumulation. Other 
second messenger systems were not examined in the latter study. 
Operational characterization of endothelin receptors 
Despite the stlUctural and transductional data with respect to endothelin receptors, the 
present classification relies largely on operational evidence " i.e. data obtained in functio-
nal or radioligand binding experiments. In addition to the frequently applied potency order 
of the endogenous ET-I and ET-3, a number of synthetic compounds has been identified 
with selectivity for ETA or ETa receptors. Some of the most often applied compounds are 
summarized in Table I. 
The operational and functional characterization of endothelin receptors is hampered 
by several pitfalls. First, endothelin peptides may be internalized after binding to the 
receptor IS. Therefore, agonists can become unavailable for classical ligand-receptor 
lSI 
The current endothelin receptor classification: Time for reconsideration? 
Table 1. The affinity (nM) of endothelin receptor ligands for ETA and ETB receptors. 
nM ETA receptors ET B receptors 
Ligand K, IC" K, IC" KD Ref. 
ET-I 3.5, 0.58, 0.92' 0.16,0.29 0.95,0.12 1.6, 0.06, 0.44 0.003 4,9,57-61 
ET-3 1000, 83, 900' 5.0, 150 2.0,0.13 1.6, 0.06, 0.11 0.014 4,9,57-61 
Sarafotoxln S6b 52' 4 
Sarafotoxin S6c 2800 1300 0.29 0.3,0.12 0.24 58-61 
[Alal,l,II,IS]ET_l 398 0.25 20 59,61 
BQI23 25, 17 13,63 31000, II 100 >10000, >100000 285 57-61 
FRI39317 I' 6.3, 13 7300' 20000, > 100000 59,60, 62 
BQ788 1300 1.2 28 
R0462005 200,360 160, 530 59,60 
Bosentan 6.5 343 63 
SB 209670 0.4 2.0 15 32 59,64 
BMS I 82874 63 1600 55000 >10000 59,65 
97-139 1000 66 
Data obtained in cell lines transfected with human or bovine(') endothelin receptors. For BQ788 
and 97-139 only radio ligand binding data obtained in membranes are available (ETA: SK-N-MC 
human neuroblastoma cell line (BQ788), and A7r5 rat aortic smooth muscle cells (97-139); ETB: 
human Girardi heart (hGH) cells). For Ref. 59, pIC" values were calculated to approximate IC" 
values. 
competition. Also the formation of ligand-receptor complexes with a different dissociative 
behaviour, depending on the ligand used, may result in complicated receptor kinetics 16. ". 
Lastly, endothelin receptors may downregulate 18 or desensitize rapidly, resulting in a 
possibly differentially altered response to various endothelin peptides '9. 
182 
Chapter 10 
10.3 Responses mediated by endothelin receptors 
Typical ETA receptors 
ETA receptors have often been found to mediate contractile responses in isolated 
smooth muscle preparations. The involvement of ETA receptors was typically established 
on the basis of the relative order of potency of ET-I and ET-3 as agonists, and on the 
inability of ET. receptor selective compounds (e.g. sarafotoxin S6c or [Ala'.3·"·"jET-I) 
to act as agonists. Moreover, both BQl23 and FRl39317 were generally used as ETA 
receptor antagonists. Typical examples of preparations with ETA receptors that mediate 
contractions include the rat 20 and guinea-pig" aOl1a (Table 2). 
Typical ETB receptors 
ET. receptors were originally considered as 'vasodilator receptors' in contrast to the 
vasoconstrictor ETA receptor. Warner and colleagues 22 showed that ET-3 and ET-Iwere 
equipotent as vasodilators, whereas ET-I had been shown to be twenty-fold more potent 
as a vasoconstrictor ". Thus, the involvement ofET. receptors was first established on the 
basis ofequipotency ofET-1 and ET-3. Later, it was shown that ET. receptors were also 
involved in smooth muscle contraction in blood vessels, such as the rabbit saphenous 
vein 24, and in the guinea-pig bronchus". In these tissues the ETA receptor antagonist 
BQ 123 failed to block the contractile responses. The latter study also employed sarafotoxin 
S6c, a selective agonist for ET. receptors. Others used [Ala'·3·1I·"jET-I, and sometimes 
IRLl620 01' BQ3020 as agonists. Until recently, only IRLl038 was available as a selective 
ET. receptor antagonist 25. ". Unforttmately, the affinity for ET. receptors was reported to 
be highly variable between batches, and data obtained with this compound should be 
considered with caution ". However, the recent development of the potent and selective 
ET. receptor antagonist, BQ788, provided a novel tool to study involvement of ET B 
receptors 28 (Table 3). 
Mixed ETA and ETB receptor populations 
In the guinea-pig trachea, BQ 123 was a weak antagonist ofET-I-induced contraction; 
sarafotoxin S6c was a p .. 1ial agonist. The contractile effect of the latter was resistant to 
antagonism by BQ 123. Thus, it was concluded that both ETA and ET. receptors mediated 
contractile responses in the guinea-pig trachea". Vasoconstriction in the isolated perfused 
rat kidney was also mediated by both ETA and ET. receptors. In this preparation, the ETA 
receptor antagonists BQ 123 and FRI39317 caused only pmial attenuation ofET-I-induced 
contractions, whereas the non-selective ET .lET. receptor antagonist PD 145065 completely 
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Table 2, Examples of studies in which the response (contraction) was concluded to be mediated 
via an ETA receptor, 
Characterization criteria 
Species Tissue Agonist Antagonist against ET-I Ref. 
Rat Thoracic aorta BT-! > BT-3; pA, BQ!23: 6.93 20 
[Ala l,l,II,151ET_l: no effect 20 
Rabbit Carotid artery BT-I > BT-3; pA, BQ!23: 6.8 30 
[Ala l ,3,II, lslET-l and 
sarafotoxin S6c: no effect 30 
BT-! > BT-3; pK, BQ!23: 7.5 24 
sarafotoxin S6c: no effect 24 
Guinea-pig Pulmonary artery BT-! > BT-3 pA, FRI393!7: 6.65 67 
Sarafotoxin S6c: no effect pKD BQ!23: 6.7 2! 
Aorta Sarafotoxin S6c: no effect pKD BQ!23: 7.1 2! 
BT-I > BT-3; pA, BQ!23: 7.4 49 
[Ala l,3,ll,ls]ET_l and 
sarafotoxin S6c: no effect 49 
Iliac artery BT-! > BT-3; pK, BQ!23: 6.6-7.2; 68 
sarafotoxin S6c: no effect pA, FR1393 17: 5.82 68 
Goat Cerebral artery BT-! > BT-3 pK, BQ!23: 7.43 34 
Human Coronary artery BT-I > BT-3 pA, BQ!23: 6.4-7.47 52 
Omental artery BT-I > BT-3 pA, BQ!23: 7.09 26 
Pulmonary artery Sarafotoxin S6c: no effect pK, BQ123: 6.2-6.8 2! 
'>' refers to 'is more potent than', 
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Table 3. Examples of studies in which the response was concluded to be mediated via an ET B 
receptor. 
Characterization criteda 
Species Tissue, response Agonist Antagonist* Ref, 
Rat Aorta relaxation IRLI620 BQ123: no errect 69 
(IRLI620) 
Rabbit Pulmonary artery ET-I ~ ET-3; BQ123: no errect 30 
contraction [Alal,J.ll,15JET~1 and (ET-I, ET-3, 30 
sarafotoxin S6c [Ala""II,IlJET-I) 
ET-I ~ ET-3; BQ3020 BQ123: no errect 70 
(BQ3020) 
BT-J = sal'afotoxin S6c BQI23 and PD124893: 43 
no errect (ET -I) 
pA, BQ788: 8.4 (BQ3020) 29 
Jugular vein ET-I ~ ET-3; BQ 123: no errect 30 
contraction [AJa1,l,ll,lS]ET_l and (BT-I, ET-3, 30 
sarafotoxin S6c [Ala""II'''JET-I) 
Saphenous vein ET-I ~ ET-3; BQ 123: no errect 24 
contraction sarafotoxil1 S6c (Safarotoxin S6c, ET-I) 
Guinea-pig Bronchus contraction Sarafotoxin S6c BQ123: no errect 2t 
(Sarafotoxin 86c, ET-I) 
Trachea contraction IRLI620 71 
ET-I ~ ET-3 FR139317: no errect 67 
(ET-I, ET-2, ET-3) 
Pig Pulmonary atieey [Alal ,l.II, lslET-1 72 
relaxation BQ3020 70 
Canine Coronary artery Sarafotoxin S6c BQ 123: no errect 44 
constriction (Sarafotoxin S6c) 
Human Bronchus contraction Sarafotoxin S6c BQ123: no errect 21 
(Sarafotoxin S6c, ET-I) 
'=' refers to 'is equipotent as'; '>' refers to 'is more potent than'. *, The agonist against which 
the antagonist was studied is indicated between brackets. 
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Table 4. Examples of studies in which the response was concluded to be mediated via a mixed 
receptor population consisting of ETA and ET B receptors 
Characterization criteria 
Species TissueJ response Agonist Antagonist* Ref. 
Rat Kidney perfusion ET-I=ET-3= BQ123: little effect 73 
sarafotoxin S6b"" (ET-lisarafotoxin 86b) 
smafotoxin S6c 
Sarafotoxin S6c BQI23 and FR139317: 29 
partial attenuation (ETMI) 
PDl45065: 29 
complete attenuation (ETM 1) 
Rabbit Pulmonary artery Sarafotoxin S6c > ETMI BQ123: antagonist 32 
(high concentrations ETM I) 
Sarafotoxin S6c: no effect"'* pA, IlQ123: 6.6 (ET-I)" 32 
Saphenous vein Sarafotoxin S6c > 10 ~M BQ 123: antagonist 
contraction ET-I = ET-3 (high concentrations ETMI) 32 
Guinea-pig Trachea Sarafotoxin S6c BQ 123: no effect 21 
contraction (sarafotoxin S6c); 
pK" IlQ123: 6.2 (ET-I) 21 
Human Internal mammary S3I'afotoxin S6c: BQ123 and FR139317: 51 
artery contraction partial agonist antagonists (ET-I) 
':::::' refers to Jis equipotent asJ; J>' refers to 'is more potent than'. *, The agonist against which 
the antagonist was studied is indicated between brackets. **, After 30 min pretreatment with 
sarafotoxin S6c. 
abolished the responses to ET-l ". 
Even in blood vessels which were previously considered to contract via ET B receptors 
exclusively, such as the rabbit saphenous vein 24 and pulmonary artery", a coexisting ETA 
receptor mediating vasoconstriction could be demonstrated by showing that BQ 123 
attenuated part of the concentration response curve to ET-I in both vessels, despite an 
186 
Chapter 10 
observed equipotency ofET-1 and ET-3 31, ", The presence of ETA receptors in the rabbit 
pUlmonary artery was confirmed by radioligand membrane binding stndies" (Table 4). 
Atypical endothelin responses 
A number of preparations yielded an agonist order of potency ofET-1 > ET-3, which 
would imply the involvement of ETA receptors, However, when the effect of the ETA 
receptor antagonist BQI23 was stndied against both ET-I and ET-3, it was found that 
BQI23 antagonized contractions to ET-3 substantially more potently than ET-I-induced 
contractions, suggesting the presence of different receptors 20 (Table SA). Pierre and 
Clarke 33 suggested that, in the rat isolated renal artery, the BQl23-sensitive contractions 
to ET-3 were mediated via ETA receptors, whereas the relatively BQ 123-insensitive ET-I-
induced contractile responses were mediated via non-ETA receptors, Although this is a 
plausible explanation ft'om the antagonist point of view, it is yet lInclear why ET-3 
recognizes an ETA receptor not recognized by ET-I, which clearly has a higher affinity 
for ETA receptors than ET-3 (Table I), 8imilar observations were made when comparing 
the antagonist potency ofBQI23 against ET-I and sarafotoxin 86b: contractile responses 
of the goat cerebral artery induced by sarafotoxin 86b were antagonized more potently by 
BQI23 than those induced by ET-I 34 (Table SA), It has been argued that the reversibility 
of receptor binding ofET-1 is different from that ofET-3 01' sarafotoxin 86b, and that this 
could account for the differences in antagonist potencies against these agonists". 
However, the latter interpretation does not explain the biphasic antagonism of sarafotoxin 
86b-induced contractions of the human saphenolls vein by BQ 123 36, or the biphasic 
displacement by BQI23 of binding with 30 pM [' 25Il-sarafotoxin 86b in the media of 
human coronary arteries 37, FUl1hermore, it should be noted that in other investigations the 
antagonist potency did not differ between these particular agonists ".40, or was even higher 
against ET-I than against the other agonist 41, 42, Thus, although the possibility of 
interference by complex endothelin receptor kinetics IS·19 should not entirely be 
disregarded, it appears that ET-I on one hand, and sarafotoxin 86b and ET-3 on the other 
hand, may exert their effects via different receptors which do not fit the current 
classification of ETA and ET B receptors, 
Warner and colleagues 43 observed an ETB receptor mediating constriction of the 
rabbit pulmonary .. tery and rat stomach strip, relatively insensitive to the non-selective 
endothelin receptor antagonist PD 142893, In contrast, PD 142893 potently antagonized the 
ET B receptor-mediated vasodilator effect in the perfused mesentery, which indicated 
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Table 5A, Examples of studies in which the response was concluded to be mediated by a single 
or mixed receptor population consisting of receptors characterized as partly atypical or as subtypes 
of ETA receptors, by using ETA receptorMselective compounds, 
Species 
Rat 
Goat 
Human 
Tissue, response 
Aorta contraction 
Vas deferens 
increased twitch 
Cerebral artery 
contraction 
Characterization criteria 
Observation 
BQI23 more potent vs, ETM3 than vs. ETMI; 
[Ala\,],Il,15]ETM l: no effect 
BQl23 and PDl42893 more potent vs, ET-3 
and sarafotoxin S6b than vs, ETM!; 
sarafotoxin S6c: no effect 
BQI23 more polent vs. sarafotoxin S6b than vs. ETMJ 
Ref. 
20 
56,74 
34 
Small omental vein BQl23 more potent vs, ETM3 than vs. ETMl 26 
26 contraction 
Coronary artery 
contraction 
Saphenous vein 
contraction 
Umbilical artery 
BQ 123 more potent vs. high than vs 
low concentrations of ETM 3j IRLI038 no effect against 26 
ETMlj sarafotoxin S6c: no effect 
BQ123 more potent vs, ET-3 than vs. ETMI 
BQ 123 and FR 139317 more potent vs, sarafotoxin S6b 
than vs, ET-I; [Ala1,J,II,ls]ETM1: no effect 
BQ 123 more potent vs, sarafotoxin S6b than vs, ET M I 
BQ123 more potent vs, high than vs, low 
concentrations of sarafotoxin S6b 
BQl23 more potent vs. sarafotoxin S6b than vs. ETMI 
26 
52 
53 
53 
36 
36 
54 
receptor heterogeneity among ETn receptors 43. Also a study in swine pulmonary artery 
revealed differences between ET. receptors mediating contraction and ET. receptors 
mediating endothelium-dependent relaxation. Only the latter receptor was sensitive to 
antagonism by the ETB receptor antagonist IRLI038 ". As was mentioned above, it should 
however be noted that questions have arisen over the use ofIRLI038 as an ETB receptor 
antagonist 27, and these experiments need verification using alternative antagonists with 
affinity for ET B receptors. Radioligand binding studies in canine coronary artelY 
membranes also indicated the possibility of ET B receptor subtypes 44. These binding sites 
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Table 5B. Examples of studies in which the response was concluded to be mediated by a single 
or mixed receptor population consisting of receptors characterized as partly atypical or as subtypes 
of ETB receptors, by using ETB receptor-selective compounds. 
Species 
Rat 
Pig 
Tissue, response 
Stomach strip 
contraction 
Perfused mesentery 
Characterization criteria 
Observation 
Contraction to sal'afotoxin S6c (more potent than 
ET-I) weakly antagonized by PDl42893 
Dilatation to sarafotoxin S6c (equipotent ET-l) 
strongly antagonized by PDl42893 
Atrium contraction ET-I, ET-3, sarafotoxin S6b equipotent; 
sarafotoxin S6c and [Alal.l,I1,IS]ET_1 no effect 
Pulmonary vein 
contraction* 
Pulmonary artery 
relaxation* 
Coronary artery 
contraction 
Isopeptide non-selective receptor, resistant to IRLI038 
Isopeptide non-selective receptor, sensitive to IRLI038 
Sarafotoxin S6c sensitive receptor recognizes ET-3, 
but not ET-I or sarafotoxin S6b 
Sarafotoxin S6c and [Alal,J,II,ls]ET_1 sensitive 
receptor [pKD BQ123: ~5 (BT-I)], and another 
receptor resistant to BQ 123 
Ref. 
43 
43 
45 
25 
48 
49 
*. The receptor affinity and selectivity for ETl1 receptors ofIRLI038 have been described to be 
highly variable, Therefore. these data must be interpreted with caution2? 
had either high (ETuH) or low (ETnL) affinity for both ET-l and ET-3, In addition, the 
ETnH site showed high affinity for sarafotoxin S6c, but not for BQ123, whereas the ETnL 
site had moderate affinity for both sarafotoxin S6c and BQI23, Coronary vasoconstriction 
induced by sarafotoxin S6c was insensitive to BQ123, indicating involvement of the 
putative ETnH receptol', No functional correlate for the ETnL site is known at present ", 
In the rat left atrium, equipotent contractile responses to ET-I, ET-2, ET-3 and sarafotoxin 
S6b were observed, indicating the involvement of ET B receplors, However, Ihe 
ineffectiveness of the ET n receptor agonists [Ala,,3,II'''jET-1 and sarafotoxin S6c would 
suggest the involvement of receptors other than conventional ET n receptors ", Similarly, 
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xenopus laevis liver membranes revealed a binding site with identical affinity for ET-l and 
ET-3. As expected for ETu receptors, BQl23 was ineffective displacing [125Il-ET_I label-
ling of this site, but sarafotoxin 86c was ineffective as well, suggesting the presence of 
a subtype of ET u receptors ". 
The nature of endothelin receptors mediating contraction of the porcine coronary 
at1ery is still controversial, but part of the receptor population does not appear to 
correspond to either ETA or ETu receptors. Ihara and co-workers 47 observed ET-I-induced 
contractile responses sensitive to antagonism by BQl23 (pA, 7.4), which were thus 
considered to be mediated via ETA receptors. The small BQ 123 non-sensitive part of the 
concentration response curve to ET-I was assigned to ETu receptors. Further studies 
agreed on the ETA receptor component based on the agonist order of potency, but also 
observed a receptor which recognized sarafotoxin 86c and ET-3, but not ET-I and 
sarafotoxin 86b ". Later, it was shown that the contractile effects of both sarafotoxin 86c 
and [Alal.3•1I •I 'lET-1 were likely to be mediated via the same ETu receptor, whereas a 
non-ETA> non-ETu type of receptor contributed to the contractile response induced by 
ET-l 49 (Table 5B). 
Elldothelill receptors ill humall blood vessels 
Endothelin receptors mediating contractions of human isolated blood vessels were 
recently reviewed by Davenport atld Maguire so. Although the contractile responses may 
be mediated via typical ETA receptors (perhaps in addition to ETB receptors 'I), there at'e 
several reports focusing on non-ETA> non-ETa receptors in human blood vessels. 
In parallel with the rat aorta 20 and the goat cerebral at1ery 34 (Table 5), BQI23 has 
been observed to be more potent against ET-3- and sarafotoxin 86b-induced contractions 
than against ET-l-induced contractile responses in the human isolated saphenous vein ", 
coronary at1ery 52. ", umbilical artery" and in small omental veins 26. Recent data obtained 
in the human isolated coronaty artelY suggest that the same discrepancy between ET-I-
and sarafotoxin 86b-induced contractile responses is also observed with other ETA receptor 
antagonists such as FRl39317 ". 
It is yet unclear whether the ET B receptor plays a significant role in vasoconstriction 
of human blood vessels. Indeed the endogenous ligand ET -3 is a less potent vaso-
constrictor agonist than ET-l. Moreover, both ET B receptor agonists BQ3020 and 
[Alal.3•1I •lSlET-l hardly contracted the human isolated coronary artery so. 8arafotoxin 86c, 
however, induced contractile responses in some (but not all) coronaty artelY so, intemal 
mannnaty artery" or saphenous vein" segments. Although this may be due to a relatively 
low ET B receptor density '0, these observations could also be related to the isopeptide non-
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selective ETB receptors, with low affinity for the ETB receptor agonists [Ala1,3,II'''jET-l 
or sal'afotoxin S6c 45, 46. 
10.4 Concluding remarks 
The above mentioned studies show us that the current ETA and ETB endothelin 
receptor classification will have to be extended, A number of responses fit the present 
criteria for the ETA receptor, but ETA receptor antagonists (like BQl23 and FR139317) 
can sometimes be shown to be more potent against ET-3 20,26," 01' sarafotoxin 
S6b 34, 36, 53, 54 than against ET-l, indicating fmiher heterogeneity of endothelin receptors, 
One may classify these receptors as subtypes of the ETA receptor, since ETA receptor 
antagonists are moderately or highly potent in these assays, whereas ET B receptor agonists 
are usually inactive (Table SA), However, since it has only been possible to detect this 
heterogeneity in assays in which both receptors mediate the same effect, a detailed 
operational analysis of the individual receptors has not yet been established, and a 
conclusive classification of these receptors is therefore best postponed, 
ET B receptors also appeal' to be heterogeneous since the relaxant but not the 
contractile responses were antagonized by PD 142893 43 , It should be noted that only the 
affinity for the antagonist is to be used as a criterium for pharmacological receptor 
classification, and not whether the receptor mediates contraction or relaxation 6,', In view 
of the effect of ET B receptor agonists and the ineffectiveness of BQ 123, it would appear 
that these receptors may be designated ETBI (pD142893 sensitive) and ETB2 (pD142893 
insensitive) receptor subtypes, Whether additional ETB receptor subtypes exist, e,g, in 
canine coronary miery 44, or whether other atypical observations m'e related to the proposed 
ETBJ or ETB2 receptor subtypes, remains to be resolved (Table 5B), 
The above mentioned novel experimental data are not yet sufficient to provide a 
conclusively extended endothelin receptor nomenclature, Indeed additional data on 
transductional mechmlisms and possibly on the sequence of the conesponding DNA are 
eagerly awaited, and the use of more agonists and antagonists in functional studies is 
vital 6,', For now we would however point out that in parlicular the current basic criterium 
of the potency difference of ET-l and ET-3 8 should be applied with the utmost restraint. 
In some smooth muscle preparations, ET-l is clearly more potent than ET-3, suggesting 
the involvement of ETA receptors, However, considering the observed antagonist potency 
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differences 20, 26, ", the two peptides may in fact induce contractions via different receptors 
(Table SA), In other tissues ET-I and ET-3 are equipotent which would traditionally point 
at ETB receptors. However, ETB receptor agonists may in some cases be inactive 45, and 
detailed analysis using ETA receptor antagonists has been used to demonstrate the presence 
of an additional ETA receptor 31, ", Given the relatively incomplete understanding of 
endothelin receptors and the limited number of selective receptor ligands, the use of a 
wide spectrum of both agonists and antagonists is required for endothelin receptor 
characterization, The non-peptide receptor antagonists, that are now becoming available, 
will certainly help the process towards a conclusive, more detailed endothelin receptor 
classification, 
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Appendix Chapter 10; Chemical names 
BQ 123: cyclo(D-Trp-D-Asp-Pro-D-Val-Leu-) 
BQ3020: Ala",I'-Ac-ET-1 [6-21] 
FR 139317: 2(R)-[2(R)-[2(S)-[[ I-(hexahydro-I H-azepinyl) ]carbonyl]amino-4-
methyl pentanoy I] amino-3-[ 3 -( 1-methyl-I H -indo I yl) ]propiony I] am i no-3 -(2-
pyridyl)proprionic acid 
IRL1620: Suc-[Glu',Ala",I']ET-1 [8-21] 
IRL I 038: ch-Val-Tyr-Phe-2ys-His-Leu-Asp-IIe-IIe-Trp 
PD 145065: Ac-(5H-dibenzyl[ a,d]cycloheptane-I 0, II-dihydro-glycine)-L-Leu-L-Asp-L-lIe-L-
lIe-L-Trp 
PD 142893: Ac-(3 ,3-D-diphenylalanine-L-Leu-L-Asp-L-IIe-L-IIe-L-Trp 
BQ788: N -cis-2,6-dimethylpiperidinocarbonyl-L-y-methylleucyl-D-I-methoxy-
carbonyltryptophanyl-D-norleucin 
Ro-46 -2005: 4 -tert -buty 1-N -[ 6-(2-hydroxy-ethoxy)-5 -(3 -methoxy -phenoxy) -4 -pyrimid iny 1]-
benzenesulphonamide 
B osen tan: 4 -tert -buty 1-N -[ 6-(2-h ydroxy -ethoxy) -5 -(2-methox y -phenoxy)-2,2 ' -bi pyrimid in -4 -Y 1]-
benzenesulfollamide 
SB 209670: (+)-(IS, 2R, 3S)-3-(2-carboxymethoxy-4-methoxyphenyl)-I-(3,4-
methylenedioxyphenyl)-5-(prop-l-yloxy)-indane-2-carboxylic acid 
BMS-182874: 5-( dimethylamino )-N-(3,4,-dimethyl-5-isoxazolyl)-I-naphtalenesulfonamide 
97-139: 27 -O-3-[2-(3-earboxy-acryloyl-amino )-5-hydroxyphenyl]acryloyloxy-myricerone 
sodium salt 
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Arginine vasopressin-induced responses of the human 
isolated coronary artery: effects of non-peptide 
receptor antagonists* 
Summary - Contractions to argmme vasopressin and the effect of non-peptide 
vasopressin receptor antagonists were studied in the human isolated coronary miery. 
The contractile response to A VP was antagonized by both the putative V, receptor 
antagonist, SR 49059, and by the repOlied V,receptor antagonist, OPC-31260 (pA,: 
9.76 and 7.31, respectively). In contrast to its reported high affinity for rat V, 
receptors, OPC-21268 antagonized the response to A VP only in a concentration of 
3 ~M (apparent pKB: 5.6). The antagonist potency order (SR 49059 > OPC-31260 
> OPC-21268) conesponds to the reported affinity order for the cloned human V, 
receptor. Therefore, the affinity of OPC-21268 appears confined to rat, but not 
human V, receptors, which raises the question whether these receptors are species 
homologues 01' separate receptor entities. 
11.1 Introduction 
Vasopressin and oxytocin are related hormones, which are released from the pituitary. 
Although vasopressin and oxytocin only differ in the third and eighth amino acid position, 
their relative potencies m'e remarkably different in functional assays. Vasopressin primarily 
contributes to cardiovascular homoeostasis by inducing vasoconstriction and by stimulating 
renal water absorption, whereas oxytocin acts as an agonist which stimulates milk-ejection 
and parturition (review, see Ref. I). Pigs have a lysine in the eighth position of vasopres-
., Based on: Bax, \v.A., Van der Graaf, P.H., Bos, E., Nisato, D. and Saxena, P.R. (1995) 
Arginine vasopressinMinduced responses of the human isolated coronary artery: Effects of 
non-peptide receptor antagonists (submitted). 
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sin instead of arginine in most other mammals " For that reason human vasopressin is 
often specified as arginine vasopressin (Figure I), 
The effects of A VP are mediated via vasopressin V I and V, receptors, respectively, 
In general, VI receptors stimulate phospholipase C, resulting in the production of inositol 
1,4,5-triphosphate (IP,) and 1,2-diacylglycerol (DAG), whereas V, receptors activate 
adenylyl cyclase, The human VI and V, receptor have both been cloned, The nucleotide 
coding sequence identity of the human VI receptor with the rat liver VI receptor, the 
human oxytocin receptor, the human V, receptor, and the rat V, receptor is 83%, 68%, 
62%, and 65% respectively" 4, 5, The existence of an additional vasopressin receptor 
subtype was postulated in the rat adenohypophysis, This receptor has been desiguated V,, 
01' Vlb as opposed to the VIOl' VI, receptor on liver, smooth muscle, and platelets', The 
recent elucidation of the aminoacid stmcture of a vasopressin receptor from the pituitmy 
appeared to indicate that this receptor did not diverge from the human V I, receptor, but 
evolved from a common ancestor at an earlier stage during the evolution, At the 
nucleotide level, the strongest homology was found between this receptor and the human 
oxytocin receptor. Therefore, the designation as V,receptor appears more appropriate than 
V
1b 
6a, 
c r.::2I- (9- Q ~ ~ 
\ ~ 
8-8-S-8-e-s-NH2 
Figure }, Structure of aI'ginine vasopressin (a), oxytocin (b), and porcine lysine vasopressin (c), 
Amino acids different from the amino acid sequence of arginine vasopressin are highlighted, 
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Antagonists for vasopressin receptors may be beneficial in the treatment of ischemic 
heart disease, hypeliension, and congestive heart failure 6b.6,. Recently, two non-peptide 
vasopressin antagonists were developed with apparent selectivity for V, receptors: 
OPC-21268 ',and SR 49059 8• '. Another non-peptide receptor antagonist, OPC-31260, was 
repOlied selective for V, receptors 10. OPC-21268 produced hypotension in spontaneously 
hypeliensive rats II, and attenuated A VP-induced vasoconstrictor responses in the human 
forearm in vivo 12. OPC-31260 had a diuretic effect in men, which was almost equipotent 
when compared to the effect of furosemide 13. 
Liu and coUeagues 14 showed that OPC-21268 did not antagonize AVP-induced con-
tractions of the human isolated internal mammary artery, whereas both the putative V, 
receptor antagonist, [d(CH,),sarcosine']AVP (SAVP), and the putative V, receptor 
antagonist, OPC-31260, acted as competitive antagonists of this response. In the present 
study, we compared the effect of SR 49059, OPC-21268, and OPC-31260, as antagonists 
against A VP-induced contractions of the human isolated coronary artery. 
11.2 Materials and methods 
Tissue preparation and experimental protocol 
Hearts were obtained from 14 organ donors, who had died of non-cardiac disorders 
(5 cerebrovascular accident, 7 poly trauma, 2 cerebral hypoxia; 9 male, 5 female; age 
10-54 years). The healis were provided by the Rotterdam Heali Valve Bank (Bio Implant 
Services Foundation) after removal of the valves for transplantation purposes. The right 
epicardial coronary artery was placed in a Krebs bicarbonate solution, aerated with 95% 
0, and 5% CO, (composition in mM: NaC1118, KCI4.7, CaCl, 2.5, MgSO, 1.2, KH,PO, 
1.2, NaHCO, 25, and glucose 8.3; pH: 7.4). 4 mm rings segment were suspended in 15 
ml organ baths containing the Krebs bical'bonate solution (37°C). The endothelium was 
left intact as verified by observing relaxation to substance P (l nM) after precontraction 
with prostaglandin F,o (pGF,o' I J.lM). In some ring segments the endothelium was remo-
ved using a cotton swab. Changes in tension were recorded using a Harvard isometric 
transducer. Tissues were stretched to a tension of 20 mN, and were subsequently exposed 
to 100 mM K+. After a washout period of30 minutes, segments were incubated with ve-
hicle (controls) or an antagonist for thirty minutes, before a cumulative concentration-res-
ponse curve was obtained. 
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Analysis of Data 
Curves were analyzed by means of a computerized curve fitting technique" to obtain 
the pO, value (-log [EC,,], moUI). pA, values were calculated according to Alunlakshana 
and Schild ". All data are presented as mean ± s.e.m .. pO, and maximal effect (EMAX) of 
agonist-induced contractions in the absence and presence of an antagonist were compared 
using a paired Student's t-test. A P value less than 0.05 was assumed to denote a signifi-
cant difference. 
Compounds 
Prostaglandin F,. (tris salt), substance P acetate, and [Arg"]-vasopressin (acetate salt) 
(purchased from Sigma Chemical Co., St. Louis, USA), were dissolved in distilled water. 
OPC-21268 (1-{ 1-[ 4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl} -3,4-dihydro-2( I H)-
quinolinone), OPC-31260 ([ 5-dimethylamino-l-{4-(2-methylbenzoylamino )benzoyl} -2,3,4, 
5-tetrahydro-IH-benzazepineJ), and SR 49059 «2S) 1-[(2R 3S)-5-chloro-3-(2-chloro-
phenyl)-I-(3,4-dimethoxybenze ne-sulfonyl)-3-hydroxy-2,3-dihydro-IH-indole-2-carbonyl]-
pY1Tolidine-2-carboxamide) were synthesized by Sanofi Recherche, Montpellier, France, 
and dissolved in dimethylsulphoxide (OMSO) at a concentration of I mM, and subse-
quently diluted in distilled water. 
11.3 Results 
100 ruM K+ caused a mean contractile response of endothelium-intact coronaty artery 
segments of 40 ± 4 mN (n=14). In these preparations, I nM substance P caused 73 ± 7% 
relaxation after precontraction with I J.IM PGF, •. Removal of the endothelium reduced 
relaxation to 10 ± 7% of the response to PGF,. (n=8). 
A VP induced concentration-dependent contractions (pD,: 9.25 ± 0.15; EMAX : 
11.8 ± 1.8% of the response to 100 lnM K\ n=14). Removal of the endothelium did not 
result in a significantly altered response to AVP (pO,: 9.30 ± 0.32; EMAX: 14.8 ± 4.3%; 
n=8). Furthermore, we did not observe relaxation after adding 0.1-1 nM A VP to coronary 
altelY segments (n=3) precontracted with 0.1 J.IM PGF,. (precontraction: 15.4 ± 1.1% of 
the response to 100 lnM K+). By contrast, addition of I nM A VP induced an additional 
contractile response of 6.7 ± 2.9% of the response to 100 nM K+. All segments subse-
quently relaxed completely to I nM substance P (Figure 2). 
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Figure 2, Original tracing of the response of an endotheliumMintact coronary m1ery segment. No 
relaxation was observed after adding 0.1-1 11M A VP to the coronary artery segment precontracted 
with 0.1 J.lM POF, •. The segment subsequently relaxed completely to I nM substance P. The 
mean response (± s.e.m.) of 3 segments is also indicated (., A.; expressed as percentage of the 
reference contractile response to potassium, 100 mM), 
SA 49059 OPC·31260 OPC·21268 
100 00 '0 o~Jf' ~ I 0'· • II; IJ ~! w 76 ~ / • /1 c: 60 0 OJ;! :g 
i!! 26 rll r· v c , j Jl/:; 0 ./:."~ 0 ,. .;f!' a • .·rA 
1 t 10 9 8 7 6 11 10 9 6 7 6 11 10 9 8 7 
·Log (AVP(, molll ·Log (AVP). molli -Log (AVP1, molll 
Figure 3. Contractions of the human isolated coronary artel)' to A VP in the absence (control: (0) 
or presence of the vasopressin receptor antagonists SR 49059, OPC-31260 and OPC-21268 
(n~5-7). Concentrations of receptor antagonists were 3 nM (+), 0,01 I,M (III), 0.03 I'M (0), 0.1 
J.lM (v), 0.3 I'M (v), 1 J.lM (0) or 3 I'M (0). 
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In endothelium-intact coronary artery segments, SR 49059 (3-30 nM) and 
OPC-31260 (0.3-3 ~M) induced a concentration-dependent parallel rightward shift of the 
AVP concentration response curve, with associated pA, values of 9.76 ± 0.16 and 
7.31 ± 0.18, respectively (n~7, Fignre 3). Schild analysis revealed that the slopes for 
SR 49059 and OPC-31260 were 1.08 ± 0.10 and 1.07 ± 0.07, respectively (not significant-
ly different from unity), indicating that these compounds antagonized the response to A VP 
in a competitive manner. OPC-21268 caused a significant rightward shift only in the 
highest concentration used (3 ~M). An apparent pKn of 5.6 ± 0.3 (n~6) was calculated, 
assuming a Schild-plot slope of unity. 
11.4 Discussion 
The most significant observation of the present study is the discrepancy between the 
two putative VI receptor antagonists SR 49059 and OPC-21268; SR 49059 was a potent 
receptor antagonist (pA,: 9.76), whereas OPC-21268 had no effect in concentrations up 
to I ~M. Even the putative V, receptor antagonist OPC-31260 lVas more potent than 
OPC-21268. The data regarding OPC-21268 appear difficult to interpret when considering 
a pKI value of 7 in rat liver membranes (V I receptor model) '. However, the present data 
are in agreement with the reported affinity for the recently cloned human V I receptor 
(Table I). Therefore, affinity for rat V I receptors is not predicative of functional antagonist 
potency at human VI receptors. The effect of OPC-31260 may be explained by its 
additional affinity for the human VI receptor (Table I). The observed pA, value of 7.31 
would mle out involvement of the putative V, receptor, for which OPC-31260 appeared 
to have supra-micromolar affinity ". 
OPC-21268 was previously shown to attenuate AVP-induced vasoconstriction of the 
human forearm I'. This effect may be explained by (i) a high plasma concentration of the 
antagonist (> I ~M), (ii) conversion into an unknown, more active metabolite, or (iii) by 
an effect at other receptors than the receptor in the human coronalY artery. 
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Table J. Comparison of the affinity of vasopressin antagonists in receptor binding assays of rat 
and human V I receptors, compared with the potency as receptor antagonist in the human coronary 
artery. 
Compound 
SR 49059 
OPC-21268 
OPC-31260 
pK, value (-log [K, (moUI)]) binding assay 
Rat V I receptor Human VI receptor 
9.10' 8.49', 8.89' 
7.21', 7.24' 4.57', 4.25' 
6.54', 6.67' 6.60', 6.47' 
pA2 value in functional assay 
Human coronary artery 
9.76 
5.6 
7.31 
I, Data from Ref. 9 (liver membranes); 2, Data from Ref. 3 (cloned receptors expressed in cell 
lines); 3, Data from Ref. 4 (cloned receptors expressed in celJ lines). 
It was observed that the maximal effect of AVP reached only 12% of the contractile 
response to 100 ruM K+. This apperu's lower than in somewhat smaller blood vessels such 
as the human internal marmnary artelY (approx. 50% of the maximum response to 
noradrenaline) ", 01' the human cerebral artelY (approx. 100% of the response to 100 ruM 
K+) ". On the other hand, we are not aware of endogenous hormones that contract the 
human isolated coronary a11e1Y with similar 01' higher potency than A VP. 
It was also investigated whether the response to A VP was modulated by the presence 
of endothelium. Although removal of the endothelium resulted in a slightly, but 
non-significantly enhanced contractile response to A VP, we observed no endothelium-
dependent relaxation to A VP in endothelium-intact vessel segnlents precontracted with 
PGF,. (Figure 2). The present data therefore provide no evidence for the involvement of 
endothelial vasopressin receptors mediating relaxation, as was also concluded in recent 
studies in the human cerebral and omental a11ery ". lB. 
In summary, A VP induces contraction of the human isolated coronary ru1ery via an 
OPC-2126B-insensitive receptor. The functional characteristics of this receptor are 
congruent with the binding characteristics of the recently cloned human V, receptor, 
which, in contrast to the rat cloned V, receptor, has low affinity for OPC-2126B. Thus, 
it may be concluded that rat and human V, receptors have a distinct pharmacological 
profile, which raises the question whether these receptors are species homologues or 
separate receptor entities. 
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Summary, general discussion, and 
implications for future research 
12.1 Summary of the thesis 
Chapter 1 provided an overview of clinical aspects of ischemic heart disease. 
Ischemic hemi diseases may clinically be subdivided in stable angina, unstable angina, 
acute myocardial infarction, and variant angina. These disorders are part of a spectIum of 
related disorders, in which the supply of oxygen does not meet the demand. This usually 
results in chest pain (angina), and a number of additional physical, chemical, and 
electrophysiological symptoms. The pathophysiology involves passive luminal obstruction 
of the blood vessel, via thrombus plugging or plaque formation, and active vasoconstric-
tion induced by disbalance of vasomotor tone. The contribution of active vasoconstrictor 
obstmction may vary from velY little in case of fixed obstruction in stable angina, up to 
almost hundred percent in case of variant angina pectoris. Angina can sometimes be 
caused by treatment with vasoconstrictor dmgs, like the anti-migraine drugs, ergotamine 
and sumatriptan. Treatment of ischemic heart disease is aimed at reducing myocardial 
ischemia and related anginal pain, and at early reperfusion and prevention of 
haemodynamic complications in myocardial infarction. Large scale clinical trials are being 
undeliaken to establish the best choice of treatment for different groups of patients. 
Chapter 2 described the physiology and pathophysiology of vasomotor tone. 
Disturbed vasomotor tone is believed to playa significant role in the above mentioned 
clinical syndromes of ischemic heart disease. Vasomotor tone is the outcome of 
contraction and relaxation, and is affected by processes within the vascular smooth muscle 
and the endothelium. Smooth muscle contraction and relaxation result primarily from the 
interaction of actin and myosin protein chains. These are regulated via a large number of 
receptors,' enzymes, ion-pumps, and ion-exchangers, many of which influence the 
concentration of cytosolic calcium, or the sensitivity of the contractile apparatus. The 
endothelium is now known to be an impOliant determinant of vasomotor tone, via the 
release of relaxant (endothelium-derived relaxing factor, EDRF) 01' contractile stimuli 
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(endothelium-derived contracting factor, EDCF), which can both have effects on the 
underlying smooth muscle. A disturbance of the equilibrium between relaxation and con-
traction can lead to decreased flow, and subsequent decreased supply of oxygen to the 
myocardium. Disturbance of equilibrium is pat1icularly likely in atherosclerotic blood 
vessels, in which the dilatory component, mediated by the endothelium, is decreased. Also 
endothelial injury after balloon angioplasty, and senun lipoproteins and cholesterol may 
be involved in dismption of the contraction-dilatation equilibrium. 
Chapter 3 provided an overview of 5-hydroxytryptamine, its receptor subtypes and 
their functional and therapeutical relevance in the cardiovascular system. The development 
and rationale of the early 'M' and 'D' receptor classification up to the present IUPHAR 
classification of receptors for 5-HT was described. Furthermore, it was pointed out that, 
although exogenous 5-HT may have profound effects on the cardiovasculat· system, 
antagonism of endogenous 5-HT has thus far not been very successful in the treatment of 
cardiovascular diseases. The use of 5-HT receptor agonists and antagonists in cardiovas-
culm' diseases has remained limited to the treatment of migraine. The disappointing results 
obtained with 5-HT receptor antagonists in diseases that involve coronary vasospasm may 
point at overestimation of the role of 5-HT in the disease process, or at the use of a 
receptor antagonist aimed (in part) at the wrong receptor. 
In Chapter 4, the receptors mediating the contractile effect of 5-HT on the human 
isolated saphenous vein were investigated, using a number of 5-HT receptor agonists and 
antagonists. The rank order of agonist potency was 5-CT '" 5-HT > methysergide '" 
sumatriptan '" a-methyl-5-HT '" RU 24969", DOl > 2-methyl-5-HT > 8-0H-DPAT. The 
5-HT, receptor antagonist, ketanserin, caused a rightwm'd shift of the upper part of the 
concentration-response curve of 5-HT and 5-CT, while causing a parallel rightward shift 
of the concentration-response curves of the selective 5-HT, receptor agonists 
a-methyl-5-HT and Dar. FUl1hermore, contractions to 5-HT were antagonized by 
methysergide, methiothepin, ICS 205-930 (tl'Opisetl'On) and flesinoxan. The responses to 
the selective 5-HT, receptor agonist sumatriptan were antagonized by methiothepin, meter-
goline, rauwolscine, and cyanopindolol, but not by ketanserin. A high correlation was 
observed between the functional pD, and pKB values of 5-HT,-like receptor agonists, and 
antagonists vs. sumatriptan, compared to their rep0l1ed binding affinities for the 5-HTlD 
receptor in radioligand binding assays of human or calf brain membranes. It is therefore 
concluded that contractions of the human isolated saphenous vein, induced by 5-HT, are 
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mediated by 5-HT, receptors as well as by a 5-HT,-like receptor resembling the 5-HTID 
subtype found in brain membranes. 
In 3 patients, undergoing hemi transplantation, saphenous vein, which had previously 
functioned as a coronm)' bypass graft for 6-11 yem's, was dissected out fi'om the heat1. 
Light microscopy revealed profound intimal thickening in the grafted veins, and contrac-
tions to potassium, 5-HTand sumatriptan were significantly smaller (E"AX' mN). However, 
both E,tAX, calculated as percentage of potassium-induced contractions, and pO, values for 
5-HT and sumatriptan were similar to those found in the veins obtained directly fi'om the 
lower leg. 
In Chapter 5 we investigated contractile responses of the human isolated coronm)' 
at1ery to 5-HT, human washed platelets, sumatriptan, and ergotamine. 5-HT and platelets 
caused contractile responses which were attenuated by ketanserin (I J.lM). In the presence 
ofketanserin (I J.lM), the adrenoceptor antagonists with accessory 5-HT, receptor affinity, 
rauwolscine and cyanopindolol, caused concentration-dependent additional antagonism 
against leftover contractions induced by low ($ I J.lM) concentrations of 5-HT. 
Sumatriptan-induced contractions were antagonized to a similar extent by both rauwolscine 
and cyanopindolol and also by metergoline, but not by ketanserin. The order of potency 
of antagonists against sumatriptan resembled the order rep01ied for the human saphenous 
vein 5-HTID-like receptor. Against platelet-induced contractile responses we observed only 
a non-significant additional antagonism by cyanopindolol or rauwolscine. It was concluded 
that, although 5-HT, receptors predominantly mediate 5-HT-induced contractions, the 
5-HT,-like receptor appears to playa role in coronary vasospasm caused by low concen-
trations of 5-HT. 
In addition, we compared the contractile effect of sumatriptan and ergotamine. Ergo-
tamine contracted the human isolated coronm)' artel), with approx. hundred-fold higher 
potency than sumatriptan. Moreover, the E,IAX of ergotamine was twice that of suma-
triptan. 
In Chapter 6 the contractile effect of human washed platelets on the human isolated 
coronm)' miery was investigated. Platelets (10'-3.1010/1) elicited concentration-dependent 
contractile responses of the coronary miel), segments. The contractile response tended to 
be decreased in vessel segments with histological signs of early atherosclerosis. 
Contraction was significantly attenuated after· pretreatment of the vessel segments with 
ketanserin, or the TxA, receptor antagonist SQ30741. Platelets obtained from the same 
platelet-donors after taking aspirin (40 mglday for 7-13 days) caused significantly lower 
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contractile responses, associated with an almost selective inhibition of the synthesis of 
thromboxane measured in the organ bath solution. The amount of 5-HT secreted in the 
organ bath remained unaltered, which explains why ketanserin significantly attenuated the 
residual contractile responses caused by platelets obtained from aspirin-treated subjects, 
whereas SQ30741 caused minor, non-significant additional attenuation. The results of the 
study therefore suggested that additional antagonism of the contractile 5-HT receptors in 
the coronary artery may increase the efficacy of low dose aspirin ill vivo. 
In the experiments described in Chapter 7, we investigated endothelin (ET) receptors 
in the human coronary attery, and in ventricular and atrial muscle, using quantitative 
receptor autoradiography. Displacement of [,"Ilsarafotoxin S6b (30 pM)- and ["'11ET-I 
(30 pM)-labelled binding sites was studied using ET-I, the ETA receptor selective ligand 
BQ-123, atld the ETD receptor selective ligand [Ala'·l.II.1S1ET-I. Specific binding was more 
dense in atrium and coronary attery than in ventricular muscle. In the coronary artery, 
binding was especially dense in the media. ET-! displaced ['''11ET-I and [12sIlsarafotoxin 
S6b monophasically in atrium, ventricle and coronary artery. [Ala'·l.II.1S1ET-! and BQ-123 
displaced ['''11ET-l and ['''Ilsarafotoxin S6b-labelled sites biphasically in the ventricle and 
in the atrium. In the human coronary atiery, [Ala'·3•II •1S1ET-1 and BQ-123 displaced 
['''I1ET-I-labelled sites monophasically (ET-I > BQ-123 > [Ala' ·3•II •1S1ET-I). By contrast, 
[Ala'·3•II•1S1ET-! and BQ-123 displaced ['''Ilsarafotoxin S6b-labelled coronary artery sites 
biphasically. The low-affinity site for [Ala
'
·
3
•
II
.
1S1ET-1 and BQ-123 conesponded to the 
binding site observed using ['''IJET-!. These data indicated that both ['''11ET-1 and 
["'Ilsat'afotoxin S6b-labelled ETA and ET D binding sites in human ventriculat' and atrial 
muscle. In the human coronary at1ety, both radioligands labelled ETA binding sites, but 
['''Ilsarafotoxin S6b also labelled a non-ETA> non-ETD binding site with relatively high 
affinity for both BQ-123 and [Ala'·l.II.1S1ET-!. 
In view of the data obtained in Chapter 7, we set out to obtainfimctiollal evidence 
of conesponding receptor heterogeneity. In Chapter 8, we therefore investigated the effect 
of the ETA receptor antagonist BQ-123 on contraction of the human isolated saphenous 
vein induced by ET-I 01' sarafotoxin S6b. Contraction to ET-l was not affected by 
BQ-123 (0.1-1 11M). By contrast, BQ-123 (0.1 - 111M) biphasically attenuated contrac-
tions to sarafotoxin S6b. These data indicated that (i.) ET-I induced contractions of the 
human saphenous vein via a BQ-123-insensitive receptor and that (Ii.) contractions to 
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sarafotoxin 86b were mediated in part via a receptor, different from the receptor mediating 
contraction to ET-l. 
In Chapter 9, we characterized endothelin receptors, that mediate contraction of the 
human isolated coronary artelY. The order of agonist potency (PD,) in endothelium-intact 
coronary artery ring segments was: ET-I '" sarafotoxin 86b > big-ET-I '" ET-3. 
[Ala'·3·"·l5jET_1 (an ETB receptor agonist) caused significant contraction at I jlM only, 
whereas 0.3 jlM big-ET-3 had no effect. Removal of the endothelium in ring segments did 
not affect the contractile response to ET-I or to sarafotoxin 86b. After a full concentration 
response curve with ET-I or sarafotoxin 86b, further contractions ofthe endotheliumintact 
coronary artery segments could only be achieved by applying ET -I in segnlents exposed 
to sarafotoxin 86b, and not the reverse. 0.1 jlM BQ-123 antagonized contractions of 
endothelium-intact ring segments induced by sarafotoxin 86b (PKB: 7.86). Only 10 jlM 
BQ-123 antagonized contractions induced by ET-I (PKB: 5.75). FRI39317 was also more 
potent against sarafotoxin 86b than against ET-l. [Ala'·3·1I·l5jET_1 (I jlM) had no effect 
on the contractile response to ET-I or to sarafotoxin 86b. Compared to ring preparations 
with intact endothelium, the pD, of ET-I increased in strip preparations with intact 
endothelium, and I jlM BQ-123 caused a rightward shift of the ET-l-induced concentra-
tion response curve in strip preparations (PKB: 6.62). Contractile responses to big-ET-I of 
endothelium-intact coronary artery segments were attenuated in the presence of 100 jlM 
phosphoramidon, indicating conversion of big-ET-I to ET-I within the coronaty artery 
segment. It was concluded that ET-I and sarafotoxin 86b contract the human isolated 
coronary artery via different receptors, which can probably be best characterized as 
subtypes of the ETA receptor. Furthennore, it was demonstrated that the type of 
preparation (ring or strip) may affect the potency ofET-1 as an agonist, and ofBQ-123 
as an antagonist. 
In Chapter 10, we reviewed typical and atypical endothelin receptors, and compared 
experimental evidence for endothelin receptor subtypes to the present official IUPHAR 
classification for endothelin receptors. It was shown that the present criteria are insuffi-
cient to characterize all endothelin receptors. Emphasis was put on the need for rigorous 
classification criteria, simultaneously applying operational, transductional, and sltuctural 
criteria. Although experimental data showed that the present classification may be insuffi-
cient, it was also made clear that there is not yet sufficient evidence to conclusively 
replace the present classification with a novel endothelin receptor scheme. 
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In Chapter 11 we studied the effect of nonpeptide receptor antagonists to arginine 
vasopressin-induced contractions of the human isolated coronary arte,y. The contractile 
response to AVP was antagonized by both the putative V, receptor antagonist, SR 49059, 
and by the reported V, receptor antagonist, OPC-31260 (PKB: 9.76 and 7.31, respectively). 
In contrast to its rep0l1ed high affinity for rat V, receptors, OPC-21268 antagonized the 
response to AVP only in a concentration of 3 "M (apparent pA,: 5.6). The antagonist 
potency order (SR 49059 > OPC-31260 > OPC-21268) conesponded to the reported 
affinity order for the cloned human V, receptor. Therefore, the affinity of OPC-21268 
appeared confined to rat, but not human V, receptors, which raised the question whether 
these receptors are species homologues or separate receptor entities. 
12.2 General discussion 
The natllre of 5-HT receptors mediating contraction of human blood vessels 
Most human blood vessels contract to 5-HT mediated via a mixed receptor population 
of 5-HT,,- and 5-HT,-like receptors. The nature of the latter receptor has remained the 
subject of considerable debate. Characterization of a functional receptor is facilitated by 
elucidation of the molecular structure of the receptor. This enables identification of regions 
where the receptor is expressed, and is essential for a rational design of agonists and 
antagonists, aimed at that particular receptor. The exact nature of the vascular, contractile 
5-HT, receptor (also called: 5-HT,x, 5-HT,-like, or 5-HTm-like) has remained unresolved, 
and evidence obtained even before the cloning era, suggests that this receptor is 
heterogeneous in nature (Chapter 3, Table 4). Recently, it was suggested that 5-HTm' 
receptors may be present in the coronary artery ',' and in the pial m1eriole 3 of man, 
However, canine coronary at1eries were found to contract via 5-HTlDa receptors 4, 
Conclusions on the presence of the 5-HTm' receptor in human coronaty arteries were 
based essentially on the single fact that ketanserin did not attenuate sumatriptan-induced 
contractile responses, which had been known for some years '.7. Unfortunately, alternative 
agonists or antagonists with more proriounced selectivity for any of these receptors, have 
not been made available. However, it should not be ruled out that 'the 5-HT,-like receptor' 
consists of a mix of several 5-HT, receptor subtypes, which may mediate contraction as 
well as relaxation. Indeed, a receptor previously classified as a 5-HT,-like receptor was 
shown to mediate relaxation via an endothelium-independent pathway', This receptor was 
classified as orphan 5-HT receptor, because of its positive linkage to adenylyl cyclase', 
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in contrast to the negative linkage of 5-HTI receptor subtypes to adenylyl cyclase 10. It was 
suggested that this receptor may be similar to the 5-HT, receptor subtype, which has a 
somewhat similar ligand affinity pattern, and which is also coupled positively to adenylyl 
cyclase 10. 10,. lOb. mRNA for the 5-HT, receptor gene was detected in human coronary mte-
ries 10'. For fUl1her characterization of the 5-HTI-like receptor, molecular biology tech-
niques should be utilized, indicating the presence of mRNA, pointing at certain 5-HT 
receptor subtypes being expressed. Functional studies, with a specifically designed spec-
trum of agonists and antagonists, should subsequently establish the functional relevance 
of this receptor. 
Development of anti-migraine drugs devoid of eoronOlY side effiels 
All presently available anti-migraine drugs have the potential of inducing coronary 
vasoconstriction II. Even modern anti-migraine drugs, like the selective 5-HTID-like recep-
tor agonist, sumatriptan, may induce cardiac ischemia in some patients 12. Attempts to 
develop drugs, devoid of this side-effect, are hampered by the fact that the precise mode 
of action of sumatriptan is not yet known in detail (see §3.4). However, two different 
approaches of anti-migraine drug development may be suggested to yield compounds, 
devoid of coronary side effects. 
First, it may be speculated that the presynaptic 5-HT receptor, mediating inhibition 
ofthe release ofinflallllnatory vasodilator peptides 13, is slightly different from the receptor 
mediating vasoconstriction in cranial blood vessels. Assuming that stimulation of 
presynaptic 5-HT receptors, and the resulting reduction of inflaJ1'Il11atory peptide release, 
is suflicient to terminate the migraine-attack, compounds may be developed with affinity 
for the presynaptic receptor, but not for the 5-HT receptor mediating vasoconstriction. 
Indeed, both human and bovine cerebral aJteries were shown to express rnRNA for the 
5-HTlDo receptor', whereas the expression of 5-HTlIJa receptor mRNA was shown in the 
human trigeminal ganglion I'. Thus, development of a 5-HTlDa receptor selective agonist 
may specifically treat the neurogenic inflammatory component of migraine, and may be 
devoid of effect on the putative coronary vasoconstrictor 5-HTIDO receptor '. However, the 
general validity of this concept needs confirmation: canine coronary arteries were shown 
to express a 5-HTIIJ« receptor rnRNA " whereas the rat trigeminal ganglion expressed 
mRNA for 5-HTm receptors, which is the rat homologue of the 5-HTlDo receptor I'. The 
latter observations demonstrated the existence of species heterogeneity of migraine related 
5-HT receptors in blood vessels and in the trigeminal ganglion, and emphasized the need 
for human models in anti-migraine drug development. 
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Secondly, it may be speculated that agonists for 5-HT receptors may behave as par-
tial agonist in some tissues, but as a full agonist in other tissues, depending on the effi-
ciency of the receptor-effect coupling and on the presence of a receptor reserve '6. A 5-HT 
receptor agonist could then theoretically act as a full agonist in the trigeminal nerve 
presynaptic 5-HT receptors -thereby possibly alleviating migraine. This same compound 
could be only a partial agonist when causing vasoconstriction in blood vessels. However, 
little experimental evidence is available yet to supp0l1 this hypothesis. 
Lastly, it may be emphasized that very little is known about the occun'ence of angina 
pectoris related to anti-migraine dlUgs in patients who usually do not belong to traditional 
groups-at-risk for coronary artery disease. Also the recently described large variability of 
the relative contribution to contraction of 5-HTID-like and 5-HT, receptors, has remained 
unexplained '. The potential mechanisms involved in coronary side effects of anti-migraine 
dlUgs are currently under investigation, and may provide information necessary for the 
development of safer anti-migraine dlUgs. 
Are 5-HT receptor antagonists potentially effective in ischemic heart disease? 
5-HT receptor antagonists have not proven very successful in the prevention of 
clinical symptoms in which 5-HT-induced coronary vasoconstriction was speculated to 
playa role. In particular, the 5-HT, receptor antagonist, ketanserin, was ineffective in 
preventing Prinzmetal's angina 17 or restenosis after PTCA IS. However, it must be kept in 
mind that the patient population in the first study was rather small for definitive 
conclusions (five patients with Prinzmetal's angina) and that ketanserin was effective in 
prevention of early restenosis or PTCA-related vasoconstriction 19-21. Indeed, mediators 
other than 5-HT appear to be responsible for chronic restenosis. Furthermore, it was 
pointed out in chapter 5 that low concentrations of 5-HT may exert their effects also via 
5-HTID-like receptors, for which ketanserin has negligible affinity. In fact, Peroutka and 
Snyder showed as early as 1979" that 5-HT in concentrations up to 0.1 11M hardly 
displaced labelling from 5-HT, binding sites, while 0.1 !IM 5-HT completely replaced 
labelling from 5-HT, binding sites. In addition, Kaumann and colleagues (1994)' 
emphasized that, in some patients, 5-HT, receptors mediating contraction may predominate 
over 5-HT, receptors. Also in atherosclerosis and restenosis, in which 5-HT may act as 
a grOwih factor, the role of 5-HT, receptor subtypes should not yet be lUled out ". Lastly, 
5-HT receptor antagonists may not only reduce the effect of 5-HT, but may also interfere 
with the amplifying interaction between 5-HT and other vasoconstrictor agonists, such as 
thromboxanes and perhaps endothelins (see Ref. 24, 25 and chapter 6). Interestingly, this 
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amplifying interaction appeared specifically linked to 5-HT, receptors 24.26. It is concluded 
that only the development of a mixed 5-HT" 5-HT, receptor antagonist, and its testing io 
clinical trials in humans, will provide a definitive answer to the question of the signi-
ficance of the role of 5-HT in coronary artery disease. 
Clinical prospects of endotilelin receptor antagonists and converting enzyme inhibitors 
Endothelin inhibitor dlUgs are on the verge of clioical trials and application, which 
is extremely early when considering that the peptide was discovered only seven years ago. 
Despite this, the potential areas for clinical application are still the subject of considerable 
debate. This paragraph will discuss these areas, and the probability of success for 
endothelin inhibitor dlUgs. 
Two different approaches are currently under investigation to attenuate the effect of 
endothelins. First, one may inhibit the convertiog enzyme, which converts the precursor 
big-ET-I to ET-I by cleavage between Trp" and Val". Recent advances have led to the 
molecular characterization of ECE-I, a membrane-bound neutral metalloprotease, which 
is expressed in endothelial cells throughout the body 27. ". This development will encourage 
the synthesis of more potent, and possibly more selective converting enzyme inhibitors 
than the presently available phosphoramidon. Secondly, one may try to develop antagonists 
for endothelin receptors that mediate the pathological effects. Indeed, the recent 
development of several non-peptide, orally active endothelin receptor antagonists, initiated 
by the rep011 on Ro-462005 29, has provided a list of interesting compounds, of which 
SB209670 30, BMS 182874 31, and bosentan 32 are the most promisiog examples revealed 
thus far. 
I. Hypertension. Although hype11ension was among the first pathological states, in 
which ET-I was believed to playa potential role ", it was recently observed that mice 
partially deficient for endothelin, were slightly hype11ensive, whereas hypotensiveness had 
been anticipated ". On the other hand, it has been shown that endothelin receptor antago-
nists may be effective in animal models of hypertension. Indeed, a sustained, dose-depen-
dent reduction in blood pressure (-40 mm Hg) could be obtained in conscious sponta-
neously hypertensive and deoxycorticosterone acetate (DOCA)-salt rats following enteric 
administmtion of SB209670 or BMS 182874, and io conscious mts with chronic heru1 
failure following administmtion of bosentan 36 (overview, see Ref. 35). Bosentan was 
shown to exe11 additive effects when co-administered with the angiotensin-converting 
enzyme inhibitor cilazepril 36. 
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2, Plilmonmy hypertension, In patients with pulmonaty hypertension, a significantly 
increased concentration of plasm a innnunoreactive ET-l has been obsel'Yed, Moreover, the 
expressioll of ET-l mRNA was augmented, which would suggest that local production of 
ET-l plays a role in the characteristic vascular dysfunction and abnormal smooth muscle 
cell proliferation associated with puhnonaty hypertension ", Recently, Goerre and collea-
gues observed increased plasma ET-l levels in mountaineers at high altitude, possibly 
associated with the degree of hypoxia-induced acute pulmonary hypertension "', 
3, Myocardial ischemia and infarction, Levels of endothelin may be increased in 
patients after acute myocardial infarction 38 or during angina in patients in whom acetyl-
choline 01' ergonovine had been shown to provoke coronaty vasospasm ", ET-l is a potent 
and efficacious constrictor of humatl coronary arteries, and some rep0l1s suggest that 
threshold concentrations of ET-l could potentiate the contractile response to 5-HT ", 
although this mechanism is still uncertain for the human coronary artery 40, ET-l immuno-
reactivity was recently shown to be significantly higher in coronaty artery atherosclerotic 
specimens obtained from patients with unstable angina, than in specimens from patients 
with stable angina ", Moreover, it was obsel'Yed that plasma endothelin concentrations, 
measured after myocat'dial infarction, are strongly related to clinical outcome 42 and I-year 
sUl'Yival (p<O,OOOI) ", Clinical evaluation of heart failure and atrial natriuretic factor 
(ANF) level, both considered predictors of mortality after myocat'dial infarction, provided 
no additional prognostic information after endothelin had been introduced into the 
analysis ", 
4, Restenosis and atherosclerosis, Endothelins have been implicated in restenosis and 
atherosclerosis, Indeed, ET-I may induce smooth muscle mitogenesis in vitro, which was 
attenuated by the ETA receptor atltagonist BQ-123 ", and ET-l was shown to release a 
diversity of other growth factors like PDGF, and transforming growth factor-ll (see Ref. 
45), Increased circulating endothelin concentrations, and augnlented tissue endothelin 
levels were obsel'Yed in patients with advanced atherosclerosis ", Levels ofET-1 were also 
elevated ill patients after undergoing PTCA 41, 48, and the novel nonpeptide endothelin 
receptor antagonist SB209670 was recently shown to reduce neointim. formation by 50% 
in a rat model of carotid artery balloon angioplasty ", 
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5. Cerebral vasospasm/allowing subarachnoid haemorrhage. Subaraclmoid haemor-
rhage (SAH) is followed by cerebral vasospasm in many patients. Plasma and cerobro-
spinal fluid (CSF) endothelin levels were elevated in patients with SAH ", and plasma 
levels of endothelin coincided with onset of vasospasm ". Interestingly, the administration 
of the ETA receptor antagonist BQ-123 prevented development of vasospasm in a SAH 
model in dogs". Bosentan and SB209670 were repOlied to exert similar protective 
effects 35. 
6. Renal disease. Endothelins may playa role in ischemia-induced acute renal failure. 
Indeed, BQ-123 protected the rat kidney against ischemia-induced acute renal failure and 
tubular cell injury", and R0462005 reduced renal vasoconstriction following reper-
fusion ". SB209670 attenuated the ischemia-induced reduction in glomerular filtration rate, 
and reversed the increases in fractional sodium excretion in both rats 54 and dogs 55. 
BQ-123 and SB209670 were also shown to be effective in preventing acute reduction in 
renal blood flow and glomerular filtration rate after intravenous administration of cyclo-
sporine A 56. ". The latter may be important because of the nephrotoxic effects of cyclo-
sporin A, in which endothelins are believed to play an impOliant role 58. ". 
7. Olher largels. Additional therapeutic targets for endothelin inhibitor drugs have 
been suggested. There is some indication for involvement of endothelins in bone re-
modelling, benign prostatic hypertrophy, and hypertension associated with hemangioendo-
thelioma 35,60,61, 
Despite these often indirect signs of involvement of endothelins in disease, it is 
obvious that only clinical trials in humans will provide definitive answers with respect to 
the therapeutic potential of en dot he lin inhibitors. Recently, Vanhoutte appropriately argued 
that disease-related increased endothelin levels could merely represent 'a last ClY for help 
of the dying cell mistreated by disease (or the investigator?), 62. Whether increased 
endothelin concentrations reflect an active role in pathophysiology, still remains to be 
established. It may also be recalled that, in rats, angiotensin-conver1ing-enzyme (ACE) 
inhibitors were extremely promising in the prevention of intimal hyperproliferation after 
balloon angioplasty". In man, however, ACE-inhibitors were not successful in the 
prevention of restenosis after percutaneous transluminal angioplasty (PTCA) 64. 
Furthermore it can not be emphasized enough that many questions still exist about the 
exact nature of the receptors involved in endothelin-induced effects (Chapter 10). 
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Knowledge of these receptors is essential for the rational development of receptor antago-
nists, and could prevent disappointing clinical results with receptor antagonists, inaccura-
tely questioning the pathophysiological role of endothelins. The novel, orally active, potent 
endothelin receptor inhibitors, and the ongoing development of EeE inhibitors are essen-
tial in providing an indication about the therapeutic potential of endothelin inhibitors in 
relevant clinical trials in man. In addition, the increasing knowledge about the role of 
endothelins may provide a better understanding about other diseases: Hirschsprung's 
disease is characterized by the congenital absence of ganglion cells in myenteric and 
submucosal plexus of the distal gastrointestinal tract. Recently, it was shown that this 
disease is closely associated with a missense mutation of the ET B receptor gene, which 
may provide novel insight in mechanisms underlying this disorder "'. 
12.3 Limitations of the applied methods 
Apart from the limitations to any in vitro model, the studies described in previous 
chapters highlighted two specific limitations of organ bath studies applying human blood 
vessels. First, the use of ring segments suspended on stainless steel tissue hooks, implies 
that drugs added to the organ bath, stimulate both intra-luminal (endothelial) and 
extraluminal (smooth muscle) cells. When receptors for the agonist under investigation are 
present on both endothelial and smooth muscle cells, it can be inferred that pathology-
related alteration of the response mediated by receptors on the endothelium, may remain 
urmoticed when studied together with the more pronounced, but unaltered response 
mediated by receptors on the smooth muscle. For instance, 5-HT may induce relaxation, 
when administered in undiseased human coronary atteries in vivo. In patients with 
coronary atiery disease, this response is reversed to contraction, probably because of loss 
of5-HT receptor-mediated responses within the endothelium ". In human coronary arteries 
in vitro, it is virtually impossible to demonstrate endothelium-dependent relaxation 
mediated by 5-HT 6. 66. Only contractile responses can be recorded, in healthy as well as 
in diseased coronary atieries. This may point at the possibility that, in the organ bath, 
smooth muscle-mediated responses are by far more important than those mediated by the 
endothelium. Therefore, altered endothelial function, as could occur in coronary attery 
disease, may not be revealed in the present set-up. 
222 
Chapter 12 
Secondly, it may be argued that a time span of up to 24 hour after cardiectomy, 
before the tissue is investigated, is too long to be able to study coronary artery reactivity. 
However, it should be recalled that the hearts, also used for homograft cardiac valve 
transplantation, are removed from brain-dead heart beating organ donors and immediately 
stored in a sterile, organ protecting solution, which even allows us to study mechanisms 
of myocardial contractility after 24 hours ". Also endothelial fimction (quantified as 
relaxation to I nM substance P) is maintained comparable to that seen in coronary arteries 
obtained from patients undergoing cardiac transplantation for reasons of idiopathic 
cardiomyopathy, and investigated immediately after explantation 68.69. Thus, it appears 
reasonable to assume that the tissue, used in our experiments, is at least as useful as 
coronary arteries studied by groups, exclusively investigating coronary atleries obtained 
from heatl tratlsplantation programs 2. 24. 70. Interestingly, coronary arteries in our laboratory 
do not commonly exhibit the spontaneous phasic contractions, as has been described to 
hamper pharmacological analysis by many investigators. Spontaneous oscillations tend to 
occur more frequently in hearts obtained fi·om diseased (transplantation) or older 
patients 71. ". Recently, it was suggested that tonic contractile responses can be studied 
accurately only when the calcium antagonist nifedipine (0.1 J.lM) is present to block 
oscillations 70. In our studies it is not necessary to add such potential interference with the 
mechanisms under investigation, since spontaneous oscillations occur in only a very small 
proportion of the experiments. 
12.4 Implications for future research 
Receptor characterization 
Receptor characterization is based on operational, transductional, and stmctural 
criteria 10.73. Studies assessing the receptors mediating an effect in human blood vessels 
should ideally consist of all three components. More specifically, attempts must be made 
to perfOlm both organ bath and receptor binding experiments. Confirmation may be 
obtained by studying involvement of certain second messenger mechanisms. In addition 
to that, attempts must be made to reveal receptor mRNA encoding certain receptors, which 
may supply reciprocal information for further experiments. When the ligand affinity 
pattern of this receptor is known, this may be used to choose conclusive ligands when 
designing further operational experiments. Molecular biology, and radioligand binding 
experiments should always be accompanied by functional organ bath studies, since isolated 
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information on the expression of a receptor mRNA and on the presence of certain binding 
sites, provides no information on their involvement in a pat1icular functional response. It 
should also be recalled that radioligand binding assays, second messenger assays, and 
molecular biology techniques usually require only little tissue, which may be an important 
advantage when considering the use of human tissues. In summary, now that drugs can 
be designed on a rational basis, attempts should be made to supply a full characterization 
of the receptor mediating a certain effect. 
Interaction of different receptor-mediated effocts 
Agonists at different receptors may be involved in an amplifying interaction, which 
exceeds the additive effects of these compounds. Little is understood about the mechanism 
involved. Interference with interaction may be just as efficient as counteraction of the 
individual effects, and furOler studies may be aimed at elucidation of this phenomenon. 
Development of more aCCl/rate models 
Organ bath in vitro techniques as used in the present studies, provide a robust method 
which allows for investigation of multiple parallel coronary miery segments. However, as 
mentioned above, the present method does not allow for detailed analysis of some effects 
mediated via the endothelium (e.g. effects induced by 5-HT and acetylcholine). A perfused 
isolated coronmy artery model may provide a method in which the luminal and extra-
luminal side may be stimulated separately, and in which the effect of atherosclerotic 
changes of the coronmy miery appear more likely to result in altered responses to certain 
phalmacological stimuli, as has also been observed in the in vivo situation. In addition to 
that, such a model would allow for in vitro analysis of the acute effects induced by 
intravascular manipulation, such as PTCA, stenting and intravascular echo. 
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Hoofdsluk I geeft een overzicht van klinische aspecten van ischemische hartziekten. 
Ischemische hm1ziekten kunnen worden onderverdeeld in stabiele angina pectoris, 
instabiele angina pectoris, acuut myocard infarct, en variant angina pectoris. Deze 
ziektebeelden zijn onderdeel van een spectnnu van gerelateerde afwijkingen, waarin de 
zuurstofvoorziening de behoefte niet adequaat dekt. Dit resulteert gewoonlijk in pijn op 
de borst (angina), en een aantal andere Iichamelijke, chemische, en electrofysiologische 
symptomen. Bij de pathofysiologie van ischemische harlziekten is ten eerste een passieve 
obstlUctie van het vaatlumen betrokken. Deze ontstaat door thrombusvonning en door de 
vorming van een atherosclerotische plaque. Ten tweede moet worden gedacht aan aclieve 
constrictie van de vaatwand door een disbalans van constrictie- en relaxatiemechanismen 
(de vasculaire tonus). De relatieve bijdrage van de aclieve vasoconstrictie vadeel1 van zeer 
gering, in geval van stabiele angina, tot vrijwel Yolledig, in geval van variant angina 
pectoris. In een eukel geval kan angina ook ontstaan als bijwerking van geneesmiddelen, 
zoals anti-migraine middelen. Behandeling van ischemische hrn1ziekten is gedcht op 
vermindedng van de ischemie van het myocard, de gerelateerde angineuze pijn, en op het 
voorkomen van hemodynamische complicaties. Grootschalige klinische tdals worden met 
regelmaat opgezet om de beste manier van behandeling te bepalen voor verschillende 
patientgroepen. 
Hoofdslul< 2 beschrijft de fysiologie en pathofYsiologie van vasculaire tonus. 
Vasculaire tonus is gedefinieerd als het evenwicht tussen relaxerende en contraherende 
mechanismen in de vaatwand. Verstoring van dit evenwicht zou een belangdjke rol kunnen 
spelen in bovengenoemde klinische syndromen van ischemische hat1ziekten. Vasculaire 
tonus is het resultaat vrnl processen in het vasculaire gladde spierweefsel en het vasculaire 
endotheel. Contractie en relaxatie van glad spierweefsel ontstaan door interactie van actine 
en myosine eiwitketens. De interactie wordt gereguleerd door een groat aantal receptoren, 
enzymen, ion-kanalen, ion-pompen, en door ion-uitwisseling. Hiermee wordt de 
concentratie van calcium in het cytosol, of de gevoeligheid van het contractiele apparaat 
belnvloed. Het endotheel heeft invloed op de vasculaire tonus door de afgifte van zowel 
relaxerende (endotheel afuankelijke relaxerende factor, EDRF), als contraherende stimuli 
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(endotheel afhankelijke contraherende factor, EDCF), die beiden een effect hebben op het 
onderliggende gladde spierweefsel. Verstoring van het evenwicht tussen relaxatie en 
contractie kan leiden tot ver/aging van de doorbloeding, met daaropvolgende vermindering 
van de zuurstofvoorziening aan het myocard. Verstoring van dit evenwicht treedt met 
name op in atherosclerotische bloedvaten, waarin de endotheel-gemedieerde dilatatoire 
component is verminderd. Oak endotheelschade na ballon angioplastie, serum Iipoprotei-
nen, en serum cholesterol, kunnen betrokken zijn bij verstoring van het evenwicht tussen 
contractie en relaxatie. 
Hoofdslnk 3 geeft een overzicht van serotonine (5-HT), de serotonine receptor 
subtypen, en de functionele en therapeutische relevantie in het cardiovasculaire systeem. 
Oak wordt de ontwikkeling geschetst van de oude 'M' - en 'D' -receptorclassificatie tot aan 
de huidige fiJPHAR c1assificatie voor serotonine receptoren. Hoewel exogeen toegediend 
serotonine een evident effect heeft op het cardiovasculaire systeem, is dit van receptor 
antagonisten tegen eventllele endogene serotonine vrijzetting nag niet overtuigend 
vastgesteld. Eigenlijk is het gebruik van serotonine agonisten en antagonisten in 
cardiovasculaire aandoeningen tot nu toe beperkt tot de behandeling van migraine. De 
teleurstellende resultaten met serotonine receptor antagonisten in coronaire vaatspasmen 
knnnen worden verklaard door overschatting van de rol die serotonine speel! in het 
ziekteproces, of door het gebl1lik van een receptor antagonist die gericht is op de 
verkeerde receptor. 
In Hoofdslnk 4 wordt beschreven hoe de receptoren werden onderzocht die de 
contractiele effecten medieren van serotonine op de vena saphena van de mens. Daarbij 
werd gebl1lik gemaakt van verschillende serotonine receptor agonisten en antagonisten. De 
potentie volgorde van de agonisten was 5-CT '" 5-HT > methysergide '" snmalriptan '" 
a-methyl-5-HT '" RU 24969", DOl > 2-methyl-5-HT > 8-0H-DPAT. De 5-HT, receptor 
antagonist, ketanserine, veroorzaakte een l'echtsverschuiving van met name het bovenste 
deel van de concentratie-effect-curve van serotonine en 5-CT, tenvijl de curve van de 
selectieve 5-HT, receptor agonisten, a-methyl-5-HT en DOl, op parallelle wijze naar 
rechts werd verplaatst door ketanserine. VerdeI' was de contractie door serotonine gevoelig 
vaal' antagonisme mel methysergide, methiothepin, ICS 205-930 (tropisetron), en 
flesinoxan. De contractie door de selectieve 5-HT, receptor agonist, sumatriptan, kon 
worden geantagoneerd met methiothepin, metergoline, l'auwolscine, en cyanopindolol 
(allen antagonist van a.m. 5-HT, receptor subtypen), maar niel met ketanserine. Tussen 
de functioneel geregistreerde pD, I pKB waarden en de eerder beschreven affiniteit Vaal' 
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5-HTID receptoren in bindingsstudies in hersenmembranen, werd een goede conelatie 
gevonden. Contracties van de vena saphena van de mens klllmen dus gemedieerd worden 
door zowel de 5-HT, receptor, alsook door een receptor die lijkt op de 5-HTID receptor 
die in hersenmembranen wordt gevonden. 
Van drie patienten die een harttransplantatie ondergingen nadat zij 6-11 jaar eerder 
een coronaire bypass operatie hadden ondergaan, werd de vena saphena van het 
geexplanteerde hart verwijderd. Hoewel lichtmicroscopisch enorme intimahyperplasie 
zichtbaar was, en hoewel de contractie op 30 mM kalium significant lager was, bleven 
zowel pD, als EMAX (wanneer berekend als percentage van kalium-geYnduceerde contractie) 
onveranderd in geval van serotonine en sumatriptan, wanneer dat werd vergeleken met de 
respons van venen die direct uit het onderbeen waren verwijderd. 
In Hoofdstnk 5 wordt een serie experimenten beschreven die zijn gericht op de 
contractiele eigenschappen van de coronairarterie van de mens in respons op serotonine, 
geactiveerde bloedplaaljes, snmatriptan, en ergotamine. Ketanserine (I !tM) remde zowel 
de contractiele respons op serotonine als de respons op plaatjes. In aanwezigheid van 
ketanserine gaven rauwolscine en cyanopindolol concentratie afhankelijke additionele 
remming van de overgebleven respons op lage concentraties (i.e. ,;1 11M) serotonine. De 
respons op sumatriptan werd op gelijke wijze geantagoneerd door rauwolscine en 
cyanopindolol en ook door metergoline, maar niet door ketanserine. De potentievolgorde 
van deze antagonisten voor sumatriptan lijkt op de volgorde zoals beschreven voor de 
5-HTID-achtige receptor in de humane vena saphena (Hoofdstuk 4). Tegen contracties door 
plaatjes was slechts een niet significant additioneel effect van rauwolscine en cyanopin-
dolol waarneembaar. De conclusie is dat 5-HT, receptoretl een 1'01 spelen bij contracties 
door serotonine in voorallage concentraties. 5-HT, receptoren spelen een belangrijke rol, 
met name bij hogere concentraties serotonine. 
VerdeI' werd gekeken naar de contractiele effecten van de anti-migraine middelen, 
sumatriptan en ergotamine, op de coronairarterie van de mens. Ergotamine was ongeveer 
honderd maal potenter en had een twee maal zo hoog maximaal effect. 
Hoofdstuk 6 beschrijft de effecten van humane bloedplaatjes (thrombocyten) op de 
coronairarterie van de mens. Plaatjes veroorzaakten concentratie afhankelijke contracties 
van dit bloedyat. De contractiele respons leek enigszins verminderd in geval van 
vaatsegrnenten met histologische tekenen van yroege atherosclerose. De contractie 
yerminderde ook wamleer het bloedyat was voorbehandeld met ketanserine of met de 
thromboxaan receptor antagonist, SQ30741. Plaatjes, verkregen van donoren die gedurende 
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7-13 dagen 40 mg/dag aspirine hadden geslikt, veroorzaakten een significant lagere 
eontraetiele respons, die gepaard ging met een vrijwel seleetieve verlaging van de in het 
orgaanbad gemeten thromboxaan eoneentratie. De hoeveellieid in het bad afgegeven 
serotonine bleef onveranderd, wat een goede verklaring lijkt voor het feit dut ketanserine 
de overgebleven respons van plaatjes van met aspirine behandelde plaaijesdonaren remde, 
terwijl de thromboxaanreceptor antagonist SQ30741 sleehts geringe, niet significante 
additionele remming van eontraetie teweeg braeht. De resultaten van deze experimenten 
suggereren dat additioneel antagonisme van eontraetiele 5-HT reeeptoren van de eoronair 
al'terie, de klinische effectiviteit van aspirine zou kUlmen verbeteren. 
In Hoofdsluk 7 wordt uiteengezet hoe endotheline (ET) reeeptoren in de earonair 
at1erie, en in het ventrikel en het atrium van het humatle hart zijn bestudeerd. Bij deze 
experimenten werd gebmik gemaakt van kwantitatieve receptor autoradiogralie. De 
verdringing werd bestudeerd van labeling met [12SIJsarafotoxin S6b (30 pM) en ['25IJET-l 
(30 pM). Als verdringings liganden werden gebruikt de ETA receptor selectieve ligande 
BQ-123, en de ET B receptor selectieve ligande [Ala l,3"I'''JET-I, De specilieke binding was 
hager in het atrium en in de coronair arterie dan in het ventrikel. In de eoronair arterie 
was de binding het grootst in de media. ET-l verdrong binding Vatl [12SIJET-l en 
["'IJsarafotoxin S6b op monofasisehe wijze in het atrium, in het ventrikel en in de 
eoronair arterie, [Ala'·3.1I·"JET-l en BQ-123 verdrongen de labeling met ["'IJET-l en 
['25IJsarafotoxin S6b op een bifasisehe manier in zowel het ventrikel als in het atrium, In 
de coronair arterie van de mens, verdrongen [Ala,,3.1I'''JET-1 en BQ-123 de binding met 
["'IJET-l op een monofasische manier (ET-l > BQ-123 > [Ala' ,3·II·"JET-l), Daarentegen 
verdrongen [Ala,,3,1I'''JET-l en BQ-123 de binding met ['25IJsarafotoxin S6b op bifasische 
wijze, De lage affiniteits-bindingsplaats van [Ala,,3,1I'''JET-l en BQ-123 cOI1'espondeerde 
met de bindingsplaats van ['25IJET-l, Hiemit vogt dat zowel ["'IJET-l als ['25IJsarafotoxin 
S6b ETA en ET B bindings plaatsen in het atrium en ventrikel bezetten, In de coronair 
arterie bezetten beide radioliganden ETA bindingsplaatsen, maar ['25IJsarafotoxin S6b 
bezette oak een non-ETA> non-ET B bindingsplaats met relatief hoge affiniteit voor BQ-123 
en voor [Ala
'
,3,II'''JET-l. 
Met in gedaehten de observaties in de receptor bindingsstudies van Hoofdstuk 7, 
wordt in Hoofdsluk 8 gezocht naar functioneel bewijs van overeenkomstige receptor 
heterogeniteit, Daartoe werden de effeeten Vatl de ETA receptor antagonist onderzoeht op 
eontraeties van de vena saphena van de mens, veroorzaakt door ET-I of sarafotoxin S6b. 
Voorbehandeling met BQ-123 (0.1-1 ~lM) liet eontractie door ET-I onveranderd, maar 
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antagoneerde contractie door sarafotoxin 86b op concentratie afbankelijke wijze. Dit 
antagonisme was bifasisch, Le. BQ-123 was met name actief ten opzichte van de hogere 
concentraties van sarafotoxin 86b. Hieruit voigt dat de contracties door ET-I worden 
gemedi~erd door een BQ-123-ongevoelige receptor, terwijl de contracties door sarafotoxin 
86b ten dele worden gemedieerd door een receptor die verschilt van de receptor die 
verantwoordelijk is voor de respons door ET-l. 
In Hoofdstuk 9 worden endotheline receptoren onderzocht die contractie medieren 
van de coronair arterie van de mens. Dit werd gedaan met behulp van verschillende 
agonisten en antagonisten voor de endotheline receptor. De potentie volgorde (PD,) van 
de agonisten was: ET-I '" sarafotoxin 86b> big-ET-I '" ET-3. [Alal.3.11.l5jET_l (een ET. 
receptor agonist) had aIleen effect in een concentratie van 111M. 0.3 11M big-ET-3 had 
geen effect. Verwijdering van het endotheel veranderde Iliets aan de contractiele respons 
van ET-I en sarafotoxin 86b. Na afloop van een volledige concentratie-effect-curve met 
ET-I of met sarafotoxin 86b, kon uitsluitend in de segmenten die waren blootgesteld aan 
sarafotoxin 86b een additionele respons worden ge[nduceerd met ET-l. Andersom was dit 
niet mogelijk. 0.1 11M BQ-123 veroorzaakte rechtsverschuiving van de COIl-
centratie-effect-curve van sarafotoxin 86b (PKD: 7.86). Daarentegen gaf uitsluitend eell 
concentratie van 10 11M BQ-123 een rechtsverschuiving van de concentratie-effect-curve 
van ET-I (PK.: 5.75). Ook de ETA receptor antagonist FRI39317 was potellter ten 
opzichte van contracties ge[nduceerd door sarafotoxin 86b dan ten opzichte van contracties 
ge[nduceerd door ET-l. [Ala'·3·1I·"jET_1 (l 11M) had geen effect op de con-
centratie-effect-curve van ET-I of sarafotoxin 86b. Vergeleken met ringsegmenten met 
intact endotheel, was de pD, in stripsegmenten met intact endotheel significant 
toegenomen. In strip segmenten zorgde I 11M BQ-123 wei voor significante 
rechtsverschuiving van de concentratie-effect curve van ET-I. De cOlltractiele respons na 
stimulatie met big-ET-I in endotheel-intacte coronair arterie segmenten was significant 
verminderd na voorbehandeling van het segment met 100 11M phosphoramidon. Dit duidde 
op conversie van big-ET-I naar ET-I in het coronair arterie segment. Hieruit voigt dat 
ET-I en sarafotoxin 86b de ge[soleerde coronair arterie van de mens contraheren via 
verschillende receptoren, die waarschijnlijk het best kunnen worden gekarakteriseerd als 
subtypen van de ETA receptor. Voorts bleek dat de manier van prepareren (ring of strip) 
de effectiviteit kan befnvloeden van ET-I als agonist, en BQ-123 als antagonist. 
235 
Swmnary in DUfch; Samenvatfing in hef Nedel'lands 
In Hoofdstul, 10 wordt een overzicht gegeven van verschillende 'lypische' en 
'atypische' endotheline receptor mechanismen, en worden momenteel bekende experimen-
tele bevindingen vergeleken met de oflicHile lUPHAR clas.ificatie voor endotheline 
receptoren. Aangetoond werd dat de huidige criteria niet voldoende zijn am aile 
endotheline receptoren te classificeren. Er werd nadmk gelegd op strenge classificatie 
criteria. Deze criteria omvatten operationele en structurele aspecten, alsmede de manier 
van receptor transductie. Hoewel experimenteel voldoende is aangetoond dat de huidige 
classificatie zal moeten worden uitgebreid, en hoewel de huidige classificatie soms zelfs 
misleidend kan zijn, werd duidelijk gemaakt dat er nog niet voldoende experimentele 
aanwijzingen zijn am te komen tot een definitieve, nieuwe receptor classificatie. 
In Hoofdstuk 11 worden de effecten beschreven van nonpeptide receptor 
antagonisten op de contractie geYnduceerd door arginine vasopressine (A VP) in de coronair 
at1erie van de mens. Contractie door A VP werd geantagoneerd door zowel de gepos-
tuleerde VI receptor antagonist, SR 49059, als door de veronderstelde V, receptor 
antagonist, OPC-31260 (pA, respectievelijk 9.76 en 7.31). In tegenstelling tot de 
beschreven hoge afliniteit Vaal' VI receptoren van de rat, was 311M OPC-21268 nodig am 
de respons op A VP te antagoneren (pA,: 5.6). De potentievolgorde van de antagonisten 
(SR 49059> OPC-31260 > OPC-21268) correspondeert met de besclu'even affiniteitsvol-
gorde voor de recent gecloneerde V I receptor van de mens. Hieruit voigt dat de 
besclu'even hoge affiniteit van OPC-21268 voor de VI receptor beperkt blijft tot de VI 
receptor van de rat, hetgeen de vraag opwerpt of we hier te maken hebben met een species 
afhankelijk verschi! van dezelfde receptor, of met twee verschillende receptor (sub )typen. 
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